{
  "$schema": "folio-library-document/v1",
  "id": "10665-352523",
  "title": "WHO operational handbook on tuberculosis: module 5: management of tuberculosis in children and adolescents",
  "variant": "pdf",
  "pages": 264,
  "tocSource": "outline",
  "tocMethod": null,
  "toc": [
    {
      "level": 1,
      "title": "Acknowledgements",
      "number": null,
      "page": 7,
      "pageLabel": "v",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-000-acknowledgements"
    },
    {
      "level": 1,
      "title": "Abbreviations",
      "number": null,
      "page": 11,
      "pageLabel": "ix",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-001-abbreviations"
    },
    {
      "level": 1,
      "title": "Definitions",
      "number": null,
      "page": 15,
      "pageLabel": "xiii",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-002-definitions"
    },
    {
      "level": 1,
      "title": "Introduction",
      "number": "1",
      "page": 21,
      "pageLabel": "1",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-003-1-introduction"
    },
    {
      "level": 2,
      "title": "Background",
      "number": "1.1",
      "page": 21,
      "pageLabel": "1",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-004-11-background"
    },
    {
      "level": 2,
      "title": "Children and adolescents as a key vulnerable population",
      "number": "1.2",
      "page": 21,
      "pageLabel": "1",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-005-12-children-and-adolescents-as-a-key-vulnerable"
    },
    {
      "level": 2,
      "title": "Rationale and objectives of this operational handbook",
      "number": "1.3",
      "page": 22,
      "pageLabel": "2",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-006-13-rationale-and-objectives-of-this-operational"
    },
    {
      "level": 2,
      "title": "Preferences of end-users regarding content and structure of this operational handbook",
      "number": "1.4",
      "page": 22,
      "pageLabel": "2",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-007-14-preferences-of-end-users-regarding-content-an"
    },
    {
      "level": 2,
      "title": "Structure of the operational handbook",
      "number": "1.5",
      "page": 23,
      "pageLabel": "3",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-008-15-structure-of-the-operational-handbook"
    },
    {
      "level": 2,
      "title": "Target audience",
      "number": "1.6",
      "page": 24,
      "pageLabel": "4",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-009-16-target-audience"
    },
    {
      "level": 1,
      "title": "TB screening and contact investigation",
      "number": "2",
      "page": 25,
      "pageLabel": "5",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-010-2-tb-screening-and-contact-investigation"
    },
    {
      "level": 2,
      "title": "Introduction",
      "number": "2.1",
      "page": 25,
      "pageLabel": "5",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-011-21-introduction"
    },
    {
      "level": 2,
      "title": "Contact investigation",
      "number": "2.2",
      "page": 26,
      "pageLabel": "6",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-012-22-contact-investigation"
    },
    {
      "level": 2,
      "title": "TB screening approaches in children and adolescents",
      "number": "2.3",
      "page": 37,
      "pageLabel": "17",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-013-23-tb-screening-approaches-in-children-and-adole"
    },
    {
      "level": 2,
      "title": "Screening children and adolescents living with HIV",
      "number": "2.4",
      "page": 44,
      "pageLabel": "24",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-014-24-screening-children-and-adolescents-living-wit"
    },
    {
      "level": 1,
      "title": "Prevention of TB in children and adolescents",
      "number": "3",
      "page": 47,
      "pageLabel": "27",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-016-3-prevention-of-tb-in-children-and-adolescents"
    },
    {
      "level": 2,
      "title": "Introduction",
      "number": "3.1",
      "page": 47,
      "pageLabel": "27",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-015-31-introduction"
    },
    {
      "level": 2,
      "title": "BCG vaccination",
      "number": "3.2",
      "page": 47,
      "pageLabel": "27",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-017-32-bcg-vaccination"
    },
    {
      "level": 2,
      "title": "TB preventive treatment",
      "number": "3.3",
      "page": 52,
      "pageLabel": "32",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-018-33-tb-preventive-treatment"
    },
    {
      "level": 2,
      "title": "TB infection prevention and control",
      "number": "3.4",
      "page": 70,
      "pageLabel": "50",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-019-34-tb-infection-prevention-and-control"
    },
    {
      "level": 1,
      "title": "TB diagnostic approaches for children and adolescents",
      "number": "4",
      "page": 73,
      "pageLabel": "53",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-021-4-tb-diagnostic-approaches-for-children-and-adol"
    },
    {
      "level": 2,
      "title": "Introduction",
      "number": "4.1",
      "page": 73,
      "pageLabel": "53",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-020-41-introduction"
    },
    {
      "level": 2,
      "title": "Diagnosing TB in children and adolescents",
      "number": "4.2",
      "page": 74,
      "pageLabel": "54",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-022-42-diagnosing-tb-in-children-and-adolescents"
    },
    {
      "level": 2,
      "title": "Diagnostic approaches: pulmonary TB",
      "number": "4.3",
      "page": 74,
      "pageLabel": "54",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-023-43-diagnostic-approaches-pulmonary-tb"
    },
    {
      "level": 2,
      "title": "Diagnostic approaches: extrapulmonary TB",
      "number": "4.4",
      "page": 99,
      "pageLabel": "79",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-024-44-diagnostic-approaches-extrapulmonary-tb"
    },
    {
      "level": 2,
      "title": "Disease severity",
      "number": "4.5",
      "page": 102,
      "pageLabel": "82",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-025-45-disease-severity"
    },
    {
      "level": 2,
      "title": "Diagnostic approaches: drug-resistant TB",
      "number": "4.6",
      "page": 103,
      "pageLabel": "83",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-026-46-diagnostic-approaches-drug-resistant-tb"
    },
    {
      "level": 1,
      "title": "Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents",
      "number": "5",
      "page": 107,
      "pageLabel": "87",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-027-5-treatment-of-drug-susceptible-and-drug-resista"
    },
    {
      "level": 2,
      "title": "Introduction",
      "number": "5.1",
      "page": 107,
      "pageLabel": "87",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-028-51-introduction"
    },
    {
      "level": 2,
      "title": "Treatment of drug-susceptible TB in children and adolescents",
      "number": "5.2",
      "page": 108,
      "pageLabel": "88",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-029-52-treatment-of-drug-susceptible-tb-in-children"
    },
    {
      "level": 2,
      "title": "Treatment of multidrug-resistant and rifampicin-resistant TB in children and adolescents",
      "number": "5.3",
      "page": 135,
      "pageLabel": "115",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-030-53-treatment-of-multidrug-resistant-and-rifampic"
    },
    {
      "level": 2,
      "title": "Practical guidance for assessment and management of post-TB health in children and adolescents",
      "number": "5.4",
      "page": 152,
      "pageLabel": "132",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-031-54-practical-guidance-for-assessment-and-managem"
    },
    {
      "level": 1,
      "title": "Models of TB care for children and adolescents",
      "number": "6",
      "page": 157,
      "pageLabel": "137",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-032-6-models-of-tb-care-for-children-and-adolescents"
    },
    {
      "level": 2,
      "title": "Introduction",
      "number": "6.1",
      "page": 157,
      "pageLabel": "137",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-033-61-introduction"
    },
    {
      "level": 2,
      "title": "Decentralized, family-centred, integrated TB services",
      "number": "6.2",
      "page": 160,
      "pageLabel": "140",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-034-62-decentralized-family-centred-integrated-tb-se"
    },
    {
      "level": 2,
      "title": "Private-sector involvement in care for children and adolescents with TB",
      "number": "6.3",
      "page": 174,
      "pageLabel": "154",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-035-63-private-sector-involvement-in-care-for-childr"
    },
    {
      "level": 2,
      "title": "Differentiated TB service delivery",
      "number": "6.4",
      "page": 178,
      "pageLabel": "158",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-036-64-differentiated-tb-service-delivery"
    },
    {
      "level": 2,
      "title": "TB and health emergencies",
      "number": "6.5",
      "page": 182,
      "pageLabel": "162",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-037-65-tb-and-health-emergencies"
    },
    {
      "level": 1,
      "title": "Special situations",
      "number": "7",
      "page": 185,
      "pageLabel": "165",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-038-7-special-situations"
    },
    {
      "level": 2,
      "title": "Management of TB in children and adolescents living with HIV",
      "number": "7.1",
      "page": 185,
      "pageLabel": "165",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-039-71-management-of-tb-in-children-and-adolescents"
    },
    {
      "level": 2,
      "title": "TB in pregnancy and management of newborns of mothers with TB disease",
      "number": "7.2",
      "page": 196,
      "pageLabel": "176",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-040-72-tb-in-pregnancy-and-management-of-newborns-of"
    },
    {
      "level": 2,
      "title": "Palliative care for children and adolescents with TB",
      "number": "7.3",
      "page": 199,
      "pageLabel": "179",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-041-73-palliative-care-for-children-and-adolescents"
    },
    {
      "level": 2,
      "title": "Care for adolescents with or at risk of TB",
      "number": "7.4",
      "page": 203,
      "pageLabel": "183",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-042-74-care-for-adolescents-with-or-at-risk-of-tb"
    },
    {
      "level": 2,
      "title": "TB in children with severe acute pneumonia",
      "number": "7.5",
      "page": 208,
      "pageLabel": "188",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-043-75-tb-in-children-with-severe-acute-pneumonia"
    },
    {
      "level": 2,
      "title": "Management of children with TB and malnutrition",
      "number": "7.6",
      "page": 210,
      "pageLabel": "190",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-044-76-management-of-children-with-tb-and-malnutriti"
    },
    {
      "level": 1,
      "title": "References",
      "number": "8",
      "page": 217,
      "pageLabel": "197",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-045-8-references"
    },
    {
      "level": 1,
      "title": "Annex 1. Selected resources on child and adolescent TB",
      "number": null,
      "page": 231,
      "pageLabel": "211",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-046-annex-1-selected-resources-on-child-and-adolesce"
    },
    {
      "level": 1,
      "title": "Annex 2. Tuberculin skin testing: administration, reading and interpretation",
      "number": null,
      "page": 234,
      "pageLabel": "214",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-047-annex-2-tuberculin-skin-testing-administration-r"
    },
    {
      "level": 1,
      "title": "Annex 3. Sample collection methods",
      "number": null,
      "page": 237,
      "pageLabel": "217",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-048-annex-3-sample-collection-methods"
    },
    {
      "level": 1,
      "title": "Annex 4. Standard operating procedures for sample collection methods",
      "number": null,
      "page": 240,
      "pageLabel": "220",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-049-annex-4-standard-operating-procedures-for-sample"
    },
    {
      "level": 1,
      "title": "Annex 5. Treatment decision algorithms",
      "number": null,
      "page": 247,
      "pageLabel": "227",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-050-annex-5-treatment-decision-algorithms"
    },
    {
      "level": 1,
      "title": "Annex 6. Dosing of medicines used in second-line multidrug-resistant TB regimens by weight band (below 46 kg)a",
      "number": null,
      "page": 254,
      "pageLabel": "234",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-051-annex-6-dosing-of-medicines-used-in-second-line"
    },
    {
      "level": 1,
      "title": "Annex 7. Overview of options for neurocognitive and functional testing at end of treatment for TB meningitis",
      "number": null,
      "page": 260,
      "pageLabel": "240",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-052-annex-7-overview-of-options-for-neurocognitive-a"
    }
  ],
  "sections": [
    {
      "id": "sec-front-matter",
      "number": null,
      "title": "Front matter",
      "level": 1,
      "pageStart": 1,
      "pageEnd": 7,
      "labelStart": "a",
      "labelEnd": "v",
      "words": 941,
      "summary": {
        "text": "The front matter of the WHO operational handbook on tuberculosis, Module 5: management of TB in children and adolescents (2022), with the ISBN and licence page, citation, disclaimers and a table of contents covering screening, prevention, diagnosis, treatment, models of care, special situations and annexes.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "adolescents living",
          "heading": false
        },
        {
          "term": "operational handbook",
          "heading": false
        },
        {
          "term": "creative commons",
          "heading": false
        },
        {
          "term": "diagnostic approaches",
          "heading": false
        },
        {
          "term": "contact investigation",
          "heading": false
        },
        {
          "term": "children",
          "heading": false
        },
        {
          "term": "suggested citation",
          "heading": false
        },
        {
          "term": "licence",
          "heading": false
        }
      ],
      "extract": "Module 5: Management of tuberculosis in children and adolescents WHO operational handbook on tuberculosis WHO operational handbook on\u0003 tuberculosis Module 5: Management of tuberculosis in children and adolescents WHO operational handbook on tuberculosis. Module 5: management of tuberculosis in children and adolescents ISBN 978-92-4-004683-2 (electronic version) ISBN 978-92-4-004684-9 (print version) © World Health",
      "extractCut": true,
      "blocks": [
        "library/10665-352523/blocks/prose-sec-front-matter"
      ]
    },
    {
      "id": "sec-000-acknowledgements",
      "number": null,
      "title": "Acknowledgements",
      "level": 1,
      "pageStart": 7,
      "pageEnd": 11,
      "labelStart": "v",
      "labelEnd": "ix",
      "words": 1553,
      "summary": {
        "text": "Acknowledges the WHO Global TB Programme staff who wrote each chapter of the child and adolescent TB handbook, the many external contributors and reviewers, and funding from Unitaid, USAID and the US CDC.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "kerri viney",
          "heading": false
        },
        {
          "term": "stellenbosch university",
          "heading": false
        },
        {
          "term": "sabine verkuijl",
          "heading": false
        },
        {
          "term": "annemieke brands",
          "heading": false
        },
        {
          "term": "makerere university",
          "heading": false
        },
        {
          "term": "mbarara university",
          "heading": false
        },
        {
          "term": "baylor college",
          "heading": false
        },
        {
          "term": "hopkins university",
          "heading": false
        }
      ],
      "extract": "Acknowledgements This operational handbook was prepared by Sabine Verkuijl, Annemieke Brands, Kerri Viney and Tiziana Masini, under the guidance of Farai Mavhunga and the overall direction of Tereza Kasaeva, Director of the World Health Organization (WHO) Global Tuberculosis (TB) Programme. The WHO Global TB Programme gratefully acknowledges the contributions of all experts who were involved in the production of the",
      "extractCut": true
    },
    {
      "id": "sec-001-abbreviations",
      "number": null,
      "title": "Abbreviations",
      "level": 1,
      "pageStart": 11,
      "pageEnd": 15,
      "labelStart": "ix",
      "labelEnd": "xiii",
      "words": 342,
      "summary": {
        "text": "A list of abbreviations used in the child and adolescent TB handbook, mostly TB and HIV medicines, tests and programme terms.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "protease inhibitor",
          "heading": false
        },
        {
          "term": "drug-resistant tuberculosis",
          "heading": false
        },
        {
          "term": "preventive therapy",
          "heading": false
        },
        {
          "term": "childhood illness",
          "heading": false
        },
        {
          "term": "abbreviations",
          "heading": true
        },
        {
          "term": "ritonavir",
          "heading": false
        },
        {
          "term": "integrated management",
          "heading": false
        },
        {
          "term": "aminotransferase",
          "heading": false
        }
      ],
      "extract": "Abbreviations ABC abacavir AIDS acquired immunodeficiency syndrome ALT alanine aminotransferase Am amikacin amoxiclav amoxicillin with clavulanic acid (also known as co-amoxiclav) aOR adjusted odds ratio ART antiretroviral therapy AST aspartate aminotransferase AZT zidovudine B (or Bdq) bedaquiline BCG bacille Calmette-Guérin CaP-TB Catalyzing Pediatric Tuberculosis Innovation Cfz clofazimine CHW community health",
      "extractCut": true
    },
    {
      "id": "sec-002-definitions",
      "number": null,
      "title": "Definitions",
      "level": 1,
      "pageStart": 15,
      "pageEnd": 21,
      "labelStart": "xiii",
      "labelEnd": "1",
      "words": 2508,
      "summary": {
        "text": "Defines key terms used in the child and adolescent TB operational handbook, such as active case-finding, adherence, advanced HIV disease and adverse events. It goes on through diagnostic, treatment, disease severity and programme terms, ending with definitions of treatment outcomes, the tuberculin skin test and TB disease. Footnotes cite WHO reporting frameworks and outcome definitions.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tuberculosis strains",
          "heading": false
        },
        {
          "term": "mdr rr-tb",
          "heading": false
        },
        {
          "term": "strains resistant",
          "heading": false
        },
        {
          "term": "tuberculosis disease",
          "heading": false
        },
        {
          "term": "children aged",
          "heading": false
        },
        {
          "term": "mycobacterium tuberculosis",
          "heading": false
        },
        {
          "term": "tuberculosis preventive",
          "heading": false
        },
        {
          "term": "aged years",
          "heading": false
        }
      ],
      "extract": "Unless otherwise specified, the terms defined here apply as used in this operational handbook. They may have different meanings in other contexts. Active (tuberculosis) case-finding: Provider-initiated screening and testing in communities by mobile teams, often using mobile X-ray and rapid molecular tests. The term is sometimes used synonymously with “systematic screening”. Adherence: Extent to which a person’s",
      "extractCut": true
    },
    {
      "id": "sec-003-1-introduction",
      "number": "1",
      "title": "Introduction",
      "level": 1,
      "pageStart": 21,
      "pageEnd": 21,
      "labelStart": "1",
      "labelEnd": "1",
      "words": 2,
      "summary": {
        "text": "A heading for chapter 1, the introduction.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "1. Introduction",
      "extractCut": false
    },
    {
      "id": "sec-004-11-background",
      "number": "1.1",
      "title": "Background",
      "level": 2,
      "pageStart": 21,
      "pageEnd": 21,
      "labelStart": "1",
      "labelEnd": "1",
      "words": 331,
      "summary": {
        "text": "Notes that children and young adolescents under 15 make up about 11% of TB cases, or 1.1 million a year, but fewer than half are notified, with the largest gap in children under 5 owing to diagnostic difficulties. It introduces the 2022 consolidated guidelines and defines a child as under 10 and an adolescent as 10–19 years.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "adolescents aged",
          "heading": false
        },
        {
          "term": "aged years",
          "heading": false
        },
        {
          "term": "young adolescents",
          "heading": false
        },
        {
          "term": "young children",
          "heading": false
        },
        {
          "term": "person aged",
          "heading": false
        },
        {
          "term": "detection gap",
          "heading": false
        },
        {
          "term": "operational handbook",
          "heading": false
        },
        {
          "term": "consolidated guidelines",
          "heading": false
        }
      ],
      "extract": "Tuberculosis (TB) is a preventable and curable disease, but it continues to impact the lives and development of millions of children and adolescents. Children and young adolescents aged under 15 years represent about 11% of all TB cases globally. This means 1.1 million children and young adolescents aged under 15 years fall ill with TB every year (1). National tuberculosis programmes (NTPs) notify less than half of",
      "extractCut": true
    },
    {
      "id": "sec-005-12-children-and-adolescents-as-a-key-vulnerable",
      "number": "1.2",
      "title": "Children and adolescents as a key vulnerable population",
      "level": 2,
      "pageStart": 21,
      "pageEnd": 22,
      "labelStart": "1",
      "labelEnd": "2",
      "words": 168,
      "summary": {
        "text": "Explains that TB in children is most common at ages 1–4, usually follows recent infection and signals ongoing community transmission, that infants face high risk of severe disease, and that adolescents often have adult-type disease and particular psychosocial needs.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "children",
          "heading": true
        },
        {
          "term": "adolescents",
          "heading": true
        },
        {
          "term": "vulnerable",
          "heading": true
        },
        {
          "term": "disease",
          "heading": false
        },
        {
          "term": "tuberculosis",
          "heading": false
        }
      ],
      "extract": "population Children can present with TB disease at any age, but most commonly between the ages of 1 and 4 years in high TB burden settings. Children who develop TB disease usually do so within a year of TB infection. The presentation of TB in children is an indicator of recent and ongoing transmission of Mycobacterium tuberculosis in the community (4). Infants and young children, especially those aged under 2 years,",
      "extractCut": true
    },
    {
      "id": "sec-006-13-rationale-and-objectives-of-this-operational",
      "number": "1.3",
      "title": "Rationale and objectives of this operational handbook",
      "level": 2,
      "pageStart": 22,
      "pageEnd": 22,
      "labelStart": "2",
      "labelEnd": "2",
      "words": 289,
      "summary": {
        "text": "States that the handbook aims to give practical guidance on implementing WHO recommendations on child and adolescent TB and to inform national policies and capacity building. It cites the UN high-level meeting targets for treating children with TB and providing preventive treatment.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "million children",
          "heading": false
        },
        {
          "term": "young adolescents",
          "heading": false
        },
        {
          "term": "million people",
          "heading": false
        },
        {
          "term": "handbook",
          "heading": true
        },
        {
          "term": "practical guidance",
          "heading": false
        },
        {
          "term": "high-level meeting",
          "heading": false
        },
        {
          "term": "united nations",
          "heading": false
        },
        {
          "term": "aged",
          "heading": false
        }
      ],
      "extract": "handbook The aim of this operational handbook is to provide practical guidance on the implementation of the World Health Organization (WHO) policy recommendations on the prevention and management of TB in children and adolescents under programmatic circumstances and at different levels of the health system. The practical guidance aims to inform the development or revision of national policies and related",
      "extractCut": true
    },
    {
      "id": "sec-007-14-preferences-of-end-users-regarding-content-an",
      "number": "1.4",
      "title": "Preferences of end-users regarding content and structure of this operational handbook",
      "level": 2,
      "pageStart": 22,
      "pageEnd": 23,
      "labelStart": "2",
      "labelEnd": "3",
      "words": 357,
      "summary": {
        "text": "Reports a survey of 182 end-users on barriers to implementing child TB recommendations and preferences for the handbook, who favoured practical content, translations, electronic versions and dissemination through webinars, regional consultations and online training.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "operational handbook",
          "heading": true
        },
        {
          "term": "respondents",
          "heading": false
        },
        {
          "term": "structure",
          "heading": true
        },
        {
          "term": "consolidated guidelines",
          "heading": false
        },
        {
          "term": "nutrition",
          "heading": false
        },
        {
          "term": "children",
          "heading": false
        },
        {
          "term": "adolescent health",
          "heading": false
        },
        {
          "term": "end-users",
          "heading": true
        }
      ],
      "extract": "structure of this operational handbook In preparation for the development of the WHO consolidated guidelines and operational handbook on the management of TB in children and adolescents, a survey was conducted among end-users to: • collect perspectives on the barriers and facilitators for the implementation of WHO recommendations on the management of TB in children and adolescents; • understand respondents’",
      "extractCut": true
    },
    {
      "id": "sec-008-15-structure-of-the-operational-handbook",
      "number": "1.5",
      "title": "Structure of the operational handbook",
      "level": 2,
      "pageStart": 23,
      "pageEnd": 24,
      "labelStart": "3",
      "labelEnd": "4",
      "words": 611,
      "summary": {
        "text": "Explains that the handbook follows the pathway from TB exposure to infection, disease, diagnosis and treatment, illustrated in a figure, and describes the chapters and colour-coded boxes for recommendations, key points and examples.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "operational handbook",
          "heading": true
        },
        {
          "term": "chapter covers",
          "heading": false
        },
        {
          "term": "undesirable effects",
          "heading": false
        },
        {
          "term": "desirable effects",
          "heading": false
        },
        {
          "term": "adolescents",
          "heading": false
        },
        {
          "term": "care system",
          "heading": false
        },
        {
          "term": "health care",
          "heading": false
        },
        {
          "term": "source guidelines",
          "heading": false
        }
      ],
      "extract": "The chapters in the handbook are structured around the pathway of TB infection and disease in an individual child or adolescent and the interface with and retention across sequential stages of care (cascade of care), as shown in Figure 1.1 (5). Figure 1.1. Pathway through TB exposure, infection and disease Un/misdiagnosed Susceptible Preventive treatment Diseased Feeling ill Diagnosed Treated Accessed health care",
      "extractCut": true
    },
    {
      "id": "sec-009-16-target-audience",
      "number": "1.6",
      "title": "Target audience",
      "level": 2,
      "pageStart": 24,
      "pageEnd": 25,
      "labelStart": "4",
      "labelEnd": "5",
      "words": 66,
      "summary": {
        "text": "Identifies the handbook's audience as national TB programmes, child health, HIV and primary care programmes, paediatricians and other health workers, schools, civil society and educators.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "health programmes",
          "heading": false
        },
        {
          "term": "health care",
          "heading": false
        },
        {
          "term": "audience",
          "heading": true
        }
      ],
      "extract": "The target audience for this handbook includes NTPs and other child health programmes that provide care for children with or at risk of TB, including maternal, newborn, child and adolescent health programmes, HIV services, and PHC programmes. The handbook also targets paediatricians and other health care workers (HCWs) in the public and private sectors, school health services, civil society and community-based",
      "extractCut": true
    },
    {
      "id": "sec-010-2-tb-screening-and-contact-investigation",
      "number": "2",
      "title": "TB screening and contact investigation",
      "level": 1,
      "pageStart": 25,
      "pageEnd": 25,
      "labelStart": "5",
      "labelEnd": "5",
      "words": 1,
      "summary": {
        "text": "A fragment of the chapter 2 heading on TB screening and contact investigation.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "investigation",
      "extractCut": false
    },
    {
      "id": "sec-011-21-introduction",
      "number": "2.1",
      "title": "Introduction",
      "level": 2,
      "pageStart": 25,
      "pageEnd": 26,
      "labelStart": "5",
      "labelEnd": "6",
      "words": 607,
      "summary": {
        "text": "Introduces chapter 2, noting that about a quarter of the world's population is infected with TB and that 7.5 million children under 15 are newly infected each year. It defines contact investigation and argues that the case detection gap justifies systematic screening of risk groups.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "contact investigation",
          "heading": false
        },
        {
          "term": "systematic screening",
          "heading": false
        },
        {
          "term": "million children",
          "heading": false
        },
        {
          "term": "adolescents aged",
          "heading": false
        },
        {
          "term": "systematic identification",
          "heading": false
        },
        {
          "term": "young adolescents",
          "heading": false
        },
        {
          "term": "tpt",
          "heading": false
        },
        {
          "term": "disease",
          "heading": false
        }
      ],
      "extract": "About a quarter of the world’s population has been infected with Mycobacterium tuberculosis. The vast majority of these people do not have TB disease (10). It is estimated that 7.5 million children and young adolescents aged under 15 years are newly infected with M. tuberculosis each year (11). Cumulatively, about 67 million children and young adolescents aged under 15 years are infected with M. tuberculosis,",
      "extractCut": true
    },
    {
      "id": "sec-012-22-contact-investigation",
      "number": "2.2",
      "title": "Contact investigation",
      "level": 2,
      "pageStart": 26,
      "pageEnd": 37,
      "labelStart": "6",
      "labelEnd": "17",
      "words": 4658,
      "summary": {
        "text": "Describes contact investigation for children and adolescents, stressing that household and close contacts of people with pulmonary TB should be systematically screened and citing the high risk of disease in infected young children without preventive treatment. It covers prioritising household contacts and planning and budgeting for facility- and community-based approaches. Country examples and boxes describe implementation experiences, including challenges such as reaching remote households and stigma. It ends with prerequisites for a community-based model from the CONTACT study in Uganda and Cameroon.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "contact investigation",
          "heading": true
        },
        {
          "term": "household contacts",
          "heading": false
        },
        {
          "term": "community-based contact",
          "heading": false
        },
        {
          "term": "contacts aged",
          "heading": false
        },
        {
          "term": "tpt eligibility",
          "heading": false
        },
        {
          "term": "child contacts",
          "heading": false
        },
        {
          "term": "close contacts",
          "heading": false
        },
        {
          "term": "tpt initiation",
          "heading": false
        }
      ],
      "extract": "that apply to children and adolescents. It also provides some examples of successful approaches. Figure 2.1. Pathway through exposure, infection and disease covered in Chapter 2 Un/misdiagnosed Susceptible Preventive treatment Diseased Feeling ill Diagnosed Treated Accessed health care system Exposed Accessed health care system Infected Did NOT access health care system Source: Roadmap towards ending TB in children",
      "extractCut": true
    },
    {
      "id": "sec-013-23-tb-screening-approaches-in-children-and-adole",
      "number": "2.3",
      "title": "TB screening approaches in children and adolescents",
      "level": 2,
      "pageStart": 37,
      "pageEnd": 44,
      "labelStart": "17",
      "labelEnd": "24",
      "words": 2624,
      "summary": {
        "text": "Explains the purpose of TB screening in children and adolescents and when it should be done, such as at every visit for those living with HIV and during contact investigation for household contacts. It describes screening tools, including symptom screening, chest X-ray and rapid molecular tests, and their use by age group. It covers practical considerations for screening child close contacts, including caregiver preferences. It ends by explaining when chest X-ray is needed before starting preventive treatment.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "symptom screen",
          "heading": false
        },
        {
          "term": "symptom screening",
          "heading": false
        },
        {
          "term": "undergo cxr",
          "heading": false
        },
        {
          "term": "contacts aged",
          "heading": false
        },
        {
          "term": "children",
          "heading": true
        },
        {
          "term": "close contacts",
          "heading": false
        },
        {
          "term": "child contacts",
          "heading": false
        },
        {
          "term": "chest x-ray",
          "heading": false
        }
      ],
      "extract": "adolescents Screening serves to identify children and adolescents who may have TB disease (presumptive TB) and who need further evaluation to make or confirm a TB diagnosis (see Chapter 4). It also helps to identify children and adolescents who are eligible for and could benefit from TPT. A screening test is not intended to be a diagnostic tool. People with positive results on a screening test should undergo further",
      "extractCut": true
    },
    {
      "id": "sec-014-24-screening-children-and-adolescents-living-wit",
      "number": "2.4",
      "title": "Screening children and adolescents living with HIV",
      "level": 2,
      "pageStart": 44,
      "pageEnd": 47,
      "labelStart": "24",
      "labelEnd": "27",
      "words": 1165,
      "summary": {
        "text": "Describes TB screening of children living with HIV, who are at much higher risk of progression and death, using a symptom and contact screen at every visit with an algorithm and noted sensitivity and specificity. It covers other screening tests, implementation and screening of adolescents, and closes with key points on screening.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "children living",
          "heading": true
        },
        {
          "term": "symptom screen",
          "heading": false
        },
        {
          "term": "screening",
          "heading": true
        },
        {
          "term": "contact investigation",
          "heading": false
        },
        {
          "term": "weight gain",
          "heading": false
        },
        {
          "term": "screening approaches",
          "heading": false
        },
        {
          "term": "poor weight",
          "heading": false
        },
        {
          "term": "adolescents",
          "heading": true
        }
      ],
      "extract": "HIV Children living with HIV have a high risk of rapid progression to severe disease and death if a diagnosis of TB is missed. A child living with HIV is 3.5 times more likely to progress to TB disease than a child who is HIV-negative (29). The risk, although greatly reduced, remains elevated in children on antiretroviral therapy (ART). An estimated 10% of paediatric deaths from TB are among children living with",
      "extractCut": true
    },
    {
      "id": "sec-015-31-introduction",
      "number": "3.1",
      "title": "Introduction",
      "level": 2,
      "pageStart": 47,
      "pageEnd": 47,
      "labelStart": "27",
      "labelEnd": "27",
      "words": 0,
      "summary": null,
      "keywords": [],
      "extract": null,
      "extractCut": false
    },
    {
      "id": "sec-016-3-prevention-of-tb-in-children-and-adolescents",
      "number": "3",
      "title": "Prevention of TB in children and adolescents",
      "level": 1,
      "pageStart": 47,
      "pageEnd": 47,
      "labelStart": "27",
      "labelEnd": "27",
      "words": 76,
      "summary": {
        "text": "Introduces chapter 3 on preventing TB in children and adolescents through BCG vaccination, preventive treatment and infection control, with a pathway figure.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "accessed health",
          "heading": false
        },
        {
          "term": "care system",
          "heading": false
        },
        {
          "term": "adolescents",
          "heading": true
        }
      ],
      "extract": "vaccination, TPT and TB infection prevention and control. This chapter relates to the section of the pathway highlighted in blue in Figure 3.1. Figure 3.1. Pathway through exposure, infection and disease covered in Chapter 3 Un/misdiagnosed Susceptible Preventive treatment Diseased Feeling ill Diagnosed Treated Accessed health care system Exposed Accessed health care system Infected Did NOT access health care system",
      "extractCut": true
    },
    {
      "id": "sec-017-32-bcg-vaccination",
      "number": "3.2",
      "title": "BCG vaccination",
      "level": 2,
      "pageStart": 47,
      "pageEnd": 52,
      "labelStart": "27",
      "labelEnd": "32",
      "words": 1873,
      "summary": {
        "text": "Describes BCG vaccine, which gives up to 90% protection against severe TB forms such as meningitis and miliary TB when given at birth and modest protection against infection. It summarises the WHO position paper recommendations on neonatal vaccination in high-burden settings and special groups. It describes local, regional and disseminated adverse events, including BCG-related immune reconstitution syndrome in people with HIV, and their management.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "bcg vaccination",
          "heading": true
        },
        {
          "term": "bovis bcg",
          "heading": false
        },
        {
          "term": "bcg vaccine",
          "heading": false
        },
        {
          "term": "disseminated bcg",
          "heading": false
        },
        {
          "term": "bcg disease",
          "heading": false
        },
        {
          "term": "administering bcg",
          "heading": false
        },
        {
          "term": "lymph nodes",
          "heading": false
        },
        {
          "term": "receive bcg",
          "heading": false
        }
      ],
      "extract": "BCG is a live attenuated bacterial vaccine derived from Mycobacterium bovis that was originally isolated in 1902 from a tuberculous cow. BCG has demonstrated significant effectiveness, but protection has not been consistent against all forms of TB in all age groups. BCG has also shown effectiveness in preventing leprosy (caused by Mycobacterium leprae) and Buruli ulcer (caused by Mycobacterium ulcerans) (31). BCG",
      "extractCut": true
    },
    {
      "id": "sec-018-33-tb-preventive-treatment",
      "number": "3.3",
      "title": "TB preventive treatment",
      "level": 2,
      "pageStart": 52,
      "pageEnd": 70,
      "labelStart": "32",
      "labelEnd": "50",
      "words": 8449,
      "summary": {
        "text": "Covers TB preventive treatment in children and adolescents, defining TB infection, its global burden and the 5–10% lifetime risk of progression, higher in young children and people with HIV. The headings show it addresses target groups for preventive treatment, ruling out TB disease, testing for infection, the available regimens and child-friendly formulations, and practical implementation. A table explains how to manage missed doses for different regimens such as 3HP and 1HP. It ends by referring other issues, such as babies born to women with TB and ART choice, to other sections and the Module 1 handbook.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "preventive treatment",
          "heading": true
        },
        {
          "term": "tpt regimen",
          "heading": false
        },
        {
          "term": "tpt course",
          "heading": false
        },
        {
          "term": "offered tpt",
          "heading": false
        },
        {
          "term": "initiating tpt",
          "heading": false
        },
        {
          "term": "tpt among",
          "heading": false
        },
        {
          "term": "receive tpt",
          "heading": false
        },
        {
          "term": "full tpt",
          "heading": false
        }
      ],
      "extract": "3.3.1. Introduction TB infection (previously called latent TB infection) is defined as a “state of persistent immune response to stimulation by M. tuberculosis antigens without evidence of TB disease” (15). The number of people worldwide estimated to have M. tuberculosis infection is 1.7 billion. Further, 7.5 million children aged under 15 years are estimated to be infected with TB every year (11). By 2014, a",
      "extractCut": true
    },
    {
      "id": "sec-019-34-tb-infection-prevention-and-control",
      "number": "3.4",
      "title": "TB infection prevention and control",
      "level": 2,
      "pageStart": 70,
      "pageEnd": 73,
      "labelStart": "50",
      "labelEnd": "53",
      "words": 1014,
      "summary": {
        "text": "Explains TB infection prevention and control in health facilities, noting that adolescents can transmit like adults and that poor practices expose children, and that COVID-19 mask use may reduce stigma. It outlines administrative, environmental and respiratory protection measures and closes with key points on prevention.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "infection control",
          "heading": true
        },
        {
          "term": "infection prevention",
          "heading": true
        },
        {
          "term": "cough etiquette",
          "heading": false
        },
        {
          "term": "tpt regimens",
          "heading": false
        },
        {
          "term": "tuberculosis infection",
          "heading": false
        },
        {
          "term": "respiratory protection",
          "heading": false
        },
        {
          "term": "care facilities",
          "heading": false
        },
        {
          "term": "environmental controls",
          "heading": false
        }
      ],
      "extract": "The End TB Strategy emphasizes the need for prevention across all efforts to end the TB epidemic, including infection prevention and control in health care services and other high-transmission settings (7). Infection prevention and control practices are critical to reduce the risk of M. tuberculosis transmission, by reducing the concentration of infectious droplet nuclei in the air and the exposure of susceptible",
      "extractCut": true
    },
    {
      "id": "sec-020-41-introduction",
      "number": "4.1",
      "title": "Introduction",
      "level": 2,
      "pageStart": 73,
      "pageEnd": 73,
      "labelStart": "53",
      "labelEnd": "53",
      "words": 140,
      "summary": {
        "text": "Introduces the diagnostic chapter, explaining that children with presumptive TB need careful clinical assessment and that bacteriological confirmation is hard in young children because of few bacilli and difficulty producing sputum.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "young children",
          "heading": false
        },
        {
          "term": "bacilli",
          "heading": false
        },
        {
          "term": "harbour",
          "heading": false
        },
        {
          "term": "bacteriological",
          "heading": false
        }
      ],
      "extract": "Diagnostic evaluation is the step in the care cascade after screening. Children and adolescents who screen positive during contact investigation or at health facility-based screening, and those who present to a health care facility with signs and symptoms of TB and who are identified as having presumptive TB must be evaluated further for TB disease. The diagnosis of TB disease is usually made based on careful",
      "extractCut": true
    },
    {
      "id": "sec-021-4-tb-diagnostic-approaches-for-children-and-adol",
      "number": "4",
      "title": "TB diagnostic approaches for children and adolescents",
      "level": 1,
      "pageStart": 73,
      "pageEnd": 74,
      "labelStart": "53",
      "labelEnd": "54",
      "words": 126,
      "summary": {
        "text": "Notes that the diagnostic chapter covers drug-susceptible, drug-resistant, pulmonary and extrapulmonary TB, with pulmonary TB in children usually involving chest lymph nodes, and shows a pathway figure.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "adolescents",
          "heading": true
        },
        {
          "term": "children",
          "heading": true
        },
        {
          "term": "accessed health",
          "heading": false
        },
        {
          "term": "care system",
          "heading": false
        }
      ],
      "extract": "with drug-susceptible TB, DR-TB, PTB and EPTB. PTB is the most common type of TB in children and adolescents. in children usually involves disease in the intrathoracic lymph nodes, but in adolescents it more commonly resembles adult-type disease with cavitary lesions (4, 6). This chapter relates to the section of the pathway highlighted in blue in Figure 4.1. Figure 4.1. Pathway through exposure, infection and",
      "extractCut": true
    },
    {
      "id": "sec-022-42-diagnosing-tb-in-children-and-adolescents",
      "number": "4.2",
      "title": "Diagnosing TB in children and adolescents",
      "level": 2,
      "pageStart": 74,
      "pageEnd": 74,
      "labelStart": "54",
      "labelEnd": "54",
      "words": 240,
      "summary": {
        "text": "Lists the groups of children and adolescents at highest risk of TB disease, such as close contacts, under-fives and those with HIV or severe malnutrition, from the WHO operational handbook on TB in children and adolescents. It sets out the components of diagnosis, including history, examination, HIV testing, bacteriological testing and chest X-ray, and advises against a trial of TB treatment as a diagnostic method.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "children",
          "heading": true
        },
        {
          "term": "adolescents",
          "heading": true
        },
        {
          "term": "diagnosing",
          "heading": true
        },
        {
          "term": "pneumonia",
          "heading": false
        },
        {
          "term": "higher risk",
          "heading": false
        },
        {
          "term": "responding",
          "heading": false
        },
        {
          "term": "sam",
          "heading": false
        }
      ],
      "extract": "Young children have a higher risk of developing TB compared with other age groups (4). Risk of TB disease is more pronounced among children and adolescents who: • are a household or other close contact with a person with PTB, especially if bacteriologically confirmed; • are aged under 5 years; • are living with HIV, especially if poorly controlled; • have severe acute malnutrition (SAM), especially if not responding",
      "extractCut": true
    },
    {
      "id": "sec-023-43-diagnostic-approaches-pulmonary-tb",
      "number": "4.3",
      "title": "Diagnostic approaches: pulmonary TB",
      "level": 2,
      "pageStart": 74,
      "pageEnd": 99,
      "labelStart": "54",
      "labelEnd": "79",
      "words": 9556,
      "summary": {
        "text": "Defines pulmonary TB in children, including intrathoracic lymph node and miliary disease, and describes typical persistent symptoms, cough patterns and the importance of a TB contact history. It covers clinical examination signs suggestive of pulmonary and extrapulmonary TB and considerations during contact investigation. The section goes on to cover diagnostic tests and treatment decision algorithms for children who cannot be confirmed bacteriologically. It ends with an example of scoring under Algorithm B and definitions of the symptoms used in the algorithms, such as cough, fever, weight loss and tachycardia.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "wfa z-score",
          "heading": false
        },
        {
          "term": "npa samples",
          "heading": false
        },
        {
          "term": "gastric aspirate",
          "heading": false
        },
        {
          "term": "respiratory stool",
          "heading": false
        },
        {
          "term": "nasopharyngeal aspirate",
          "heading": false
        },
        {
          "term": "children aged",
          "heading": false
        },
        {
          "term": "stool specimens",
          "heading": false
        },
        {
          "term": "child aged",
          "heading": false
        }
      ],
      "extract": "PTB refers to any bacteriologically confirmed or clinically diagnosed case of TB involving the lung parenchyma or tracheobronchial tree. Tuberculous mediastinal and/or hilar intrathoracic lymphadenopathy is also classified as PTB, following an expert consultation convened by WHO in September 2021.15 Miliary TB is classified as PTB because there are lesions in the lungs. Tuberculous pleural effusion without",
      "extractCut": true
    },
    {
      "id": "sec-024-44-diagnostic-approaches-extrapulmonary-tb",
      "number": "4.4",
      "title": "Diagnostic approaches: extrapulmonary TB",
      "level": 2,
      "pageStart": 99,
      "pageEnd": 102,
      "labelStart": "79",
      "labelEnd": "82",
      "words": 1206,
      "summary": {
        "text": "Defines extrapulmonary TB in children and notes it is common in young children and those with HIV, calling for urgent evaluation or referral of very ill children. It reproduces WHO recommendations on using Xpert MTB/RIF and Ultra on non-respiratory specimens such as CSF, lymph node aspirates and blood. A table lists typical presentations and investigations for different extrapulmonary sites, such as TB meningitis, miliary and abdominal TB.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "node biopsy",
          "heading": false
        },
        {
          "term": "lymph node",
          "heading": false
        },
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "pericardial fluid",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "synovial fluid",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "pleural fluid",
          "heading": false
        }
      ],
      "extract": "EPTB refers to any bacteriologically confirmed or clinically diagnosed case of TB involving organs other than the lungs (e.g. pleura, peripheral lymph nodes, abdomen, genitourinary tract, skin, joints and bones, meninges) (71). The classification of intrathoracic lymphadenopathy in children was updated following an expert consultation in September 2021 as PTB. EPTB is common in young children and in children and",
      "extractCut": true
    },
    {
      "id": "sec-025-45-disease-severity",
      "number": "4.5",
      "title": "Disease severity",
      "level": 2,
      "pageStart": 102,
      "pageEnd": 103,
      "labelStart": "82",
      "labelEnd": "83",
      "words": 201,
      "summary": {
        "text": "Explains how TB disease severity is assessed in children, since those aged 3 months to 16 years with non-severe drug-susceptible TB can receive a shorter 4-month regimen. It defines non-severe disease by clinical and chest X-ray findings and stresses that assessing severity should not delay treatment.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "disease severity",
          "heading": true
        },
        {
          "term": "lymph node",
          "heading": false
        },
        {
          "term": "treatment regimen",
          "heading": false
        },
        {
          "term": "month treatment",
          "heading": false
        },
        {
          "term": "young adolescents",
          "heading": false
        },
        {
          "term": "cxr",
          "heading": false
        }
      ],
      "extract": "In children and adolescents, severity of TB disease ranges from mild to severe. Children with non- severe, drug-susceptible TB are now eligible to receive a shortened 4-month treatment regimen. For consideration of a 4-month treatment regimen for non-severe, drug-susceptible PTB in children and young adolescents aged 3 months to 16 years, non-severe TB is defined based on the clinical presentation of disease as",
      "extractCut": true
    },
    {
      "id": "sec-026-46-diagnostic-approaches-drug-resistant-tb",
      "number": "4.6",
      "title": "Diagnostic approaches: drug-resistant TB",
      "level": 2,
      "pageStart": 103,
      "pageEnd": 107,
      "labelStart": "83",
      "labelEnd": "87",
      "words": 1189,
      "summary": {
        "text": "Describes how to diagnose drug-resistant TB in children, emphasizing collection of respiratory or stool samples for rapid molecular tests that detect rifampicin resistance and the role of source-case information. It reproduces WHO recommendations on molecular tests for resistance to isoniazid, fluoroquinolones and other drugs. Key messages stress prioritizing bacteriological testing for all children with presumed TB.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "culture-based phenotypic",
          "heading": false
        },
        {
          "term": "culture-based dst",
          "heading": false
        },
        {
          "term": "second-line lpas",
          "heading": false
        },
        {
          "term": "confirmed dr-tb",
          "heading": false
        },
        {
          "term": "bacteriological testing",
          "heading": false
        },
        {
          "term": "conditional recommendation",
          "heading": false
        },
        {
          "term": "mdr rr-tb",
          "heading": false
        },
        {
          "term": "automated naats",
          "heading": false
        }
      ],
      "extract": "The clinical presentation of DR-TB in a child or adolescent is similar to that of other forms of TB in a child or adolescent. When DR-TB is suspected, it is important to collect respiratory samples (stool, expectorated or induced sputum, NPA sample or gastric aspirate) for bacteriological confirmation by Xpert MTB/RIF or Xpert Ultra when possible. Truenat MTB or MTB Plus may also be used for sputum specimens. Xpert",
      "extractCut": true
    },
    {
      "id": "sec-027-5-treatment-of-drug-susceptible-and-drug-resista",
      "number": "5",
      "title": "Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents",
      "level": 1,
      "pageStart": 107,
      "pageEnd": 107,
      "labelStart": "87",
      "labelEnd": "87",
      "words": 10,
      "summary": {
        "text": "A chapter title fragment on treating both drug-susceptible and drug-resistant TB, pulmonary and extrapulmonary, in young people.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "and drug-resistant pulmonary and extrapulmonary TB in children and adolescents",
      "extractCut": false
    },
    {
      "id": "sec-028-51-introduction",
      "number": "5.1",
      "title": "Introduction",
      "level": 2,
      "pageStart": 107,
      "pageEnd": 108,
      "labelStart": "87",
      "labelEnd": "88",
      "words": 193,
      "summary": {
        "text": "Introduces the treatment chapter, which covers regimens for drug-susceptible and drug-resistant TB, TB meningitis and post-TB health, including the new 4-month regimen. It notes that treatment outcomes in children are generally excellent and that most child TB deaths occur in those never treated, with a figure illustrating the cascade from exposure to treatment.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "accessed health",
          "heading": false
        },
        {
          "term": "care system",
          "heading": false
        },
        {
          "term": "treatment",
          "heading": false
        },
        {
          "term": "children",
          "heading": false
        },
        {
          "term": "dr-tb",
          "heading": false
        },
        {
          "term": "susceptible",
          "heading": false
        }
      ],
      "extract": "This chapter summarizes the treatment options available for children and adolescents to treat drug- susceptible TB and DR-TB and pulmonary and extrapulmonary forms of TB (including TBM), and considerations related to post-TB health. It includes operational guidance on various new treatment approaches, including a 4-month treatment regimen, and important implementation considerations such as availability of",
      "extractCut": true
    },
    {
      "id": "sec-029-52-treatment-of-drug-susceptible-tb-in-children",
      "number": "5.2",
      "title": "Treatment of drug-susceptible TB in children and adolescents",
      "level": 2,
      "pageStart": 108,
      "pageEnd": 135,
      "labelStart": "88",
      "labelEnd": "115",
      "words": 11023,
      "summary": {
        "text": "Sets out the principles of managing drug-susceptible TB in children and adolescents, from medicine management and comorbidities to family involvement, adherence support and recording. It describes the recommended regimens, including the 4-month regimen for non-severe TB based on the SHINE trial, the rifapentine–moxifloxacin regimen for adolescents aged 12 and over, and a 6-month intensive regimen for TB meningitis. It also covers child-friendly fixed-dose formulations, dose adjustment as children gain weight, adverse events and monitoring. Key messages summarize these points and require all children treated for TB to be registered and reported to the national TB programme.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tbm regimen",
          "heading": false
        },
        {
          "term": "intensive tbm",
          "heading": false
        },
        {
          "term": "month regimen",
          "heading": false
        },
        {
          "term": "treatment regimen",
          "heading": false
        },
        {
          "term": "adolescents",
          "heading": true
        },
        {
          "term": "intensive phase",
          "heading": false
        },
        {
          "term": "children",
          "heading": true
        },
        {
          "term": "fdc formulations",
          "heading": false
        }
      ],
      "extract": "adolescents 5.2.1. Principles of TB management To achieve the goals of successful TB treatment in children and adolescents, clinical and programmatic management should include the following components and skills: • management of TB medicines; • recognizing clinical signs indicating the need for urgent care; • managing comorbidities, including undernutrition; • managing adverse events; • implementing infection",
      "extractCut": true
    },
    {
      "id": "sec-030-53-treatment-of-multidrug-resistant-and-rifampic",
      "number": "5.3",
      "title": "Treatment of multidrug-resistant and rifampicin-resistant TB in children and adolescents",
      "level": 2,
      "pageStart": 135,
      "pageEnd": 152,
      "labelStart": "115",
      "labelEnd": "132",
      "words": 7500,
      "summary": {
        "text": "Describes the practical treatment of children with multidrug- and rifampicin-resistant TB, starting with estimates that tens of thousands of children develop MDR-TB each year yet few are diagnosed. It presents the WHO drug groupings and recommendations favouring the shorter all-oral bedaquiline regimen or individualized longer regimens, now with bedaquiline and delamanid allowed at all ages. It covers monitoring, adverse events and implementation issues. Key messages call for specimen collection, empirical treatment based on the source case, child-friendly formulations, avoiding injectables and social support for families.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mdr rr-tb",
          "heading": false
        },
        {
          "term": "rr-tb regimens",
          "heading": false
        },
        {
          "term": "all-oral bedaquiline-containing",
          "heading": false
        },
        {
          "term": "rr-tb aged",
          "heading": false
        },
        {
          "term": "rr-tb treatment",
          "heading": false
        },
        {
          "term": "rr-tb tbm",
          "heading": false
        },
        {
          "term": "shorter all-oral",
          "heading": false
        },
        {
          "term": "rr-tb source",
          "heading": false
        }
      ],
      "extract": "resistant TB in children and adolescents This section describes a practical approach to the treatment of children with rifampicin-resistant tuberculosis (RR-TB) and MDR-TB (resistant to both rifampicin and isoniazid). It covers identifying children who should be treated for MDR/RR-TB, deciding on the most appropriate treatment regimen, monitoring, and other implementation issues related to treatment. 5.3.1.",
      "extractCut": true
    },
    {
      "id": "sec-031-54-practical-guidance-for-assessment-and-managem",
      "number": "5.4",
      "title": "Practical guidance for assessment and management of post-TB health in children and adolescents",
      "level": 2,
      "pageStart": 152,
      "pageEnd": 157,
      "labelStart": "132",
      "labelEnd": "137",
      "words": 1619,
      "summary": {
        "text": "Introduces post-TB health in children and adolescents, noting that consequences of TB can persist after treatment and need to be measured and managed. It describes long-term complications of TB meningitis, such as neurodisability, blindness and hormonal problems, with an end-of-treatment assessment table. It also covers assessment of post-TB lung disease using imaging and spirometry and tools for measuring health-related quality of life in children.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "post-tb health",
          "heading": true
        },
        {
          "term": "post-tb lung",
          "heading": false
        },
        {
          "term": "survive tbm",
          "heading": false
        },
        {
          "term": "neurological sequelae",
          "heading": false
        },
        {
          "term": "children",
          "heading": true
        },
        {
          "term": "lung disease",
          "heading": false
        },
        {
          "term": "residual symptoms",
          "heading": false
        },
        {
          "term": "occupational therapist",
          "heading": false
        }
      ],
      "extract": "management of post-TB health in children and adolescents 5.4.1. Post-TB health Awareness of the consequences of TB disease in children and adolescents that go beyond survival and completion of treatment has increased (131, 132). Each child or adolescent on TB treatment should be assigned a mutually exclusive treatment outcome at the end of treatment, but follow-up and care may need to go beyond the conclusion of TB",
      "extractCut": true
    },
    {
      "id": "sec-032-6-models-of-tb-care-for-children-and-adolescents",
      "number": "6",
      "title": "Models of TB care for children and adolescents",
      "level": 1,
      "pageStart": 157,
      "pageEnd": 157,
      "labelStart": "137",
      "labelEnd": "137",
      "words": 2,
      "summary": {
        "text": "A section heading fragment on models of TB care for children and adolescents.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "and adolescents",
      "extractCut": false
    },
    {
      "id": "sec-033-61-introduction",
      "number": "6.1",
      "title": "Introduction",
      "level": 2,
      "pageStart": 157,
      "pageEnd": 160,
      "labelStart": "137",
      "labelEnd": "140",
      "words": 1462,
      "summary": {
        "text": "Explains that TB care for children in high-burden countries is often centralized and poorly integrated with child health, nutrition and HIV services, leading to missed cases and delays. It cites the 2018 Roadmap's key action on community engagement. It then reproduces WHO recommendations on decentralized, family-centred and integrated care and on community-based, lay-provider and video-supported treatment support.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "conditional recommendation",
          "heading": false
        },
        {
          "term": "certainty evidence",
          "heading": false
        },
        {
          "term": "video-supported treatment",
          "heading": false
        },
        {
          "term": "moderate certainty",
          "heading": false
        },
        {
          "term": "treatment adherence",
          "heading": false
        },
        {
          "term": "treatment support",
          "heading": false
        },
        {
          "term": "tuberculosis treatment",
          "heading": false
        },
        {
          "term": "treatment administration",
          "heading": false
        }
      ],
      "extract": "In high TB burden countries, the capacity to manage TB in children and adolescents is often centralized at the tertiary or secondary level of health care rather than being decentralized at the PHC level where children and adolescents with TB or TB exposure commonly seek care (5, 157). Care at higher levels in the health system is often managed in a vertical, non-integrated way. Children and adolescents with TB may",
      "extractCut": true
    },
    {
      "id": "sec-034-62-decentralized-family-centred-integrated-tb-se",
      "number": "6.2",
      "title": "Decentralized, family-centred, integrated TB services",
      "level": 2,
      "pageStart": 160,
      "pageEnd": 174,
      "labelStart": "140",
      "labelEnd": "154",
      "words": 5680,
      "summary": {
        "text": "Explains what decentralizing child and adolescent TB services means and the interventions needed, such as training health workers, access to diagnostics and medicines, and follow-up. It describes a flexible approach for national programmes, health workforce tasks at each level of care in a table, and integration with other child health services. The section includes country examples, such as integrating childhood TB into IMNCI services in Addis Ababa with a sharp rise in contact screening and preventive treatment. It notes that services including gastric aspiration can be decentralized to primary care with supporting packages.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "district ntp",
          "heading": false
        },
        {
          "term": "phc level",
          "heading": false
        },
        {
          "term": "family-centred",
          "heading": true
        },
        {
          "term": "child contacts",
          "heading": false
        },
        {
          "term": "reach ntp",
          "heading": false
        },
        {
          "term": "phc facilities",
          "heading": false
        },
        {
          "term": "adolescents aged",
          "heading": false
        },
        {
          "term": "children aged",
          "heading": false
        }
      ],
      "extract": "services Decentralization includes the provision of, access to or capacity for child and adolescent TB services at a lower level of the health system than the lowest level where it is currently routinely provided. In most settings, decentralization applies to the district hospital level (first referral level), PHC level or community level. Interventions to facilitate decentralization include capacity-building of",
      "extractCut": true
    },
    {
      "id": "sec-035-63-private-sector-involvement-in-care-for-childr",
      "number": "6.3",
      "title": "Private-sector involvement in care for children and adolescents with TB",
      "level": 2,
      "pageStart": 174,
      "pageEnd": 178,
      "labelStart": "154",
      "labelEnd": "158",
      "words": 2000,
      "summary": {
        "text": "Explains that many children with TB first seek care from private providers and that national programmes must engage the private sector. It sets out key actions from the WHO public–private mix roadmap applied to child TB, such as mapping providers, setting targets, funding and working with paediatric associations. A case study from India describes linking over 1100 children treated by private providers to free public fixed-dose combinations, with the proportion rising from 29% to 65%. It also notes challenges such as treatment delays, pharmacy hours and pill burden.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "private-sector",
          "heading": true
        },
        {
          "term": "private-sector medicines",
          "heading": false
        },
        {
          "term": "private providers",
          "heading": false
        },
        {
          "term": "private sector",
          "heading": false
        },
        {
          "term": "private mix",
          "heading": false
        },
        {
          "term": "public fdcs",
          "heading": false
        },
        {
          "term": "private facilities",
          "heading": false
        },
        {
          "term": "private health",
          "heading": false
        }
      ],
      "extract": "and adolescents with TB 6.3.1. Background In many high TB burden countries, the majority of missing people with TB, including children, seek treatment from private providers or other care providers not linked to the public sector at least once (174). The private sector is also a common point of care for children presenting with common illnesses, such as cough, fever and diarrhoea, especially in countries with a",
      "extractCut": true
    },
    {
      "id": "sec-036-64-differentiated-tb-service-delivery",
      "number": "6.4",
      "title": "Differentiated TB service delivery",
      "level": 2,
      "pageStart": 178,
      "pageEnd": 182,
      "labelStart": "158",
      "labelEnd": "162",
      "words": 1616,
      "summary": {
        "text": "Introduces differentiated service delivery, a people-centred approach developed for HIV care, and how it can be applied to TB services for children and adolescents. It discusses aligning TB treatment and preventive therapy with multimonth antiretroviral dispensing and family-centred care, while noting risks of fewer screening opportunities. Illustrated examples show models for children receiving TB preventive treatment, such as a child contact of a caregiver with HIV and TB supported by SMS.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "dsd models",
          "heading": false
        },
        {
          "term": "orange bars",
          "heading": false
        },
        {
          "term": "initiates tpt",
          "heading": false
        },
        {
          "term": "clinic visit",
          "heading": false
        },
        {
          "term": "art clinic",
          "heading": false
        },
        {
          "term": "orange bar",
          "heading": false
        },
        {
          "term": "orange solid",
          "heading": false
        },
        {
          "term": "striped orange",
          "heading": false
        }
      ],
      "extract": "6.4.1. Background The concept of DSD (previously referred to as differentiated care) is increasingly being applied during the provision of comprehensive HIV services (78). In the context of HIV, DSD is a people-centred approach that simplifies and adapts HIV services to better serve the needs of people living with HIV and to optimize the available resources in health systems. DSD is premised on the fact that",
      "extractCut": true
    },
    {
      "id": "sec-037-65-tb-and-health-emergencies",
      "number": "6.5",
      "title": "TB and health emergencies",
      "level": 2,
      "pageStart": 182,
      "pageEnd": 185,
      "labelStart": "162",
      "labelEnd": "165",
      "words": 912,
      "summary": {
        "text": "Describes how health emergencies such as COVID-19 disrupted TB services, citing the fall in notified TB cases from 7.1 million in 2019 to 5.8 million in 2020. It discusses the direct and indirect effects of emergencies on child and adolescent TB services and outlines measures to maintain care. It concludes that mitigation approaches should take account of the particular needs of children and adolescents with or exposed to TB.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "health emergencies",
          "heading": true
        },
        {
          "term": "covid pandemic",
          "heading": false
        },
        {
          "term": "children aged",
          "heading": false
        },
        {
          "term": "tb-related deaths",
          "heading": false
        },
        {
          "term": "aged years",
          "heading": false
        },
        {
          "term": "tpt",
          "heading": false
        },
        {
          "term": "innovative approaches",
          "heading": false
        },
        {
          "term": "invasive sample",
          "heading": false
        }
      ],
      "extract": "Health emergencies, such as the COVID-19 pandemic, are associated with a disruption in health service delivery, either directly due to the focused attention given to the emergency or indirectly due to measures implemented to control the emergency. The COVID-19 pandemic has reversed years of progress in providing essential TB services and reducing the disease burden of TB. There has been a large global drop in the",
      "extractCut": true
    },
    {
      "id": "sec-038-7-special-situations",
      "number": "7",
      "title": "Special situations",
      "level": 1,
      "pageStart": 185,
      "pageEnd": 185,
      "labelStart": "165",
      "labelEnd": "165",
      "words": 18,
      "summary": {
        "text": "Introduces the chapter on special situations in managing TB in children and adolescents.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "This chapter covers a range of special situations related to the management of TB in children and adolescents:",
      "extractCut": false
    },
    {
      "id": "sec-039-71-management-of-tb-in-children-and-adolescents",
      "number": "7.1",
      "title": "Management of TB in children and adolescents living with HIV",
      "level": 2,
      "pageStart": 185,
      "pageEnd": 196,
      "labelStart": "165",
      "labelEnd": "176",
      "words": 5380,
      "summary": {
        "text": "Lists the special situations covered in the chapter and opens section 7.1 on TB in children and adolescents living with HIV, who face higher risks of TB infection, disease and death. It covers HIV testing recommendations, TB screening with symptom screening and chest radiography, and prevention through preventive treatment for household contacts. Later parts address treatment and co-management with antiretroviral therapy. It ends with guidance on recognising and managing TB immune reconstitution inflammatory syndrome, including when to continue treatment, use anti-inflammatory drugs or refer.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "adolescents living",
          "heading": true
        },
        {
          "term": "children living",
          "heading": true
        },
        {
          "term": "dtg ral",
          "heading": false
        },
        {
          "term": "lpv r-based",
          "heading": false
        },
        {
          "term": "ral dose",
          "heading": false
        },
        {
          "term": "dtg dosing",
          "heading": false
        },
        {
          "term": "tdf efv",
          "heading": false
        },
        {
          "term": "dose adjustment",
          "heading": false
        }
      ],
      "extract": "• Section 7.2: TB in pregnancy and management of newborns of mothers with TB disease; • Section 7.3: palliative care for children and adolescents with TB; • Section 7.4: care for adolescents with or at risk of TB; • Section 7.5: TB in children with pneumonia; • Section 7.6: management of children with TB and malnutrition. 7.1. Management of TB in children and adolescents living with HIV This section outlines how to",
      "extractCut": true
    },
    {
      "id": "sec-040-72-tb-in-pregnancy-and-management-of-newborns-of",
      "number": "7.2",
      "title": "TB in pregnancy and management of newborns of mothers with TB disease",
      "level": 2,
      "pageStart": 196,
      "pageEnd": 199,
      "labelStart": "176",
      "labelEnd": "179",
      "words": 1512,
      "summary": {
        "text": "Describes the contribution of TB to maternal mortality and adverse pregnancy and perinatal outcomes, and covers TB screening for pregnant women living with HIV with a table of screening tool accuracy. It then addresses diagnosis and management of congenital and neonatal TB. It closes with care for well newborns of mothers with TB, including preventive treatment, referral for MDR/RR-TB exposure and infection control.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "neonates born",
          "heading": false
        },
        {
          "term": "neonates exposed",
          "heading": false
        },
        {
          "term": "non-pregnant women",
          "heading": false
        },
        {
          "term": "pregnant women",
          "heading": false
        },
        {
          "term": "postpartum women",
          "heading": false
        },
        {
          "term": "pregnancy",
          "heading": true
        },
        {
          "term": "weight gain",
          "heading": false
        },
        {
          "term": "women living",
          "heading": false
        }
      ],
      "extract": "of mothers with TB disease TB contributes to 6–15% of all maternal mortality and leads to adverse pregnancy outcomes (187). A national registry study found incidence rate ratios for TB in pregnant and postpartum women of 1.4 and 1.9, respectively, compared with non-pregnant women (188). TB in pregnancy is associated with adverse maternal outcomes and complications during birth, such as pre-eclampsia, eclampsia,",
      "extractCut": true
    },
    {
      "id": "sec-041-73-palliative-care-for-children-and-adolescents",
      "number": "7.3",
      "title": "Palliative care for children and adolescents with TB",
      "level": 2,
      "pageStart": 199,
      "pageEnd": 203,
      "labelStart": "179",
      "labelEnd": "183",
      "words": 1711,
      "summary": {
        "text": "Covers palliative care for children and adolescents with TB, starting from the 2014 World Health Assembly resolution calling for better access to palliative care. It describes circumstances in which children with TB may need palliative care and actions to make it available. A table gives examples of managing symptoms such as breathlessness and cough in children with advanced lung disease.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "children palliative",
          "heading": true
        },
        {
          "term": "palliative care",
          "heading": true
        },
        {
          "term": "paediatric palliative",
          "heading": false
        },
        {
          "term": "providing palliative",
          "heading": false
        },
        {
          "term": "require palliative",
          "heading": false
        },
        {
          "term": "mdr rr-tb",
          "heading": false
        },
        {
          "term": "end-of-life care",
          "heading": false
        },
        {
          "term": "pain management",
          "heading": false
        }
      ],
      "extract": "7.3.1. Introduction In 2014, World Health Assembly Resolution WHA67.19 called upon WHO and Member States to improve access to palliative care as a core component of health systems, with an emphasis on PHC and community- and home-based care (197). WHO is supporting integration of palliative care into all relevant global disease control and health system plans and is promoting improved access to palliative care for",
      "extractCut": true
    },
    {
      "id": "sec-042-74-care-for-adolescents-with-or-at-risk-of-tb",
      "number": "7.4",
      "title": "Care for adolescents with or at risk of TB",
      "level": 2,
      "pageStart": 203,
      "pageEnd": 208,
      "labelStart": "183",
      "labelEnd": "188",
      "words": 2173,
      "summary": {
        "text": "Describes the needs of adolescents with TB, who often have infectious adult-type disease and face stigma, peer pressure, comorbidities and risk behaviours. Sections follow a framework of physical and mental health, connectedness, safety and support, education and skills, agency and resilience, and substance use with late presentation to care. Each area sets out actions for adolescent-friendly services. The block ends by calling for collaboration with other sectors on basic needs such as food security and continued schooling.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "adolescents",
          "heading": true
        },
        {
          "term": "adolescents aged",
          "heading": false
        },
        {
          "term": "treatment adherence",
          "heading": false
        },
        {
          "term": "good-quality adolescent",
          "heading": false
        },
        {
          "term": "adolescent engagement",
          "heading": false
        },
        {
          "term": "tb-related stigma",
          "heading": false
        },
        {
          "term": "among adolescents",
          "heading": false
        },
        {
          "term": "some adolescents",
          "heading": false
        }
      ],
      "extract": "Adolescents with TB often present with bacteriologically infectious disease typical in adults (e.g. cavities seen on CXR) and therefore pose a high risk for transmission in households and congregate settings such as schools. Adolescents face unique challenges due to peer pressure and fear of stigma, increasing prevalence of comorbidities such as HIV, and risk behaviours such as use of alcohol, tobacco and other",
      "extractCut": true
    },
    {
      "id": "sec-043-75-tb-in-children-with-severe-acute-pneumonia",
      "number": "7.5",
      "title": "TB in children with severe acute pneumonia",
      "level": 2,
      "pageStart": 208,
      "pageEnd": 210,
      "labelStart": "188",
      "labelEnd": "190",
      "words": 988,
      "summary": {
        "text": "Discusses TB as a cause or comorbidity of severe pneumonia in young children, citing a systematic review finding TB in about 5-10% of under-fives with pneumonia in endemic countries. It notes that clinical features have low specificity, and includes boxes on implications for implementation and findings of the TB-Speed Pneumonia study on Xpert Ultra testing.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "severe pneumonia",
          "heading": true
        },
        {
          "term": "tb-speed pneumonia",
          "heading": false
        },
        {
          "term": "recurrent pneumonia",
          "heading": false
        },
        {
          "term": "pneumonia study",
          "heading": false
        },
        {
          "term": "children",
          "heading": true
        },
        {
          "term": "intervention arm",
          "heading": false
        },
        {
          "term": "control arm",
          "heading": false
        },
        {
          "term": "children presenting",
          "heading": false
        }
      ],
      "extract": "TB is a common cause or comorbidity in children with clinically diagnosed pneumonia. A systematic review on TB in acute respiratory infection found that M. tuberculosis was identified in around 5–10% of children with pneumonia aged under 5 years in TB endemic countries (223). Limited data from clinical and autopsy studies suggest that TB was also associated with mortality in these children. Prevalence studies,",
      "extractCut": true
    },
    {
      "id": "sec-044-76-management-of-children-with-tb-and-malnutriti",
      "number": "7.6",
      "title": "Management of children with TB and malnutrition",
      "level": 2,
      "pageStart": 210,
      "pageEnd": 217,
      "labelStart": "190",
      "labelEnd": "197",
      "words": 2413,
      "summary": {
        "text": "Explains the two-way link between undernutrition and TB in children, citing estimates that about 19% of TB cases are attributable to undernourishment and varied TB prevalence among acutely malnourished children. It covers diagnosis and treatment of TB in malnourished children and nutritional care for children and adolescents with TB. Key points include evaluating children with severe acute malnutrition who fail to gain weight for TB and using a 6-month regimen for them.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "malnutrition",
          "heading": true
        },
        {
          "term": "therapeutic nutritional",
          "heading": false
        },
        {
          "term": "moderate undernutrition",
          "heading": false
        },
        {
          "term": "nutritional treatment",
          "heading": false
        },
        {
          "term": "nutritional supplementation",
          "heading": false
        },
        {
          "term": "severe malnutrition",
          "heading": false
        },
        {
          "term": "nutritional care",
          "heading": false
        },
        {
          "term": "acute malnutrition",
          "heading": false
        }
      ],
      "extract": "malnutrition 7.6.1. Introduction By reducing cell-mediated immunity, undernutrition increases the risk of TB, while the catabolic effect of TB disease results in weight loss and wasting, creating a vicious cycle (105, 228). Globally, about 45% of deaths in children aged under 5 years are attributable to undernutrition (228). Undernutrition may be acute or chronic and categorized as moderate or severe. Data from the",
      "extractCut": true
    },
    {
      "id": "sec-045-8-references",
      "number": "8",
      "title": "References",
      "level": 1,
      "pageStart": 217,
      "pageEnd": 231,
      "labelStart": "197",
      "labelEnd": "211",
      "words": 5910,
      "summary": {
        "text": "The reference list for the operational handbook on managing TB in children and adolescents, with 230 citations including WHO TB reports and guidelines and studies on paediatric TB, HIV, pregnancy and malnutrition.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "accessed december",
          "heading": false
        },
        {
          "term": "infect dis",
          "heading": false
        },
        {
          "term": "lung dis",
          "heading": false
        },
        {
          "term": "tuberc lung",
          "heading": false
        },
        {
          "term": "lancet infect",
          "heading": false
        },
        {
          "term": "clin infect",
          "heading": false
        },
        {
          "term": "accessed march",
          "heading": false
        },
        {
          "term": "pediatr infect",
          "heading": false
        }
      ],
      "extract": "1. Global tuberculosis report 2021. Geneva: World Health Organization; 2021 (https://apps.who.int/iris/ handle/10665/346387, accessed 1 December 2021). 2. Snow KJ, Sismanidis C, Denholm J, et al. The incidence of tuberculosis among adolescents and young adults: a global estimate. Eur Respir J. 2018;51(2):1702352. 3. WHO consolidated guidelines on tuberculosis. Module 5: management of tuberculosis in children and",
      "extractCut": true
    },
    {
      "id": "sec-046-annex-1-selected-resources-on-child-and-adolesce",
      "number": null,
      "title": "Annex 1. Selected resources on child and adolescent TB",
      "level": 1,
      "pageStart": 231,
      "pageEnd": 234,
      "labelStart": "211",
      "labelEnd": "214",
      "words": 730,
      "summary": {
        "text": "An annex listing selected resources on child and adolescent TB, including the WHO roadmap, operational handbooks, training materials and research and implementation projects such as TB-Speed.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "uploads tb-speed",
          "heading": false
        },
        {
          "term": "uploads pipeline",
          "heading": false
        },
        {
          "term": "wp-content uploads",
          "heading": false
        },
        {
          "term": "org wp-content",
          "heading": false
        },
        {
          "term": "tuberculosis treatment",
          "heading": false
        },
        {
          "term": "expansion childhoodtb",
          "heading": false
        },
        {
          "term": "adolescent",
          "heading": true
        },
        {
          "term": "paediatric tuberculosis",
          "heading": false
        }
      ],
      "extract": "Annex 1. Selected resources on child and adolescent TB Roadmap Roadmap towards ending TB in children and adolescents, second edition. Geneva: World Health Organization; 2018 (https://apps.who.int/iris/bitstream/handle/10665/275422/9789241514798-eng. pdf?sequence=1&isAllowed=y). WHO operational handbooks WHO operational handbook on tuberculosis. Module 1: prevention – tuberculosis preventive treatment. Geneva: World",
      "extractCut": true
    },
    {
      "id": "sec-047-annex-2-tuberculin-skin-testing-administration-r",
      "number": null,
      "title": "Annex 2. Tuberculin skin testing: administration, reading and interpretation",
      "level": 1,
      "pageStart": 234,
      "pageEnd": 237,
      "labelStart": "214",
      "labelEnd": "217",
      "words": 1324,
      "summary": {
        "text": "An annex explaining how to give, read and interpret a tuberculin skin test by the Mantoux method using 5 tuberculin units. It covers the injection technique, measuring induration and thresholds for a positive result. It also discusses causes of false-positive and false-negative results.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tuberculin skin",
          "heading": true
        },
        {
          "term": "inject tuberculin",
          "heading": false
        },
        {
          "term": "widest edges",
          "heading": false
        },
        {
          "term": "induration across",
          "heading": false
        },
        {
          "term": "ruler line",
          "heading": false
        },
        {
          "term": "fine line",
          "heading": false
        },
        {
          "term": "ballpoint pen",
          "heading": false
        },
        {
          "term": "forearm",
          "heading": false
        }
      ],
      "extract": "administration, reading and interpretation This annex provides information on administering, reading and interpreting tuberculin skin tests (TSTs). A TST is the intradermal injection of a combination of mycobacterial antigens that elicit a delayed-type hypersensitivity immune response, represented by induration, which can be measured in millimetres. The standard method of identifying people infected with",
      "extractCut": true
    },
    {
      "id": "sec-048-annex-3-sample-collection-methods",
      "number": null,
      "title": "Annex 3. Sample collection methods",
      "level": 1,
      "pageStart": 237,
      "pageEnd": 240,
      "labelStart": "217",
      "labelEnd": "220",
      "words": 706,
      "summary": {
        "text": "An annex describing respiratory and non-respiratory specimens for diagnosing TB in children and adolescents, with tables giving each procedure, suitable age group, minimum volume and best collection time.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "gastric aspirate",
          "heading": false
        },
        {
          "term": "aspirate lavage",
          "heading": false
        },
        {
          "term": "bacteriological yield",
          "heading": false
        },
        {
          "term": "nasopharyngeal aspirate",
          "heading": false
        },
        {
          "term": "aspiration biopsy",
          "heading": false
        },
        {
          "term": "sample collection",
          "heading": true
        },
        {
          "term": "fine-needle aspiration",
          "heading": false
        },
        {
          "term": "collection methods",
          "heading": true
        }
      ],
      "extract": "Annex 3. Sample collection methods This annex provides an overview of respiratory and non-respiratory specimens that can be used to diagnose TB in children and adolescents, with a short description for each, the age group in which they can be used, the minimum volume required for testing, and the optimal time of collection. Table A3.1. Respiratory specimens Specimen Description of procedure Age group Minimum volume",
      "extractCut": true
    },
    {
      "id": "sec-049-annex-4-standard-operating-procedures-for-sample",
      "number": null,
      "title": "Annex 4. Standard operating procedures for sample collection methods",
      "level": 1,
      "pageStart": 240,
      "pageEnd": 247,
      "labelStart": "220",
      "labelEnd": "227",
      "words": 3001,
      "summary": {
        "text": "An annex giving standard operating procedures for collecting samples from children for rapid molecular TB testing by expectoration, gastric aspiration, nasopharyngeal aspiration and sputum induction. It opens with biosafety and infection-control precautions for these aerosol-generating procedures, such as dedicated ventilated rooms, respirators and disinfection. Each method then has a background note and step-by-step instructions for preparing the child, carrying out the procedure and handling the specimen. The annex closes with advice on obtaining specimens from young children who cannot expectorate and on sterilizing reusable equipment.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "nasogastric catheter",
          "heading": false
        },
        {
          "term": "nasogastric tube",
          "heading": false
        },
        {
          "term": "sterile saline",
          "heading": false
        },
        {
          "term": "sterile container",
          "heading": false
        },
        {
          "term": "hypertonic saline",
          "heading": false
        },
        {
          "term": "sputum container",
          "heading": false
        },
        {
          "term": "operating procedures",
          "heading": true
        },
        {
          "term": "specimen container",
          "heading": false
        }
      ],
      "extract": "procedures for sample collection methods This annex provides examples of standard operating procedures for the most common methods of obtaining clinical samples from children for rapid molecular testing: expectoration, gastric aspiration, nasopharyngeal aspiration (NPA) and sputum induction. Biosafety and infection prevention and control practices to be followed during cough-inducing and aerosol-generating",
      "extractCut": true
    },
    {
      "id": "sec-050-annex-5-treatment-decision-algorithms",
      "number": null,
      "title": "Annex 5. Treatment decision algorithms",
      "level": 1,
      "pageStart": 247,
      "pageEnd": 254,
      "labelStart": "227",
      "labelEnd": "234",
      "words": 2804,
      "summary": {
        "text": "An annex presenting treatment decision algorithms for children under 10 with suspected pulmonary TB, starting with how the scoring models were built from pooled individual patient data and set at 85% sensitivity. It explains the triage steps for danger signs, high-risk children and rapid molecular testing that come before scoring. Two algorithms are shown, one for settings with chest X-ray and one without, assigning points to symptoms and radiographic features with a threshold of more than 10 for starting treatment. Operational guidance follows, including age-specific definitions of signs such as fast breathing and a worked scoring example.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "decision algorithms",
          "heading": true
        },
        {
          "term": "treatment decision",
          "heading": true
        },
        {
          "term": "swollen lymph",
          "heading": false
        },
        {
          "term": "beats minute",
          "heading": false
        },
        {
          "term": "lymph nodes",
          "heading": false
        },
        {
          "term": "cxr features",
          "heading": false
        },
        {
          "term": "child aged",
          "heading": false
        },
        {
          "term": "children aged",
          "heading": false
        }
      ],
      "extract": "algorithms Methodology for developing the treatment decision algorithms Individual-level participant diagnostic evaluations and outcome data in children aged under 10 years presenting for evaluation of PTB were solicited from studies carried out in geographically diverse high TB burden settings. Missing data were imputed using multiple imputations by chained equations. Prediction models were built to classify",
      "extractCut": true
    },
    {
      "id": "sec-051-annex-6-dosing-of-medicines-used-in-second-line",
      "number": null,
      "title": "Annex 6. Dosing of medicines used in second-line multidrug-resistant TB regimens by weight band (below 46 kg)a",
      "level": 1,
      "pageStart": 254,
      "pageEnd": 260,
      "labelStart": "234",
      "labelEnd": "240",
      "words": 2697,
      "summary": {
        "text": "An annex tabulating weight-band dosing of second-line medicines for multidrug-resistant TB in children and adolescents under 46 kg, grouped as in WHO regimens. Introductory notes cover preferring child-friendly dispersible tablets, dissolving tablets in water to give measured volumes, and seeking expert advice for infants. The table gives daily doses, formulations and usual maximum doses for drugs such as levofloxacin, moxifloxacin, bedaquiline and linezolid. Footnotes explain special cases, including pyridoxine use and giving carbapenems only with clavulanate.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "weight band",
          "heading": true
        },
        {
          "term": "amoxicillin clavulanate",
          "heading": false
        },
        {
          "term": "tab",
          "heading": false
        },
        {
          "term": "dispersible tablets",
          "heading": false
        },
        {
          "term": "weeks months",
          "heading": false
        },
        {
          "term": "dosing",
          "heading": true
        },
        {
          "term": "crushed adult",
          "heading": false
        },
        {
          "term": "children weighing",
          "heading": false
        }
      ],
      "extract": "multidrug-resistant TB regimens by weight band (below 46 kg)a • Dosing guidance is based on currently available data and may be revised once additional data are available. • For patients weighing ≥46 kg, please refer to Table A in Annex 1 of the WHO operational handbook on tuberculosis. Module 4: treatment – drug-resistant tuberculosis: Dosing of medicines used in second-line multidrug-resistant TB regimens by",
      "extractCut": true
    },
    {
      "id": "sec-052-annex-7-overview-of-options-for-neurocognitive-a",
      "number": null,
      "title": "Annex 7. Overview of options for neurocognitive and functional testing at end of treatment for TB meningitis",
      "level": 1,
      "pageStart": 260,
      "pageEnd": 264,
      "labelStart": "240",
      "labelEnd": "244",
      "words": 385,
      "summary": {
        "text": "An annex table listing tools and timing for neurodevelopmental, neurocognitive, functional and behavioural testing of children at the end of TB meningitis treatment. It notes that these tools are not adapted for low- and middle-income countries and closes with sources and WHO contact details.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "neurocognitive",
          "heading": true
        },
        {
          "term": "functional testing",
          "heading": true
        },
        {
          "term": "throughout schooling",
          "heading": false
        },
        {
          "term": "meningitis",
          "heading": true
        },
        {
          "term": "range years",
          "heading": false
        },
        {
          "term": "age range",
          "heading": false
        },
        {
          "term": "range months",
          "heading": false
        },
        {
          "term": "san antonio",
          "heading": false
        }
      ],
      "extract": "neurocognitive and functional testing at end of treatment for TB meningitis Table A7.1. Options for neurocognitive and functional testing at end of treatment for TB meningitis Outcome Measure Timing Neurodevelopmental Minimal: • Ages and Stages Questionnaire (age range 0–5 years) a Optimal: • Bailey Scale of Infant Development, 3rd edition (age range 1–42 months) b • Mullen Scale Early Learning (age range 0–68",
      "extractCut": true
    }
  ],
  "checks": {
    "tocAlignment": {
      "listed_not_found": {
        "count": 0,
        "items": []
      },
      "found_not_listed": {
        "count": 0,
        "items": []
      },
      "page_mismatch": {
        "count": 0,
        "items": []
      }
    },
    "figureSequenceGaps": [
      "figure 2.5",
      "figure 2.6",
      "table 5.6",
      "table 5.9"
    ],
    "pageLabelConflicts": {
      "count": 0,
      "items": []
    }
  },
  "withheld": false,
  "keywords": [
    {
      "term": "children aged",
      "heading": false
    },
    {
      "term": "children tuberculosis",
      "heading": false
    },
    {
      "term": "children years",
      "heading": false
    },
    {
      "term": "adolescents aged",
      "heading": false
    },
    {
      "term": "children living",
      "heading": true
    },
    {
      "term": "screening children",
      "heading": true
    },
    {
      "term": "young children",
      "heading": false
    },
    {
      "term": "children treated",
      "heading": false
    },
    {
      "term": "children diagnosed",
      "heading": false
    },
    {
      "term": "tuberculosis treatment",
      "heading": false
    },
    {
      "term": "child aged",
      "heading": false
    },
    {
      "term": "among children",
      "heading": false
    }
  ],
  "pageLabels": [
    {
      "physical": 1,
      "label": "a",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 2,
      "label": "b",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 3,
      "label": "i",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 4,
      "label": "ii",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 5,
      "label": "iii",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 6,
      "label": "iv",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 7,
      "label": "v",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 8,
      "label": "vi",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 9,
      "label": "vii",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 10,
      "label": "viii",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 11,
      "label": "ix",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 12,
      "label": "x",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 13,
      "label": "xi",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 14,
      "label": "xii",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 15,
      "label": "xiii",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 16,
      "label": "xiv",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 17,
      "label": "xv",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 18,
      "label": "xvi",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 19,
      "label": "xvii",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 20,
      "label": "xviii",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 21,
      "label": "1",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 22,
      "label": "2",
      "source": "pdf-labels",
      "confidence": 1
    },
    {
      "physical": 23,
      "label": "3",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 24,
      "label": "4",
      "source": "pdf-labels",
      "confidence": 1
    },
    {
      "physical": 25,
      "label": "5",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 26,
      "label": "6",
      "source": "pdf-labels",
      "confidence": 1
    },
    {
      "physical": 27,
      "label": "7",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 28,
      "label": "8",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 29,
      "label": "9",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 30,
      "label": "10",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 31,
      "label": "11",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 32,
      "label": "12",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 33,
      "label": "13",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 34,
      "label": "14",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 35,
      "label": "15",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 36,
      "label": "16",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 37,
      "label": "17",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 38,
      "label": "18",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 39,
      "label": "19",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 40,
      "label": "20",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 41,
      "label": "21",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 42,
      "label": "22",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 43,
      "label": "23",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 44,
      "label": "24",
      "source": "pdf-labels",
      "confidence": 1
    },
    {
      "physical": 45,
      "label": "25",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 46,
      "label": "26",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 47,
      "label": "27",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 48,
      "label": "28",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 49,
      "label": "29",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 50,
      "label": "30",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 51,
      "label": "31",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 52,
      "label": "32",
      "source": "pdf-labels",
      "confidence": 1
    },
    {
      "physical": 53,
      "label": "33",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 54,
      "label": "34",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 55,
      "label": "35",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 56,
      "label": "36",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 57,
      "label": "37",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 58,
      "label": "38",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 59,
      "label": "39",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 60,
      "label": "40",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 61,
      "label": "41",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 62,
      "label": "42",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 63,
      "label": "43",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 64,
      "label": "44",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 65,
      "label": "45",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 66,
      "label": "46",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 67,
      "label": "47",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 68,
      "label": "48",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 69,
      "label": "49",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 70,
      "label": "50",
      "source": "pdf-labels",
      "confidence": 1
    },
    {
      "physical": 71,
      "label": "51",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 72,
      "label": "52",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 73,
      "label": "53",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 74,
      "label": "54",
      "source": "pdf-labels",
      "confidence": 1
    },
    {
      "physical": 75,
      "label": "55",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 76,
      "label": "56",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 77,
      "label": "57",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 78,
      "label": "58",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 79,
      "label": "59",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 80,
      "label": "60",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 81,
      "label": "61",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 82,
      "label": "62",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 83,
      "label": "63",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 84,
      "label": "64",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 85,
      "label": "65",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 86,
      "label": "66",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 87,
      "label": "67",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 88,
      "label": "68",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 89,
      "label": "69",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 90,
      "label": "70",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 91,
      "label": "71",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 92,
      "label": "72",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 93,
      "label": "73",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 94,
      "label": "74",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 95,
      "label": "75",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 96,
      "label": "76",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 97,
      "label": "77",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 98,
      "label": "78",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 99,
      "label": "79",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 100,
      "label": "80",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 101,
      "label": "81",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 102,
      "label": "82",
      "source": "pdf-labels",
      "confidence": 1
    },
    {
      "physical": 103,
      "label": "83",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 104,
      "label": "84",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 105,
      "label": "85",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 106,
      "label": "86",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 107,
      "label": "87",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 108,
      "label": "88",
      "source": "pdf-labels",
      "confidence": 1
    },
    {
      "physical": 109,
      "label": "89",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 110,
      "label": "90",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 111,
      "label": "91",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 112,
      "label": "92",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 113,
      "label": "93",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 114,
      "label": "94",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 115,
      "label": "95",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 116,
      "label": "96",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 117,
      "label": "97",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 118,
      "label": "98",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 119,
      "label": "99",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 120,
      "label": "100",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 121,
      "label": "101",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 122,
      "label": "102",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 123,
      "label": "103",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 124,
      "label": "104",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 125,
      "label": "105",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 126,
      "label": "106",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 127,
      "label": "107",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 128,
      "label": "108",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 129,
      "label": "109",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 130,
      "label": "110",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 131,
      "label": "111",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 132,
      "label": "112",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 133,
      "label": "113",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 134,
      "label": "114",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 135,
      "label": "115",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 136,
      "label": "116",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 137,
      "label": "117",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 138,
      "label": "118",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 139,
      "label": "119",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 140,
      "label": "120",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 141,
      "label": "121",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 142,
      "label": "122",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 143,
      "label": "123",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 144,
      "label": "124",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 145,
      "label": "125",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 146,
      "label": "126",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 147,
      "label": "127",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 148,
      "label": "128",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 149,
      "label": "129",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 150,
      "label": "130",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 151,
      "label": "131",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 152,
      "label": "132",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 153,
      "label": "133",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 154,
      "label": "134",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 155,
      "label": "135",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 156,
      "label": "136",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 157,
      "label": "137",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 158,
      "label": "138",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 159,
      "label": "139",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 160,
      "label": "140",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 161,
      "label": "141",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 162,
      "label": "142",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 163,
      "label": "143",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 164,
      "label": "144",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 165,
      "label": "145",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 166,
      "label": "146",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 167,
      "label": "147",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 168,
      "label": "148",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 169,
      "label": "149",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 170,
      "label": "150",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 171,
      "label": "151",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 172,
      "label": "152",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 173,
      "label": "153",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 174,
      "label": "154",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 175,
      "label": "155",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 176,
      "label": "156",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 177,
      "label": "157",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 178,
      "label": "158",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 179,
      "label": "159",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 180,
      "label": "160",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 181,
      "label": "161",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 182,
      "label": "162",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 183,
      "label": "163",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 184,
      "label": "164",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 185,
      "label": "165",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 186,
      "label": "166",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 187,
      "label": "167",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 188,
      "label": "168",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 189,
      "label": "169",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 190,
      "label": "170",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 191,
      "label": "171",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 192,
      "label": "172",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 193,
      "label": "173",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 194,
      "label": "174",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 195,
      "label": "175",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 196,
      "label": "176",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 197,
      "label": "177",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 198,
      "label": "178",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 199,
      "label": "179",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 200,
      "label": "180",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 201,
      "label": "181",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 202,
      "label": "182",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 203,
      "label": "183",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 204,
      "label": "184",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 205,
      "label": "185",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 206,
      "label": "186",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 207,
      "label": "187",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 208,
      "label": "188",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 209,
      "label": "189",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 210,
      "label": "190",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 211,
      "label": "191",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 212,
      "label": "192",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 213,
      "label": "193",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 214,
      "label": "194",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 215,
      "label": "195",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 216,
      "label": "196",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 217,
      "label": "197",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 218,
      "label": "198",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 219,
      "label": "199",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 220,
      "label": "200",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 221,
      "label": "201",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 222,
      "label": "202",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 223,
      "label": "203",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 224,
      "label": "204",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 225,
      "label": "205",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 226,
      "label": "206",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 227,
      "label": "207",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 228,
      "label": "208",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 229,
      "label": "209",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 230,
      "label": "210",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 231,
      "label": "211",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 232,
      "label": "212",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 233,
      "label": "213",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 234,
      "label": "214",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 235,
      "label": "215",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 236,
      "label": "216",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 237,
      "label": "217",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 238,
      "label": "218",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 239,
      "label": "219",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 240,
      "label": "220",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 241,
      "label": "221",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 242,
      "label": "222",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 243,
      "label": "223",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 244,
      "label": "224",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 245,
      "label": "225",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 246,
      "label": "226",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 247,
      "label": "227",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 248,
      "label": "228",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 249,
      "label": "229",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 250,
      "label": "230",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 251,
      "label": "231",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 252,
      "label": "232",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 253,
      "label": "233",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 254,
      "label": "234",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 255,
      "label": "235",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 256,
      "label": "236",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 257,
      "label": "237",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 258,
      "label": "238",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 259,
      "label": "239",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 260,
      "label": "240",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 261,
      "label": "241",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 262,
      "label": "242",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 263,
      "label": "243",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 264,
      "label": "244",
      "source": "pdf-labels",
      "confidence": 0.7
    }
  ],
  "figures": [
    {
      "kind": "figure",
      "number": "1.1",
      "title": "Pathway through TB exposure, infection and disease",
      "page": 23,
      "pageLabel": "3",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "figure",
      "number": "2.1",
      "title": "Pathway through exposure, infection and disease covered in Chapter 2",
      "page": 26,
      "pageLabel": "6",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "figure",
      "number": "2.2",
      "title": "Costing items to strengthen contact investigation",
      "page": 29,
      "pageLabel": "9",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "figure",
      "number": "2.3",
      "title": "Algorithm for TB screening in children with symptoms",
      "page": 40,
      "pageLabel": "20",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "figure",
      "number": "2.4",
      "title": "Algorithm for TB screening of children with chest-X-ray",
      "page": 41,
      "pageLabel": "21",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "figure",
      "number": "2.7",
      "title": "Algorithm for sequential negative serial TB screening in children with",
      "page": 43,
      "pageLabel": "23",
      "confidence": 0.6,
      "evidence": [
        "graphic"
      ]
    },
    {
      "kind": "figure",
      "number": "2.8",
      "title": "Algorithm for TB screening of children living with HIV with symptoms",
      "page": 44,
      "pageLabel": "24",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "graphic"
      ]
    },
    {
      "kind": "figure",
      "number": "3.1",
      "title": "Pathway through exposure, infection and disease covered in Chapter 3",
      "page": 47,
      "pageLabel": "27",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "figure",
      "number": "3.2",
      "title": "Injection techniques",
      "page": 49,
      "pageLabel": "29",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "figure",
      "number": "3.3",
      "title": "Administering BCG injection",
      "page": 50,
      "pageLabel": "30",
      "confidence": 0.7,
      "evidence": [
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "table",
      "number": "3.1",
      "title": "TB preventive treatment options",
      "page": 60,
      "pageLabel": "40",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "3.2",
      "title": "Dosing for recommended TB preventive treatment regimens",
      "page": 62,
      "pageLabel": "42",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "3.3",
      "title": "Dosing recommendations for use of levofloxacin as TB preventive treatment",
      "page": 64,
      "pageLabel": "44",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "3.4",
      "title": "TB preventive treatment completion criteria",
      "page": 67,
      "pageLabel": "47",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "figure",
      "number": "4.1",
      "title": "Pathway through exposure, infection and disease covered in Chapter 4",
      "page": 73,
      "pageLabel": "53",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "figure",
      "number": "4.2",
      "title": "Differentiated cough patterns",
      "page": 75,
      "pageLabel": "55",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "figure",
      "number": "4.3",
      "title": "Examples of abnormal growth curves",
      "page": 77,
      "pageLabel": "57",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "table",
      "number": "4.1",
      "title": "WHO-approved respiratory samples for diagnosis of pulmonary TB",
      "page": 80,
      "pageLabel": "60",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "4.2",
      "title": "Diagnostic accuracy of Xpert MTB/RIF and Ultra in paediatric specimen types",
      "page": 81,
      "pageLabel": "61",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "4.3",
      "title": "Commonly used stool processing methods to detect TB using a molecular",
      "page": 82,
      "pageLabel": "62",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "4.4",
      "title": "Summary of WHO-recommended rapid diagnostic tests and specimen types",
      "page": 85,
      "pageLabel": "65",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "figure",
      "number": "4.4",
      "title": "Algorithm A",
      "page": 93,
      "pageLabel": "73",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "figure",
      "number": "4.5",
      "title": "Algorithm B",
      "page": 94,
      "pageLabel": "74",
      "confidence": 0.7,
      "evidence": [
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "table",
      "number": "4.5",
      "title": "Danger and priority signs of severe illness or health problems in children",
      "page": 95,
      "pageLabel": "75",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "4.6",
      "title": "Typical clinical features of extrapulmonary TB and suggested investigations",
      "page": 101,
      "pageLabel": "81",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "figure",
      "number": "5.1",
      "title": "Pathway through exposure, infection and disease covered in Chapter 5",
      "page": 107,
      "pageLabel": "87",
      "confidence": 0.7,
      "evidence": [
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "table",
      "number": "5.1",
      "title": "Pulmonary TB treatment regimens by age group, disease severity and local",
      "page": 111,
      "pageLabel": "91",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "5.2",
      "title": "Treatment regimens for extrapulmonary TB",
      "page": 117,
      "pageLabel": "97",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "5.3",
      "title": "Recommended dosages of first-line TB medicines for use in children and",
      "page": 118,
      "pageLabel": "98",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "5.4",
      "title": "Recommended interim dosing for the 6-month intensive regimen (6HRZEto)",
      "page": 119,
      "pageLabel": "99",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "5.5",
      "title": "Dosing table for first-line medicines (excluding the short intensive TBM",
      "page": 120,
      "pageLabel": "100",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "5.7",
      "title": "Recommended dosage by weight for children and adolescents weighing over",
      "page": 123,
      "pageLabel": "103",
      "confidence": 0.7,
      "evidence": [
        "referenced"
      ]
    },
    {
      "kind": "table",
      "number": "5.8",
      "title": "Recommended dosage by weight for adolescents being treated with the",
      "page": 123,
      "pageLabel": "103",
      "confidence": 0.7,
      "evidence": [
        "referenced"
      ]
    },
    {
      "kind": "table",
      "number": "5.10",
      "title": "Management of treatment interruption in children and adolescents on drug-",
      "page": 132,
      "pageLabel": "112",
      "confidence": 0.7,
      "evidence": [
        "referenced"
      ]
    },
    {
      "kind": "table",
      "number": "5.11",
      "title": "WHO drug groupings",
      "page": 137,
      "pageLabel": "117",
      "confidence": 0.7,
      "evidence": [
        "referenced"
      ]
    },
    {
      "kind": "figure",
      "number": "5.2",
      "title": "TB medicines and duration of treatment for the standardized all-oral",
      "page": 140,
      "pageLabel": "120",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "table",
      "number": "5.12",
      "title": "Possible individualized multidrug-resistant and rifampicin-resistant TB",
      "page": 143,
      "pageLabel": "123",
      "confidence": 0.7,
      "evidence": [
        "referenced"
      ]
    },
    {
      "kind": "table",
      "number": "5.13",
      "title": "Cerebrospinal fluid penetration of TB medicines used for treatment of",
      "page": 144,
      "pageLabel": "124",
      "confidence": 0.7,
      "evidence": [
        "referenced"
      ]
    },
    {
      "kind": "table",
      "number": "5.14",
      "title": "Adverse effects of medicines used for multidrug-resistant and rifampicin-",
      "page": 147,
      "pageLabel": "127",
      "confidence": 0.7,
      "evidence": [
        "referenced"
      ]
    },
    {
      "kind": "table",
      "number": "5.15",
      "title": "End-of-treatment clinical assessment in children with TB meningitis",
      "page": 154,
      "pageLabel": "134",
      "confidence": 0.7,
      "evidence": [
        "referenced"
      ]
    },
    {
      "kind": "table",
      "number": "5.16",
      "title": "End-of-treatment assessment of post-TB lung disease in children",
      "page": 155,
      "pageLabel": "135",
      "confidence": 0.7,
      "evidence": [
        "referenced"
      ]
    },
    {
      "kind": "table",
      "number": "5.17",
      "title": "Practical guidance to mitigate and assess post-TB morbidity in children with",
      "page": 155,
      "pageLabel": "135",
      "confidence": 0.7,
      "evidence": [
        "referenced"
      ]
    },
    {
      "kind": "table",
      "number": "6.1",
      "title": "Health care workers’ tasks at different levels of care",
      "page": 162,
      "pageLabel": "142",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "6.2",
      "title": "Aspects to consider when planning for the provision of decentralized, family-",
      "page": 164,
      "pageLabel": "144",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "6.3",
      "title": "Opportunities for integrating TB services into other services",
      "page": 166,
      "pageLabel": "146",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "7.1",
      "title": "Preferred and alternative first-line antiretroviral therapy regimens for",
      "page": 192,
      "pageLabel": "172",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "7.2",
      "title": "Changes needed to antiretroviral therapy regimens for neonates, children",
      "page": 193,
      "pageLabel": "173",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "7.3",
      "title": "TB preventive treatment options for children and adolescents on",
      "page": 195,
      "pageLabel": "175",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "7.4",
      "title": "Diagnostic accuracy of WHO-recommended screening tools in pregnant",
      "page": 197,
      "pageLabel": "177",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "figure",
      "number": "7.1",
      "title": "Palliative care",
      "page": 200,
      "pageLabel": "180",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "table",
      "number": "7.5",
      "title": "Actions to promote accessibility and availability of palliative care for children",
      "page": 202,
      "pageLabel": "182",
      "confidence": 0.6,
      "evidence": [
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "7.6",
      "title": "Examples of symptom management for children and adolescents with TB in",
      "page": 203,
      "pageLabel": "183",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "figure",
      "number": "7.2",
      "title": "New and relapse TB case notification rates by age group for children and",
      "page": 204,
      "pageLabel": "184",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "table",
      "number": "A2.1",
      "title": "Causes of false-negative and false-positive tuberculin skin tests",
      "page": 236,
      "pageLabel": "216",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "figure",
      "number": "A5.1",
      "title": "Algorithm A (for settings with chest X-ray) and Algorithm B (for settings",
      "page": 248,
      "pageLabel": "228",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "table",
      "number": "A5.1",
      "title": "Danger and priority signs of severe illness or health problems in",
      "page": 250,
      "pageLabel": "230",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "A7.1",
      "title": "Options for neurocognitive and functional testing at end of treatment for TB",
      "page": 260,
      "pageLabel": "240",
      "confidence": 0.6,
      "evidence": [
        "in-sequence"
      ]
    }
  ],
  "images": [
    {
      "id": "vfig-p023",
      "file": "figures/vfig-p023.webp",
      "page": 23,
      "shows": [
        "Figure 1.1"
      ],
      "narratives": {
        "en": "Pathway diagram of TB exposure, infection and disease drawn as coloured bands: from 'Exposed' to an 'Infected' circle with lungs icon, then branching to 'Accessed health care system' (leading to preventive treatment) or 'Did NOT access health care system' (leading to Diseased, Feeling ill, Accessed health care system, Diagnosed and Treated, with a side branch for 'Un/misdiagnosed'). The render is cropped: the left edge (Susceptible/Exposed) and some stage labels along the top are cut off.",
        "ar": "مخطط مسار التعرض للسل والعدوى والمرض مرسوم على شكل أشرطة ملونة: من «التعرض» إلى دائرة «العدوى» مع أيقونة رئتين، ثم يتفرع إلى «الوصول إلى النظام الصحي» (المؤدي إلى العلاج الوقائي) أو «عدم الوصول إلى النظام الصحي» (المؤدي إلى المرض، ثم الشعور بالمرض، ثم الوصول إلى النظام الصحي، ثم التشخيص، ثم العلاج، مع فرع جانبي لـ«عدم التشخيص/التشخيص الخاطئ»). الصورة مقصوصة: الحافة اليسرى (المعرَّض للخطر/التعرض) وبعض تسميات المراحل في الأعلى غير ظاهرة.",
        "zh": "以彩色条带绘制的结核病暴露、感染和发病路径图：从“暴露”到带有肺部图标的“感染”圆圈，随后分为“就诊于卫生保健系统”（通向预防性治疗）或“未就诊于卫生保健系统”（通向发病、感觉不适、就诊于卫生保健系统、确诊和治疗，另有“未诊断/误诊”分支）。 该渲染图被裁剪：左侧边缘（易感/暴露）和顶部部分阶段标签被截去。",
        "es": "Diagrama de la trayectoria de exposición, infección y enfermedad tuberculosa dibujado como bandas de colores: de «Expuesto» a un círculo «Infectado» con un icono de pulmones, que se bifurca en «Acceso al sistema de atención de salud» (que conduce al tratamiento preventivo) o «Sin acceso al sistema de atención de salud» (que conduce a Enfermo, Sensación de malestar, Acceso al sistema de atención de salud, Diagnosticado y Tratado, con una rama lateral «No diagnosticado o mal diagnosticado»). La imagen está recortada: el borde izquierdo (Susceptible/Expuesto) y algunas etiquetas de etapas en la parte superior quedan cortados.",
        "fr": "Schéma du parcours d'exposition, d'infection et de maladie tuberculeuse dessiné sous forme de bandes colorées : de « Exposé » à un cercle « Infecté » avec une icône de poumons, puis bifurcation vers « A accédé au système de santé » (menant au traitement préventif) ou « N'a PAS accédé au système de santé » (menant à Malade, Se sent malade, A accédé au système de santé, Diagnostiqué et Traité, avec une branche latérale « Non diagnostiqué/mal diagnostiqué »). Le rendu est rogné : le bord gauche (Sensible/Exposé) et certaines étiquettes d'étapes en haut sont coupés.",
        "ru": "Схема пути от контакта с ТБ к инфицированию и заболеванию в виде цветных полос: от «Контакт» к кругу «Инфицирован» со значком легких, затем разветвление на «Обращение в систему здравоохранения» (ведет к профилактическому лечению) и «НЕ обращался в систему здравоохранения» (ведет к этапам «Болен», «Плохое самочувствие», «Обращение в систему здравоохранения», «Диагноз поставлен», «Лечение», с боковой ветвью «Не диагностирован/диагностирован неверно»). Изображение обрезано: левый край («Восприимчивый»/«Контакт») и некоторые подписи этапов вверху не видны."
      },
      "state": "draft"
    },
    {
      "id": "vfig-p026",
      "file": "figures/vfig-p026.webp",
      "page": 26,
      "shows": [
        "Figure 2.1"
      ],
      "narratives": {
        "en": "Pathway diagram of TB exposure, infection and disease drawn as coloured bands: from 'Exposed' to an 'Infected' circle with lungs icon, then branching to 'Accessed health care system' (leading to preventive treatment) or 'Did NOT access health care system' (leading to Diseased, Feeling ill, Accessed health care system, Diagnosed and Treated, with a side branch for 'Un/misdiagnosed'). A blue circle highlights the stages covered in Chapter 2: Susceptible, Exposed and Infected.",
        "ar": "مخطط مسار التعرض للسل والعدوى والمرض مرسوم على شكل أشرطة ملونة: من «التعرض» إلى دائرة «العدوى» مع أيقونة رئتين، ثم يتفرع إلى «الوصول إلى النظام الصحي» (المؤدي إلى العلاج الوقائي) أو «عدم الوصول إلى النظام الصحي» (المؤدي إلى المرض، ثم الشعور بالمرض، ثم الوصول إلى النظام الصحي، ثم التشخيص، ثم العلاج، مع فرع جانبي لـ«عدم التشخيص/التشخيص الخاطئ»). تُبرز دائرة زرقاء المراحل التي يتناولها الفصل 2: المعرَّض للخطر، والتعرض، والعدوى.",
        "zh": "以彩色条带绘制的结核病暴露、感染和发病路径图：从“暴露”到带有肺部图标的“感染”圆圈，随后分为“就诊于卫生保健系统”（通向预防性治疗）或“未就诊于卫生保健系统”（通向发病、感觉不适、就诊于卫生保健系统、确诊和治疗，另有“未诊断/误诊”分支）。 蓝色圆圈突出了第2章涵盖的阶段：易感、暴露和感染。",
        "es": "Diagrama de la trayectoria de exposición, infección y enfermedad tuberculosa dibujado como bandas de colores: de «Expuesto» a un círculo «Infectado» con un icono de pulmones, que se bifurca en «Acceso al sistema de atención de salud» (que conduce al tratamiento preventivo) o «Sin acceso al sistema de atención de salud» (que conduce a Enfermo, Sensación de malestar, Acceso al sistema de atención de salud, Diagnosticado y Tratado, con una rama lateral «No diagnosticado o mal diagnosticado»). Un círculo azul destaca las etapas tratadas en el capítulo 2: Susceptible, Expuesto e Infectado.",
        "fr": "Schéma du parcours d'exposition, d'infection et de maladie tuberculeuse dessiné sous forme de bandes colorées : de « Exposé » à un cercle « Infecté » avec une icône de poumons, puis bifurcation vers « A accédé au système de santé » (menant au traitement préventif) ou « N'a PAS accédé au système de santé » (menant à Malade, Se sent malade, A accédé au système de santé, Diagnostiqué et Traité, avec une branche latérale « Non diagnostiqué/mal diagnostiqué »). Un cercle bleu met en évidence les étapes traitées au chapitre 2 : Sensible, Exposé et Infecté.",
        "ru": "Схема пути от контакта с ТБ к инфицированию и заболеванию в виде цветных полос: от «Контакт» к кругу «Инфицирован» со значком легких, затем разветвление на «Обращение в систему здравоохранения» (ведет к профилактическому лечению) и «НЕ обращался в систему здравоохранения» (ведет к этапам «Болен», «Плохое самочувствие», «Обращение в систему здравоохранения», «Диагноз поставлен», «Лечение», с боковой ветвью «Не диагностирован/диагностирован неверно»). Синим кругом выделены этапы, рассматриваемые в главе 2: «Восприимчивый», «Контакт» и «Инфицирован»."
      },
      "state": "draft"
    },
    {
      "id": "vfig-p029",
      "file": "figures/vfig-p029.webp",
      "page": 29,
      "shows": [
        "Figure 2.2"
      ],
      "narratives": {
        "en": "Diagram of costing items to strengthen contact investigation (Figure 2.2): five orange steps, each with an arrow listing cost items – identification of contacts (health care workers' time to interview the index TB patient; travel support for household or workplace visits); clinical evaluation (staff time for evaluation and follow-up; enabler or travel support for contacts); testing for TB disease or eligibility for TPT (travel support to the testing site; strengthening specimen collection transport); provide access to TPT (staff time for referral and follow-up); recording and reporting (data capture tools such as the WHO Prevent TB mobile application; staff time).",
        "ar": "مخطط لبنود التكاليف اللازمة لتعزيز تقصّي المخالطين (الشكل 2.2): خمس خطوات برتقالية، لكل منها سهم يسرد بنود التكاليف – تحديد المخالطين (وقت العاملين الصحيين لإجراء مقابلة مع مريض السل الدالّ؛ ودعم السفر لزيارة المنزل أو مكان العمل)؛ والتقييم السريري (وقت العاملين للتقييم والمتابعة؛ ودعم تمكيني أو دعم سفر للمخالطين)؛ واختبار مرض السل أو الأهلية للعلاج الوقائي من السل (دعم السفر إلى موقع الاختبار؛ وتعزيز نقل العينات المجمّعة)؛ وإتاحة العلاج الوقائي من السل (وقت العاملين للإحالة والمتابعة)؛ والتسجيل والإبلاغ (أدوات جمع البيانات مثل تطبيق WHO Prevent TB للهاتف المحمول؛ ووقت العاملين).",
        "zh": "加强接触者调查的成本项目示意图（图2.2）：五个橙色步骤，每个步骤带一个箭头列出成本项目——识别接触者（卫生工作者访谈指示病例的时间；家访或工作场所访视的交通支持）；临床评估（评估和随访的人员时间；接触者的激励或交通支持）；检测结核病或结核病预防性治疗（TPT）适用性（前往检测点的交通支持；加强标本采集运送）；提供TPT（转诊和随访的人员时间）；记录和报告（数据采集工具，如世卫组织Prevent TB移动应用程序；人员时间）。",
        "es": "Diagrama de las partidas de costos para fortalecer la investigación de contactos (figura 2.2): cinco pasos en naranja, cada uno con una flecha que enumera partidas de costos: identificación de contactos (tiempo del personal de salud para entrevistar al caso índice de TB; apoyo para desplazamientos a domicilio o lugar de trabajo); evaluación clínica (tiempo del personal para la evaluación y el seguimiento; incentivos o apoyo para desplazamientos de los contactos); pruebas de enfermedad tuberculosa o de idoneidad para el TPT (apoyo para desplazamientos al lugar de las pruebas; fortalecimiento del transporte de muestras); acceso al TPT (tiempo del personal para derivación y seguimiento); registro y notificación (herramientas de recopilación de datos, como la aplicación móvil WHO Prevent TB; tiempo del personal).",
        "fr": "Schéma des postes de coûts pour renforcer la recherche des contacts (figure 2.2) : cinq étapes orange, chacune accompagnée d'une flèche énumérant des postes de coûts – identification des contacts (temps des agents de santé pour l'entretien avec le cas index de TB ; aide aux déplacements pour les visites au domicile ou au lieu de travail) ; évaluation clinique (temps du personnel pour l'évaluation et le suivi ; mesures incitatives ou aide aux déplacements des contacts) ; dépistage de la TB-maladie ou de l'admissibilité au TPT (aide aux déplacements vers le site de dépistage ; renforcement du transport des échantillons) ; accès au TPT (temps du personnel pour l'orientation et le suivi) ; enregistrement et notification (outils de saisie des données tels que l'application mobile WHO Prevent TB ; temps du personnel).",
        "ru": "Схема статей затрат на усиление обследования контактов (рисунок 2.2): пять оранжевых этапов, у каждого — стрелка с перечнем статей затрат: выявление контактов (время медработников на опрос индексного пациента с ТБ; транспортная поддержка для посещения домохозяйства или места работы); клиническое обследование (время персонала на обследование и наблюдение; стимулирующая или транспортная поддержка контактов); тестирование на ТБ или на показания к ПЛТ (транспортная поддержка для поездки в место тестирования; укрепление транспортировки образцов); обеспечение доступа к ПЛТ (время персонала на направление и наблюдение); учет и отчетность (средства сбора данных, например мобильное приложение WHO Prevent TB; время персонала)."
      },
      "state": "draft"
    },
    {
      "id": "vfig-p040",
      "file": "figures/vfig-p040.webp",
      "page": 40,
      "shows": [
        "Figure 2.3"
      ],
      "narratives": {
        "en": "Flowchart for TB screening of child contacts aged under 15 years using TB symptoms (Figure 2.3). A positive symptom screen leads to 'Refer for diagnostic evaluation including mWRD & clinical evaluation as indicated'; a negative screen leads to 'Negative Screen – Refer for TPT'.",
        "ar": "مخطط انسيابي لتحرّي السل لدى الأطفال المخالطين دون سن 15 سنة باستخدام أعراض السل (الشكل 2.3). تؤدي نتيجة التحرّي الإيجابية للأعراض إلى «الإحالة للتقييم التشخيصي بما في ذلك اختبار mWRD والتقييم السريري حسب الاقتضاء»؛ وتؤدي النتيجة السلبية إلى «تحرٍّ سلبي – الإحالة للعلاج الوقائي من السل».",
        "zh": "使用结核病症状对15岁以下儿童接触者进行结核病筛查的流程图（图2.3）。症状筛查阳性者转向“转诊进行诊断评估，包括mWRD检测和必要的临床评估”；筛查阴性者转向“筛查阴性——转诊接受结核病预防性治疗（TPT）”。",
        "es": "Diagrama de flujo para el cribado de TB en niños menores de 15 años que son contactos, basado en los síntomas de TB (figura 2.3). Un cribado de síntomas positivo conduce a «Derivar para evaluación diagnóstica, incluidas mWRD y evaluación clínica según corresponda»; un cribado negativo conduce a «Cribado negativo – Derivar para TPT».",
        "fr": "Logigramme du dépistage de la TB chez les enfants contacts de moins de 15 ans à partir des symptômes de TB (figure 2.3). Un dépistage des symptômes positif mène à « Orienter vers une évaluation diagnostique, y compris mWRD et évaluation clinique selon les besoins » ; un dépistage négatif mène à « Dépistage négatif – Orienter vers le TPT ».",
        "ru": "Блок-схема скрининга на ТБ детей-контактов в возрасте до 15 лет по симптомам ТБ (рисунок 2.3). Положительный результат скрининга по симптомам ведет к «направлению на диагностическое обследование, включая mWRD и клиническое обследование по показаниям»; отрицательный — к «отрицательному результату скрининга и направлению на ПЛТ»."
      },
      "state": "draft"
    },
    {
      "id": "vfig-p041",
      "file": "figures/vfig-p041.webp",
      "page": 41,
      "shows": [
        "Figure 2.4"
      ],
      "narratives": {
        "en": "Flowchart for TB screening of child contacts aged under 15 years using chest X-ray (CXR) (Figure 2.4). A positive CXR leads to 'Refer for diagnostic evaluation including mWRD & clinical evaluation as indicated'; a negative CXR leads to 'Negative Screen – Refer for TPT'.",
        "ar": "مخطط انسيابي لتحرّي السل لدى الأطفال المخالطين دون سن 15 سنة باستخدام التصوير الشعاعي للصدر (CXR) (الشكل 2.4). تؤدي النتيجة الإيجابية إلى «الإحالة للتقييم التشخيصي بما في ذلك اختبار mWRD والتقييم السريري حسب الاقتضاء»؛ وتؤدي النتيجة السلبية إلى «تحرٍّ سلبي – الإحالة للعلاج الوقائي من السل».",
        "zh": "使用胸部X线（CXR）对15岁以下儿童接触者进行结核病筛查的流程图（图2.4）。胸部X线阳性者转向“转诊进行诊断评估，包括mWRD检测和必要的临床评估”；阴性者转向“筛查阴性——转诊接受TPT”。",
        "es": "Diagrama de flujo para el cribado de TB en niños menores de 15 años que son contactos mediante radiografía de tórax (CXR) (figura 2.4). Una radiografía positiva conduce a «Derivar para evaluación diagnóstica, incluidas mWRD y evaluación clínica según corresponda»; una negativa conduce a «Cribado negativo – Derivar para TPT».",
        "fr": "Logigramme du dépistage de la TB chez les enfants contacts de moins de 15 ans par radiographie thoracique (CXR) (figure 2.4). Une radiographie positive mène à « Orienter vers une évaluation diagnostique, y compris mWRD et évaluation clinique selon les besoins » ; une radiographie négative mène à « Dépistage négatif – Orienter vers le TPT ».",
        "ru": "Блок-схема скрининга на ТБ детей-контактов в возрасте до 15 лет с помощью рентгенографии грудной клетки (CXR) (рисунок 2.4). Положительный результат ведет к «направлению на диагностическое обследование, включая mWRD и клиническое обследование по показаниям»; отрицательный — к «отрицательному результату скрининга и направлению на ПЛТ»."
      },
      "state": "draft"
    },
    {
      "id": "vfig-p042",
      "file": "figures/vfig-p042.webp",
      "page": 42,
      "shows": [
        "Figure 2.5",
        "Figure 2.6"
      ],
      "narratives": {
        "en": "Two flowcharts for TB screening of child contacts aged under 15 years. Left (Figure 2.5, parallel screening): TB symptoms and CXR are both assessed; if either or both are positive, the child is referred for diagnostic evaluation including mWRD and clinical evaluation, and if both are negative, 'Negative Screen – Refer for TPT'. Right (Figure 2.6, sequential positive serial screening): children with positive symptoms then have a CXR; a positive CXR leads to diagnostic evaluation, while a negative symptom screen leads to 'Negative Screen – Refer for TPT' and a negative CXR to 'Negative Screen – Explore alternate diagnoses – Refer for TPT'.",
        "ar": "مخططان انسيابيان لتحرّي السل لدى الأطفال المخالطين دون سن 15 سنة. اليسار (الشكل 2.5، التحرّي المتوازي): تُقيَّم أعراض السل والتصوير الشعاعي للصدر معاً؛ وإذا كانت إحداهما أو كلتاهما إيجابية يُحال الطفل للتقييم التشخيصي بما في ذلك اختبار mWRD والتقييم السريري، وإذا كانتا سلبيتين فـ«تحرٍّ سلبي – الإحالة للعلاج الوقائي من السل». اليمين (الشكل 2.6، التحرّي المتسلسل الإيجابي): يخضع الأطفال ذوو الأعراض الإيجابية بعد ذلك للتصوير الشعاعي للصدر؛ وتؤدي النتيجة الإيجابية إلى التقييم التشخيصي، بينما يؤدي التحرّي السلبي للأعراض إلى «تحرٍّ سلبي – الإحالة للعلاج الوقائي من السل»، ويؤدي التصوير السلبي إلى «تحرٍّ سلبي – استكشاف تشخيصات بديلة – الإحالة للعلاج الوقائي من السل».",
        "zh": "两个针对15岁以下儿童接触者的结核病筛查流程图。左图（图2.5，平行筛查）：同时评估结核病症状和胸部X线；任一项或两项阳性则转诊进行包括mWRD检测和临床评估在内的诊断评估，两项均阴性则“筛查阴性——转诊接受TPT”。右图（图2.6，序贯阳性串联筛查）：症状阳性的儿童再行胸部X线检查；X线阳性者进行诊断评估，症状筛查阴性者为“筛查阴性——转诊接受TPT”，X线阴性者为“筛查阴性——探查其他诊断——转诊接受TPT”。",
        "es": "Dos diagramas de flujo para el cribado de TB en niños menores de 15 años que son contactos. Izquierda (figura 2.5, cribado en paralelo): se evalúan tanto los síntomas de TB como la CXR; si uno o ambos son positivos, se deriva al niño para evaluación diagnóstica, incluidas mWRD y evaluación clínica, y si ambos son negativos, «Cribado negativo – Derivar para TPT». Derecha (figura 2.6, cribado seriado secuencial positivo): los niños con síntomas positivos se someten después a CXR; una CXR positiva conduce a la evaluación diagnóstica, mientras que un cribado de síntomas negativo conduce a «Cribado negativo – Derivar para TPT» y una CXR negativa a «Cribado negativo – Explorar diagnósticos alternativos – Derivar para TPT».",
        "fr": "Deux logigrammes du dépistage de la TB chez les enfants contacts de moins de 15 ans. À gauche (figure 2.5, dépistage en parallèle) : les symptômes de TB et la CXR sont évalués tous deux ; si l'un ou les deux sont positifs, l'enfant est orienté vers une évaluation diagnostique, y compris mWRD et évaluation clinique, et si les deux sont négatifs, « Dépistage négatif – Orienter vers le TPT ». À droite (figure 2.6, dépistage séquentiel positif en série) : les enfants présentant des symptômes passent ensuite une CXR ; une CXR positive mène à l'évaluation diagnostique, tandis qu'un dépistage des symptômes négatif mène à « Dépistage négatif – Orienter vers le TPT » et une CXR négative à « Dépistage négatif – Envisager d'autres diagnostics – Orienter vers le TPT ».",
        "ru": "Две блок-схемы скрининга на ТБ детей-контактов в возрасте до 15 лет. Слева (рисунок 2.5, параллельный скрининг): оцениваются и симптомы ТБ, и CXR; если один или оба результата положительны, ребенка направляют на диагностическое обследование, включая mWRD и клиническое обследование, а если оба отрицательны — «отрицательный результат скрининга, направление на ПЛТ». Справа (рисунок 2.6, последовательный положительный серийный скрининг): детям с положительным результатом по симптомам затем проводят CXR; положительная CXR ведет к диагностическому обследованию, отрицательный скрининг по симптомам — к «отрицательному результату скрининга, направлению на ПЛТ», а отрицательная CXR — к «отрицательному результату скрининга, поиску альтернативных диагнозов, направлению на ПЛТ»."
      },
      "state": "draft"
    },
    {
      "id": "vfig-p043",
      "file": "figures/vfig-p043.webp",
      "page": 43,
      "shows": [
        "Figure 2.7"
      ],
      "narratives": {
        "en": "Flowchart for sequential negative serial TB screening of child contacts aged under 15 years (Figure 2.7). Children with positive TB symptoms go directly to diagnostic evaluation including mWRD and clinical evaluation; those with negative symptoms have a CXR, where a positive result also leads to diagnostic evaluation and a negative result to 'Negative Screen – Refer for TPT'.",
        "ar": "مخطط انسيابي للتحرّي المتسلسل السلبي عن السل لدى الأطفال المخالطين دون سن 15 سنة (الشكل 2.7). ينتقل الأطفال ذوو الأعراض الإيجابية مباشرة إلى التقييم التشخيصي بما في ذلك اختبار mWRD والتقييم السريري؛ أما ذوو الأعراض السلبية فيخضعون للتصوير الشعاعي للصدر، حيث تؤدي النتيجة الإيجابية أيضاً إلى التقييم التشخيصي وتؤدي النتيجة السلبية إلى «تحرٍّ سلبي – الإحالة للعلاج الوقائي من السل».",
        "zh": "针对15岁以下儿童接触者的序贯阴性串联结核病筛查流程图（图2.7）。结核病症状阳性的儿童直接进行包括mWRD检测和临床评估在内的诊断评估；症状阴性者行胸部X线检查，结果阳性者同样进行诊断评估，阴性者为“筛查阴性——转诊接受TPT”。",
        "es": "Diagrama de flujo del cribado seriado secuencial negativo de TB en niños menores de 15 años que son contactos (figura 2.7). Los niños con síntomas de TB positivos pasan directamente a la evaluación diagnóstica, incluidas mWRD y evaluación clínica; los que tienen síntomas negativos se someten a CXR, cuyo resultado positivo también conduce a la evaluación diagnóstica y el negativo a «Cribado negativo – Derivar para TPT».",
        "fr": "Logigramme du dépistage séquentiel négatif en série de la TB chez les enfants contacts de moins de 15 ans (figure 2.7). Les enfants présentant des symptômes de TB passent directement à l'évaluation diagnostique, y compris mWRD et évaluation clinique ; ceux sans symptômes passent une CXR, dont un résultat positif mène aussi à l'évaluation diagnostique et un résultat négatif à « Dépistage négatif – Orienter vers le TPT ».",
        "ru": "Блок-схема последовательного отрицательного серийного скрининга на ТБ детей-контактов в возрасте до 15 лет (рисунок 2.7). Дети с положительным результатом по симптомам ТБ сразу направляются на диагностическое обследование, включая mWRD и клиническое обследование; детям с отрицательным результатом проводят CXR, положительный результат которой также ведет к диагностическому обследованию, а отрицательный — к «отрицательному результату скрининга, направлению на ПЛТ»."
      },
      "state": "draft"
    },
    {
      "id": "vfig-p044",
      "file": "figures/vfig-p044.webp",
      "page": 44,
      "shows": [
        "Figure 2.8"
      ],
      "narratives": {
        "en": "Flowchart for TB symptom screening of children living with HIV aged under 10 years (Figure 2.8). A positive symptom screen leads to referral for diagnostic evaluation including mWRD and clinical evaluation; a negative screen leads to 'Negative Screen – Refer for TPT'.",
        "ar": "مخطط انسيابي لتحرّي أعراض السل لدى الأطفال المتعايشين مع فيروس العوز المناعي البشري دون سن 10 سنوات (الشكل 2.8). تؤدي النتيجة الإيجابية إلى الإحالة للتقييم التشخيصي بما في ذلك اختبار mWRD والتقييم السريري؛ وتؤدي النتيجة السلبية إلى «تحرٍّ سلبي – الإحالة للعلاج الوقائي من السل».",
        "zh": "对10岁以下艾滋病毒感染儿童进行结核病症状筛查的流程图（图2.8）。症状筛查阳性者转诊进行包括mWRD检测和临床评估在内的诊断评估；阴性者为“筛查阴性——转诊接受TPT”。",
        "es": "Diagrama de flujo del cribado de síntomas de TB en niños menores de 10 años con VIH (figura 2.8). Un cribado positivo conduce a la derivación para evaluación diagnóstica, incluidas mWRD y evaluación clínica; uno negativo conduce a «Cribado negativo – Derivar para TPT».",
        "fr": "Logigramme du dépistage des symptômes de TB chez les enfants de moins de 10 ans vivant avec le VIH (figure 2.8). Un dépistage positif mène à l'orientation vers une évaluation diagnostique, y compris mWRD et évaluation clinique ; un dépistage négatif mène à « Dépistage négatif – Orienter vers le TPT ».",
        "ru": "Блок-схема скрининга по симптомам ТБ детей в возрасте до 10 лет, живущих с ВИЧ (рисунок 2.8). Положительный результат ведет к направлению на диагностическое обследование, включая mWRD и клиническое обследование; отрицательный — к «отрицательному результату скрининга, направлению на ПЛТ»."
      },
      "state": "draft"
    },
    {
      "id": "vfig-p047",
      "file": "figures/vfig-p047.webp",
      "page": 47,
      "shows": [
        "Figure 3.1"
      ],
      "narratives": {
        "en": "Pathway diagram of TB exposure, infection and disease drawn as coloured bands: from 'Exposed' to an 'Infected' circle with lungs icon, then branching to 'Accessed health care system' (leading to preventive treatment) or 'Did NOT access health care system' (leading to Diseased, Feeling ill, Accessed health care system, Diagnosed and Treated, with a side branch for 'Un/misdiagnosed'). A blue oval highlights the stages covered in Chapter 3: Exposed, Infected, Accessed health care system and Preventive treatment. The left edge of the render is cropped.",
        "ar": "مخطط مسار التعرض للسل والعدوى والمرض مرسوم على شكل أشرطة ملونة: من «التعرض» إلى دائرة «العدوى» مع أيقونة رئتين، ثم يتفرع إلى «الوصول إلى النظام الصحي» (المؤدي إلى العلاج الوقائي) أو «عدم الوصول إلى النظام الصحي» (المؤدي إلى المرض، ثم الشعور بالمرض، ثم الوصول إلى النظام الصحي، ثم التشخيص، ثم العلاج، مع فرع جانبي لـ«عدم التشخيص/التشخيص الخاطئ»). يُبرز شكل بيضاوي أزرق المراحل التي يتناولها الفصل 3: التعرض، والعدوى، والوصول إلى النظام الصحي، والعلاج الوقائي. والحافة اليسرى من الصورة مقصوصة.",
        "zh": "以彩色条带绘制的结核病暴露、感染和发病路径图：从“暴露”到带有肺部图标的“感染”圆圈，随后分为“就诊于卫生保健系统”（通向预防性治疗）或“未就诊于卫生保健系统”（通向发病、感觉不适、就诊于卫生保健系统、确诊和治疗，另有“未诊断/误诊”分支）。 蓝色椭圆突出了第3章涵盖的阶段：暴露、感染、就诊于卫生保健系统和预防性治疗。渲染图左侧边缘被裁剪。",
        "es": "Diagrama de la trayectoria de exposición, infección y enfermedad tuberculosa dibujado como bandas de colores: de «Expuesto» a un círculo «Infectado» con un icono de pulmones, que se bifurca en «Acceso al sistema de atención de salud» (que conduce al tratamiento preventivo) o «Sin acceso al sistema de atención de salud» (que conduce a Enfermo, Sensación de malestar, Acceso al sistema de atención de salud, Diagnosticado y Tratado, con una rama lateral «No diagnosticado o mal diagnosticado»). Un óvalo azul destaca las etapas tratadas en el capítulo 3: Expuesto, Infectado, Acceso al sistema de atención de salud y Tratamiento preventivo. El borde izquierdo de la imagen está recortado.",
        "fr": "Schéma du parcours d'exposition, d'infection et de maladie tuberculeuse dessiné sous forme de bandes colorées : de « Exposé » à un cercle « Infecté » avec une icône de poumons, puis bifurcation vers « A accédé au système de santé » (menant au traitement préventif) ou « N'a PAS accédé au système de santé » (menant à Malade, Se sent malade, A accédé au système de santé, Diagnostiqué et Traité, avec une branche latérale « Non diagnostiqué/mal diagnostiqué »). Un ovale bleu met en évidence les étapes traitées au chapitre 3 : Exposé, Infecté, A accédé au système de santé et Traitement préventif. Le bord gauche du rendu est rogné.",
        "ru": "Схема пути от контакта с ТБ к инфицированию и заболеванию в виде цветных полос: от «Контакт» к кругу «Инфицирован» со значком легких, затем разветвление на «Обращение в систему здравоохранения» (ведет к профилактическому лечению) и «НЕ обращался в систему здравоохранения» (ведет к этапам «Болен», «Плохое самочувствие», «Обращение в систему здравоохранения», «Диагноз поставлен», «Лечение», с боковой ветвью «Не диагностирован/диагностирован неверно»). Синим овалом выделены этапы, рассматриваемые в главе 3: «Контакт», «Инфицирован», «Обращение в систему здравоохранения» и «Профилактическое лечение». Левый край изображения обрезан."
      },
      "state": "draft"
    },
    {
      "id": "vfig-p049",
      "file": "figures/vfig-p049.webp",
      "page": 49,
      "shows": [
        "Figure 3.2"
      ],
      "narratives": {
        "en": "Line drawing of injection techniques (Figure 3.2): three syringes enter the skin at different angles – intramuscular (vertical, reaching the muscle), subcutaneous (angled, into the subcutaneous layer) and intradermal (almost flat, into the dermis). Layers labelled dermis (skin), subcutaneous layer and muscle. Labels at the right edge are partly cut off.",
        "ar": "رسم خطي لتقنيات الحقن (الشكل 3.2): ثلاث محاقن تدخل الجلد بزوايا مختلفة – داخل العضل (عمودياً حتى العضلة)، وتحت الجلد (بزاوية مائلة إلى الطبقة تحت الجلدية)، وداخل الأدمة (بشكل شبه مسطح في الأدمة). والطبقات مُعلَّمة: الأدمة (الجلد)، والطبقة تحت الجلدية، والعضلة. والتسميات عند الحافة اليمنى مقصوصة جزئياً.",
        "zh": "注射技术线条图（图3.2）：三支注射器以不同角度刺入皮肤——肌内注射（垂直，达肌肉）、皮下注射（倾斜，进入皮下层）和皮内注射（几乎平行，进入真皮）。各层标注为真皮（皮肤）、皮下层和肌肉。右侧边缘的标签部分被截去。",
        "es": "Dibujo lineal de las técnicas de inyección (figura 3.2): tres jeringas penetran en la piel con ángulos distintos: intramuscular (vertical, hasta el músculo), subcutánea (en ángulo, en la capa subcutánea) e intradérmica (casi paralela, en la dermis). Las capas se rotulan dermis (piel), capa subcutánea y músculo. Las etiquetas del borde derecho están parcialmente cortadas.",
        "fr": "Dessin au trait des techniques d'injection (figure 3.2) : trois seringues pénètrent la peau selon des angles différents – intramusculaire (verticale, jusqu'au muscle), sous-cutanée (inclinée, dans la couche sous-cutanée) et intradermique (presque à plat, dans le derme). Les couches sont étiquetées derme (peau), couche sous-cutanée et muscle. Les étiquettes du bord droit sont partiellement coupées.",
        "ru": "Контурный рисунок техник инъекций (рисунок 3.2): три шприца входят в кожу под разными углами — внутримышечно (вертикально, до мышцы), подкожно (под углом, в подкожный слой) и внутрикожно (почти параллельно, в дерму). Слои подписаны: дерма (кожа), подкожный слой и мышца. Подписи у правого края частично обрезаны."
      },
      "state": "draft"
    },
    {
      "id": "img-p050-1",
      "file": "images/img-p050-1.webp",
      "page": 50,
      "narratives": {
        "en": "Close-up photograph illustrating administration of BCG (Figure 3.3): a hand holds a small syringe whose needle is inserted almost flat into the skin of a child's arm, which rests on white cloth.",
        "ar": "صورة فوتوغرافية مقرّبة توضح إعطاء لقاح BCG (الشكل 3.3): يد تمسك محقنة صغيرة إبرتها مُدخلة بشكل شبه مسطح في جلد ذراع طفل مستندة على قماش أبيض.",
        "zh": "演示卡介苗（BCG）接种的特写照片（图3.3）：一只手持小注射器，针头几乎平行地刺入放在白布上的儿童手臂皮肤。",
        "es": "Fotografía de primer plano que ilustra la administración de la BCG (figura 3.3): una mano sostiene una jeringa pequeña cuya aguja está insertada casi en paralelo en la piel del brazo de un niño, apoyado sobre una tela blanca.",
        "fr": "Photographie en gros plan illustrant l'administration du BCG (figure 3.3) : une main tient une petite seringue dont l'aiguille est introduite presque à plat dans la peau du bras d'un enfant, posé sur un linge blanc.",
        "ru": "Крупный фотоснимок, иллюстрирующий введение вакцины БЦЖ (рисунок 3.3): рука держит небольшой шприц, игла которого введена почти параллельно в кожу руки ребенка, лежащей на белой ткани."
      },
      "state": "draft"
    },
    {
      "id": "vfig-p058",
      "file": "figures/vfig-p058.webp",
      "page": 58,
      "shows": [
        "Figure 3.4"
      ],
      "narratives": {
        "en": "Algorithm for TB infection testing and TB preventive treatment in children and adolescents (Figure 3.4), with three entry groups: HIV positive, household contact and other risk group. People living with HIV are screened for any symptom (current cough, fever, weight loss or night sweats); symptomatic people living with HIV and symptomatic contacts are investigated for TB disease. Asymptomatic contacts under 5 years go to the preventive-treatment decision; those aged 5 years and over and other risk groups have TST or IGRA, then CXR if positive or unavailable (abnormal CXR leads to TB investigation). The decision box 'Preventive treatment contraindicated?' leads to 'Defer' or 'Give preventive treatment', and all paths end with 'Follow up for TB disease as necessary, even for patients who have completed preventive treatment'.",
        "ar": "خوارزمية اختبار العدوى بالسل والعلاج الوقائي من السل لدى الأطفال والمراهقين (الشكل 3.4)، بثلاث فئات دخول: المصابون بفيروس العوز المناعي البشري، والمخالطون المنزليون، وفئات الخطر الأخرى. يُتحرّى لدى المتعايشين مع الفيروس وجود أي عَرَض (سعال حالي أو حمى أو فقدان وزن أو تعرّق ليلي)؛ ويُستقصى مرض السل لدى من لديهم أعراض ولدى المخالطين الذين لديهم أعراض. ينتقل المخالطون الذين لا أعراض لديهم دون 5 سنوات إلى قرار العلاج الوقائي؛ أما من هم في سن 5 سنوات فأكثر وفئات الخطر الأخرى فيخضعون لاختبار TST أو IGRA، ثم للتصوير الشعاعي للصدر إذا كانت النتيجة إيجابية أو غير متاحة (ويؤدي التصوير غير الطبيعي إلى استقصاء السل). تؤدي خانة القرار «هل العلاج الوقائي مضاد استطباب؟» إلى «تأجيل» العلاج الوقائي أو «إعطائه»، وتنتهي جميع المسارات بعبارة «متابعة مرض السل حسب الضرورة، حتى للمرضى الذين أتموا العلاج الوقائي».",
        "zh": "儿童和青少年结核感染检测及结核病预防性治疗算法（图3.4），有三个入口人群：艾滋病毒阳性者、家庭接触者和其他风险人群。艾滋病毒感染者筛查有无任何症状（当前咳嗽、发热、体重减轻或盗汗）；有症状者及有症状的接触者接受结核病调查。无症状的5岁以下接触者进入预防性治疗决策；5岁及以上者和其他风险人群接受TST或IGRA检测，结果阳性或无法检测时再行胸部X线（X线异常者接受结核病调查）。决策框“是否存在预防性治疗禁忌？”通向“推迟”或“给予预防性治疗”，所有路径最终均为“必要时随访结核病，即使是已完成预防性治疗的患者”。",
        "es": "Algoritmo de pruebas de infección tuberculosa y tratamiento preventivo de la TB en niños y adolescentes (figura 3.4), con tres grupos de entrada: VIH positivo, contacto domiciliario y otro grupo de riesgo. A las personas con VIH se les cribe cualquier síntoma (tos actual, fiebre, pérdida de peso o sudores nocturnos); las personas sintomáticas y los contactos sintomáticos se investigan para descartar enfermedad tuberculosa. Los contactos asintomáticos menores de 5 años pasan a la decisión sobre el tratamiento preventivo; los de 5 años o más y otros grupos de riesgo se someten a TST o IGRA y luego a CXR si el resultado es positivo o no está disponible (una CXR anormal conduce a investigar la TB). La casilla de decisión «¿Está contraindicado el tratamiento preventivo?» conduce a «Aplazar» o «Administrar tratamiento preventivo», y todas las vías terminan en «Seguimiento de la enfermedad tuberculosa según sea necesario, incluso en pacientes que han completado el tratamiento preventivo».",
        "fr": "Algorithme pour le test de l'infection tuberculeuse et le traitement préventif de la TB chez les enfants et les adolescents (figure 3.4), avec trois groupes d'entrée : séropositifs pour le VIH, contacts familiaux et autres groupes à risque. Les personnes vivant avec le VIH font l'objet d'un dépistage de tout symptôme (toux actuelle, fièvre, perte de poids ou sueurs nocturnes) ; les personnes symptomatiques et les contacts symptomatiques font l'objet d'une recherche de TB-maladie. Les contacts asymptomatiques de moins de 5 ans passent à la décision de traitement préventif ; ceux de 5 ans et plus et les autres groupes à risque passent un TST ou un IGRA, puis une CXR si le résultat est positif ou indisponible (une CXR anormale mène à la recherche de TB). La case de décision « Traitement préventif contre-indiqué ? » mène à « Différer » ou « Administrer le traitement préventif », et tous les parcours aboutissent à « Suivi de la TB-maladie si nécessaire, même pour les patients ayant terminé le traitement préventif ».",
        "ru": "Алгоритм тестирования на туберкулезную инфекцию и профилактического лечения ТБ у детей и подростков (рисунок 3.4) с тремя исходными группами: ВИЧ-положительные, домашние контакты и другие группы риска. У людей, живущих с ВИЧ, выявляют любой симптом (текущий кашель, лихорадка, потеря массы тела или ночная потливость); лица с симптомами и контакты с симптомами обследуются на ТБ. Контакты без симптомов в возрасте до 5 лет переходят к решению о профилактическом лечении; лицам 5 лет и старше и другим группам риска проводят TST или IGRA, затем CXR при положительном результате или его отсутствии (патологическая CXR ведет к обследованию на ТБ). Блок решения «Противопоказано ли профилактическое лечение?» ведет к «Отложить» или «Назначить профилактическое лечение», и все пути заканчиваются указанием «Наблюдение на предмет ТБ по мере необходимости, даже у пациентов, завершивших профилактическое лечение»."
      },
      "state": "draft"
    },
    {
      "id": "vfig-p073",
      "file": "figures/vfig-p073.webp",
      "page": 73,
      "shows": [
        "Figure 4.1"
      ],
      "narratives": {
        "en": "Pathway diagram of TB exposure, infection and disease drawn as coloured bands: from 'Exposed' to an 'Infected' circle with lungs icon, then branching to 'Accessed health care system' (leading to preventive treatment) or 'Did NOT access health care system' (leading to Diseased, Feeling ill, Accessed health care system, Diagnosed and Treated, with a side branch for 'Un/misdiagnosed'). A blue oval highlights the stages covered in Chapter 4: Diseased, Feeling ill, Accessed health care system, Diagnosed and Treated. The left edge of the render is cropped.",
        "ar": "مخطط مسار التعرض للسل والعدوى والمرض مرسوم على شكل أشرطة ملونة: من «التعرض» إلى دائرة «العدوى» مع أيقونة رئتين، ثم يتفرع إلى «الوصول إلى النظام الصحي» (المؤدي إلى العلاج الوقائي) أو «عدم الوصول إلى النظام الصحي» (المؤدي إلى المرض، ثم الشعور بالمرض، ثم الوصول إلى النظام الصحي، ثم التشخيص، ثم العلاج، مع فرع جانبي لـ«عدم التشخيص/التشخيص الخاطئ»). يُبرز شكل بيضاوي أزرق المراحل التي يتناولها الفصل 4: المرض، والشعور بالمرض، والوصول إلى النظام الصحي، والتشخيص، والعلاج. والحافة اليسرى من الصورة مقصوصة.",
        "zh": "以彩色条带绘制的结核病暴露、感染和发病路径图：从“暴露”到带有肺部图标的“感染”圆圈，随后分为“就诊于卫生保健系统”（通向预防性治疗）或“未就诊于卫生保健系统”（通向发病、感觉不适、就诊于卫生保健系统、确诊和治疗，另有“未诊断/误诊”分支）。 蓝色椭圆突出了第4章涵盖的阶段：发病、感觉不适、就诊于卫生保健系统、确诊和治疗。渲染图左侧边缘被裁剪。",
        "es": "Diagrama de la trayectoria de exposición, infección y enfermedad tuberculosa dibujado como bandas de colores: de «Expuesto» a un círculo «Infectado» con un icono de pulmones, que se bifurca en «Acceso al sistema de atención de salud» (que conduce al tratamiento preventivo) o «Sin acceso al sistema de atención de salud» (que conduce a Enfermo, Sensación de malestar, Acceso al sistema de atención de salud, Diagnosticado y Tratado, con una rama lateral «No diagnosticado o mal diagnosticado»). Un óvalo azul destaca las etapas tratadas en el capítulo 4: Enfermo, Sensación de malestar, Acceso al sistema de atención de salud, Diagnosticado y Tratado. El borde izquierdo de la imagen está recortado.",
        "fr": "Schéma du parcours d'exposition, d'infection et de maladie tuberculeuse dessiné sous forme de bandes colorées : de « Exposé » à un cercle « Infecté » avec une icône de poumons, puis bifurcation vers « A accédé au système de santé » (menant au traitement préventif) ou « N'a PAS accédé au système de santé » (menant à Malade, Se sent malade, A accédé au système de santé, Diagnostiqué et Traité, avec une branche latérale « Non diagnostiqué/mal diagnostiqué »). Un ovale bleu met en évidence les étapes traitées au chapitre 4 : Malade, Se sent malade, A accédé au système de santé, Diagnostiqué et Traité. Le bord gauche du rendu est rogné.",
        "ru": "Схема пути от контакта с ТБ к инфицированию и заболеванию в виде цветных полос: от «Контакт» к кругу «Инфицирован» со значком легких, затем разветвление на «Обращение в систему здравоохранения» (ведет к профилактическому лечению) и «НЕ обращался в систему здравоохранения» (ведет к этапам «Болен», «Плохое самочувствие», «Обращение в систему здравоохранения», «Диагноз поставлен», «Лечение», с боковой ветвью «Не диагностирован/диагностирован неверно»). Синим овалом выделены этапы, рассматриваемые в главе 4: «Болен», «Плохое самочувствие», «Обращение в систему здравоохранения», «Диагноз поставлен» и «Лечение». Левый край изображения обрезан."
      },
      "state": "draft"
    },
    {
      "id": "vfig-p075",
      "file": "figures/vfig-p075.webp",
      "page": 75,
      "shows": [
        "Figure 4.2"
      ],
      "narratives": {
        "en": "Line chart of differentiated cough patterns (Figure 4.2): intensity of cough (no scale) against duration in weeks (0–4). 'Acute cough with delayed recovery' (dotted red) peaks around week 1 and then declines; 'Recurrent acute cough' (dashed blue) shows two separate peaks near weeks 0.7 and 2.4; 'Persistent, non-remitting cough' (solid orange) rises steadily over 4 weeks. Below are a note on persistent cough (88.9% associated with TB in the cited study), the source, and the start of Box 4.1 listing common symptoms of TB in children.",
        "ar": "مخطط خطي لأنماط السعال المتمايزة (الشكل 4.2): شدة السعال (بدون مقياس) مقابل المدة بالأسابيع (0–4). «السعال الحاد مع تأخر التعافي» (منقّط أحمر) يبلغ ذروته نحو الأسبوع 1 ثم ينخفض؛ و«السعال الحاد المتكرر» (متقطع أزرق) يُظهر ذروتين منفصلتين قرب الأسبوعين 0.7 و2.4؛ و«السعال المستمر غير المنقطع» (متصل برتقالي) يرتفع باطّراد على مدى 4 أسابيع. وفي الأسفل ملاحظة عن السعال المستمر (مرتبط بالسل بنسبة 88.9% في الدراسة المذكورة)، والمصدر، وبداية الإطار 4.1 الذي يسرد الأعراض الشائعة للسل لدى الأطفال.",
        "zh": "不同咳嗽模式的折线图（图4.2）：咳嗽强度（无刻度）对应持续时间（周，0–4）。“恢复延迟的急性咳嗽”（红色点线）在第1周左右达到峰值后下降；“复发性急性咳嗽”（蓝色虚线）在约第0.7周和第2.4周出现两个独立峰值；“持续性、不缓解咳嗽”（橙色实线）在4周内稳步上升。下方为关于持续性咳嗽的说明（在所引研究中88.9%与结核病相关）、来源，以及列出儿童结核病常见症状的专栏4.1开头部分。",
        "es": "Gráfico de líneas de los patrones de tos diferenciados (figura 4.2): intensidad de la tos (sin escala) frente a la duración en semanas (0–4). La «tos aguda con recuperación tardía» (punteada roja) alcanza su máximo hacia la semana 1 y luego disminuye; la «tos aguda recurrente» (discontinua azul) muestra dos picos separados hacia las semanas 0,7 y 2,4; la «tos persistente que no remite» (continua naranja) aumenta de forma constante durante 4 semanas. Debajo figuran una nota sobre la tos persistente (asociada a la TB en el 88,9% de los casos en el estudio citado), la fuente y el inicio del recuadro 4.1, que enumera los síntomas comunes de la TB en los niños.",
        "fr": "Graphique linéaire des profils de toux différenciés (figure 4.2) : intensité de la toux (sans échelle) en fonction de la durée en semaines (0–4). La « toux aiguë avec rétablissement tardif » (pointillés rouges) culmine vers la semaine 1 puis diminue ; la « toux aiguë récurrente » (tirets bleus) présente deux pics distincts vers les semaines 0,7 et 2,4 ; la « toux persistante sans rémission » (trait plein orange) augmente régulièrement sur 4 semaines. En dessous figurent une note sur la toux persistante (associée à la TB dans 88,9 % des cas dans l'étude citée), la source et le début de l'encadré 4.1 énumérant les symptômes courants de la TB chez l'enfant.",
        "ru": "Линейный график различных типов кашля (рисунок 4.2): интенсивность кашля (без шкалы) в зависимости от продолжительности в неделях (0–4). «Острый кашель с замедленным выздоровлением» (красная пунктирная линия) достигает пика около 1-й недели, затем снижается; «рецидивирующий острый кашель» (синяя штриховая линия) имеет два отдельных пика около 0,7 и 2,4 недели; «стойкий непрекращающийся кашель» (оранжевая сплошная линия) неуклонно нарастает в течение 4 недель. Ниже приведены примечание о стойком кашле (в цитируемом исследовании в 88,9% случаев связан с ТБ), источник и начало вставки 4.1 с перечнем распространенных симптомов ТБ у детей."
      },
      "state": "draft"
    },
    {
      "id": "img-p077-1",
      "file": "images/img-p077-1.webp",
      "page": 77,
      "narratives": {
        "en": "WHO Child Growth Standards chart 'Weight-for-age GIRLS, Birth to 5 years (z-scores)' on a pink background. Weight (kg, about 2 to 30) is plotted against age (completed months and years, birth to 5 years), with curved z-score lines labelled 3, 2, 0, −2 and −3 that rise with age.",
        "ar": "مخطط معايير نمو الطفل لمنظمة الصحة العالمية «الوزن مقابل العمر – البنات، من الولادة حتى 5 سنوات (الدرجات المعيارية z)» على خلفية وردية. يُرسم الوزن (كغ، من نحو 2 إلى 30) مقابل العمر (بالأشهر والسنوات المكتملة، من الولادة حتى 5 سنوات)، مع خطوط منحنية للدرجات المعيارية مُعلَّمة 3 و2 و0 و−2 و−3 ترتفع مع العمر.",
        "zh": "世卫组织儿童生长标准图表“女童年龄别体重，出生至5岁（Z评分）”，粉色背景。体重（千克，约2至30）对应年龄（足月月龄和岁数，出生至5岁），标注为3、2、0、−2和−3的Z评分曲线随年龄上升。",
        "es": "Gráfico de los Patrones de Crecimiento Infantil de la OMS «Peso para la edad NIÑAS, del nacimiento a los 5 años (puntuaciones z)» sobre fondo rosa. El peso (kg, de 2 a 30 aproximadamente) se representa frente a la edad (meses y años cumplidos, del nacimiento a los 5 años), con curvas de puntuación z rotuladas 3, 2, 0, −2 y −3 que ascienden con la edad.",
        "fr": "Courbe des normes OMS de croissance de l'enfant « Poids pour l'âge FILLES, de la naissance à 5 ans (z-scores) » sur fond rose. Le poids (kg, d'environ 2 à 30) est représenté en fonction de l'âge (mois et années révolus, de la naissance à 5 ans), avec des courbes de z-scores étiquetées 3, 2, 0, −2 et −3 qui montent avec l'âge.",
        "ru": "Диаграмма стандартов роста детей ВОЗ «Масса тела к возрасту, ДЕВОЧКИ, от рождения до 5 лет (z-оценки)» на розовом фоне. Масса тела (кг, примерно от 2 до 30) отложена относительно возраста (полных месяцев и лет, от рождения до 5 лет); кривые z-оценок с метками 3, 2, 0, −2 и −3 поднимаются с возрастом."
      },
      "state": "draft"
    },
    {
      "id": "vfig-p077",
      "file": "figures/vfig-p077.webp",
      "page": 77,
      "shows": [
        "Figure 4.3"
      ],
      "narratives": {
        "en": "Page render with two text boxes (weight loss or failure to thrive; other causes of chronic lung disease) above Figure 4.3, 'Examples of abnormal growth curves': a WHO weight-for-age chart for girls (birth to 5 years, z-score lines 3, 2, 0, −2, −3) with two plotted cases. Case 1, a girl aged 14 months, grew just below the +3 z-score line and then flattened, about 4 kg below her expected weight; case 2, a girl aged 2 years 7 months, grew along the +2 line and then had a static weight for 5 months, about 2 kg below expected.",
        "ar": "صفحة مُصوَّرة فيها إطاران نصيان (فقدان الوزن أو قصور النمو؛ والأسباب الأخرى لأمراض الرئة المزمنة) فوق الشكل 4.3 «أمثلة على منحنيات النمو غير الطبيعية»: مخطط منظمة الصحة العالمية للوزن مقابل العمر للبنات (من الولادة حتى 5 سنوات، خطوط الدرجات المعيارية 3 و2 و0 و−2 و−3) مع حالتين مرسومتين. الحالة 1، طفلة عمرها 14 شهراً، نمت تحت خط الدرجة +3 مباشرة ثم تسطّح منحناها، وهي أقل من وزنها المتوقع بنحو 4 كغ؛ والحالة 2، طفلة عمرها سنتان و7 أشهر، نمت على امتداد خط +2 ثم ثبت وزنها 5 أشهر، وهي أقل من الوزن المتوقع بنحو 2 كغ.",
        "zh": "页面渲染图，图4.3“异常生长曲线示例”上方有两个文本框（体重减轻或生长迟缓；慢性肺病的其他病因）：世卫组织女童年龄别体重图（出生至5岁，Z评分线3、2、0、−2、−3），绘有两个病例。病例1为14个月女童，生长曲线位于+3 Z评分线略下方，随后趋平，比预期体重低约4千克；病例2为2岁7个月女童，沿+2线生长，随后体重5个月停滞，比预期低约2千克。",
        "es": "Imagen de página con dos recuadros de texto (pérdida de peso o retraso del crecimiento; otras causas de enfermedad pulmonar crónica) sobre la figura 4.3, «Ejemplos de curvas de crecimiento anormales»: un gráfico de la OMS de peso para la edad en niñas (del nacimiento a los 5 años, curvas de puntuación z 3, 2, 0, −2, −3) con dos casos representados. El caso 1, una niña de 14 meses, creció justo por debajo de la curva +3 y después se estancó, unos 4 kg por debajo del peso esperado; el caso 2, una niña de 2 años y 7 meses, creció a lo largo de la curva +2 y luego mantuvo un peso estático durante 5 meses, unos 2 kg por debajo de lo esperado.",
        "fr": "Rendu de page avec deux encadrés de texte (perte de poids ou retard de croissance ; autres causes de maladie pulmonaire chronique) au-dessus de la figure 4.3, « Exemples de courbes de croissance anormales » : une courbe OMS de poids pour l'âge chez les filles (de la naissance à 5 ans, courbes de z-scores 3, 2, 0, −2, −3) avec deux cas tracés. Le cas 1, une fillette de 14 mois, a grandi juste sous la courbe +3 puis sa courbe s'est aplatie, environ 4 kg sous le poids attendu ; le cas 2, une fillette de 2 ans et 7 mois, a suivi la courbe +2 puis a eu un poids stable pendant 5 mois, environ 2 kg sous le poids attendu.",
        "ru": "Изображение страницы с двумя текстовыми вставками (потеря массы тела или задержка развития; другие причины хронических заболеваний легких) над рисунком 4.3 «Примеры аномальных кривых роста»: диаграмма ВОЗ «масса тела к возрасту» для девочек (от рождения до 5 лет, кривые z-оценок 3, 2, 0, −2, −3) с двумя нанесенными случаями. Случай 1 — девочка 14 месяцев, росла чуть ниже кривой +3, затем кривая выровнялась; масса примерно на 4 кг ниже ожидаемой. Случай 2 — девочка 2 лет 7 месяцев, росла по кривой +2, затем масса 5 месяцев не менялась; примерно на 2 кг ниже ожидаемой."
      },
      "state": "draft"
    },
    {
      "id": "img-p078-1",
      "file": "images/img-p078-1.webp",
      "page": 78,
      "narratives": {
        "en": "WHO Child Growth Standards chart 'Weight-for-age BOYS, Birth to 5 years (z-scores)' on a blue background. Weight (kg, about 2 to 28) is plotted against age (completed months and years, birth to 5 years), with curved z-score lines labelled 3, 2, 0, −2 and −3 that rise with age.",
        "ar": "مخطط معايير نمو الطفل لمنظمة الصحة العالمية «الوزن مقابل العمر – الأولاد، من الولادة حتى 5 سنوات (الدرجات المعيارية z)» على خلفية زرقاء. يُرسم الوزن (كغ، من نحو 2 إلى 28) مقابل العمر (بالأشهر والسنوات المكتملة، من الولادة حتى 5 سنوات)، مع خطوط منحنية للدرجات المعيارية مُعلَّمة 3 و2 و0 و−2 و−3 ترتفع مع العمر.",
        "zh": "世卫组织儿童生长标准图表“男童年龄别体重，出生至5岁（Z评分）”，蓝色背景。体重（千克，约2至28）对应年龄（足月月龄和岁数，出生至5岁），标注为3、2、0、−2和−3的Z评分曲线随年龄上升。",
        "es": "Gráfico de los Patrones de Crecimiento Infantil de la OMS «Peso para la edad NIÑOS, del nacimiento a los 5 años (puntuaciones z)» sobre fondo azul. El peso (kg, de 2 a 28 aproximadamente) se representa frente a la edad (meses y años cumplidos, del nacimiento a los 5 años), con curvas de puntuación z rotuladas 3, 2, 0, −2 y −3 que ascienden con la edad.",
        "fr": "Courbe des normes OMS de croissance de l'enfant « Poids pour l'âge GARÇONS, de la naissance à 5 ans (z-scores) » sur fond bleu. Le poids (kg, d'environ 2 à 28) est représenté en fonction de l'âge (mois et années révolus, de la naissance à 5 ans), avec des courbes de z-scores étiquetées 3, 2, 0, −2 et −3 qui montent avec l'âge.",
        "ru": "Диаграмма стандартов роста детей ВОЗ «Масса тела к возрасту, МАЛЬЧИКИ, от рождения до 5 лет (z-оценки)» на синем фоне. Масса тела (кг, примерно от 2 до 28) отложена относительно возраста (полных месяцев и лет, от рождения до 5 лет); кривые z-оценок с метками 3, 2, 0, −2 и −3 поднимаются с возрастом."
      },
      "state": "draft"
    },
    {
      "id": "vfig-p093",
      "file": "figures/vfig-p093.webp",
      "page": 93,
      "shows": [
        "Figure 4.4"
      ],
      "narratives": {
        "en": "Treatment decision algorithm for children with presumptive pulmonary TB (Figure 4.4, Algorithm A). It starts with danger signs (stabilize and/or transfer), then children under 2 years, living with HIV and/or with severe acute malnutrition go straight to specimen collection for mWRD testing (e.g. Xpert MTB/RIF or Ultra) and urine LF-LAM, while others are first treated for the most likely non-TB condition and followed up in 1–2 weeks. If mWRD or LF-LAM detects Mycobacterium tuberculosis, or there was close or household TB contact in the previous 12 months, appropriate TB treatment is initiated; otherwise signs and symptoms and CXR features are scored (e.g. cough longer than 2 weeks +2, fever longer than 2 weeks +5, enlarged lymph nodes on CXR +17, miliary pattern +15, tachypnoea −1), and TB treatment is started if Sum A + Sum B > 10, or the child is followed up in 1–2 weeks.",
        "ar": "خوارزمية قرار العلاج للأطفال المشتبه بإصابتهم بالسل الرئوي (الشكل 4.4، الخوارزمية A). تبدأ بعلامات الخطر (التثبيت و/أو النقل)، ثم ينتقل الأطفال دون سن سنتين أو المتعايشون مع فيروس العوز المناعي البشري و/أو المصابون بسوء التغذية الحاد الوخيم مباشرة إلى جمع العينات لاختبار mWRD (مثل Xpert MTB/RIF أو Ultra) واختبار LF-LAM في البول، بينما يُعالَج الآخرون أولاً من الحالة غير السلية الأرجح ويُتابَعون بعد 1–2 أسبوع. إذا كشف اختبار mWRD أو LF-LAM عن المتفطرة السلية، أو وُجد مخالطة وثيقة أو منزلية لمريض سل خلال الأشهر الـ12 السابقة، يُبدأ علاج السل المناسب؛ وإلا تُحتسب درجات العلامات والأعراض وسمات التصوير الشعاعي للصدر (مثل سعال لأكثر من أسبوعين +2، وحمى لأكثر من أسبوعين +5، وتضخم العقد اللمفية في التصوير +17، والنمط الدخني +15، وتسرّع التنفس −1)، ويُبدأ علاج السل إذا كان مجموع A + مجموع B > 10، وإلا يُتابَع الطفل بعد 1–2 أسبوع.",
        "zh": "疑似肺结核儿童的治疗决策算法（图4.4，算法A）。首先评估危险体征（稳定病情和/或转诊），随后2岁以下、感染艾滋病毒和/或患有重度急性营养不良的儿童直接采集标本进行mWRD检测（如Xpert MTB/RIF或Ultra）及尿液LF-LAM检测，其他儿童则先治疗最可能的非结核病病症并于1–2周后随访。如mWRD或LF-LAM检出结核分枝杆菌，或过去12个月内有密切或家庭结核病接触史，则开始适当的结核病治疗；否则对体征和症状以及胸部X线特征进行评分（如咳嗽超过2周+2，发热超过2周+5，胸片示淋巴结肿大+17，粟粒样改变+15，呼吸急促−1），若A总分+B总分>10则开始结核病治疗，否则1–2周后随访。",
        "es": "Algoritmo de decisión terapéutica para niños con presunta TB pulmonar (figura 4.4, algoritmo A). Comienza con los signos de peligro (estabilizar y/o trasladar); después, los niños menores de 2 años, con VIH y/o con malnutrición aguda grave pasan directamente a la recogida de muestras para pruebas mWRD (p. ej., Xpert MTB/RIF o Ultra) y LF-LAM en orina, mientras que los demás reciben primero tratamiento para la afección no tuberculosa más probable y seguimiento en 1–2 semanas. Si la mWRD o la LF-LAM detectan Mycobacterium tuberculosis, o hubo contacto estrecho o domiciliario con TB en los 12 meses anteriores, se inicia el tratamiento antituberculoso adecuado; de lo contrario, se puntúan los signos y síntomas y los hallazgos de la CXR (p. ej., tos de más de 2 semanas +2, fiebre de más de 2 semanas +5, adenopatías en la CXR +17, patrón miliar +15, taquipnea −1) y se inicia el tratamiento si Suma A + Suma B > 10; si no, se hace seguimiento en 1–2 semanas.",
        "fr": "Algorithme de décision thérapeutique pour les enfants présumés atteints de TB pulmonaire (figure 4.4, algorithme A). Il commence par les signes de danger (stabiliser et/ou transférer) ; ensuite, les enfants de moins de 2 ans, vivant avec le VIH et/ou souffrant de malnutrition aiguë sévère passent directement au prélèvement d'échantillons pour un test mWRD (par ex. Xpert MTB/RIF ou Ultra) et un LF-LAM urinaire, tandis que les autres sont d'abord traités pour l'affection non tuberculeuse la plus probable et revus dans 1 à 2 semaines. Si le mWRD ou le LF-LAM détecte Mycobacterium tuberculosis, ou en cas de contact étroit ou familial avec la TB au cours des 12 mois précédents, un traitement antituberculeux approprié est instauré ; sinon, les signes et symptômes et les caractéristiques de la CXR sont notés (par ex. toux de plus de 2 semaines +2, fièvre de plus de 2 semaines +5, adénopathies à la CXR +17, aspect miliaire +15, tachypnée −1), et le traitement est instauré si Somme A + Somme B > 10, sinon l'enfant est revu dans 1 à 2 semaines.",
        "ru": "Алгоритм принятия решения о лечении детей с предполагаемым туберкулезом легких (рисунок 4.4, алгоритм A). Он начинается с признаков опасности (стабилизировать и/или перевести), затем дети в возрасте до 2 лет, живущие с ВИЧ и/или с тяжелой острой недостаточностью питания, сразу переходят к сбору образцов для тестирования mWRD (например, Xpert MTB/RIF или Ultra) и LF-LAM мочи, а остальных сначала лечат от наиболее вероятного заболевания, не связанного с ТБ, и повторно осматривают через 1–2 недели. Если mWRD или LF-LAM выявляют Mycobacterium tuberculosis или в предыдущие 12 месяцев был тесный или домашний контакт с ТБ, начинается соответствующее лечение ТБ; в противном случае проводится балльная оценка признаков и симптомов и рентгенологических признаков (например, кашель более 2 недель +2, лихорадка более 2 недель +5, увеличение лимфоузлов на CXR +17, милиарная картина +15, тахипноэ −1), и лечение ТБ начинается, если сумма A + сумма B > 10, иначе ребенка повторно осматривают через 1–2 недели."
      },
      "state": "draft"
    },
    {
      "id": "vfig-p094",
      "file": "figures/vfig-p094.webp",
      "page": 94,
      "shows": [
        "Figure 4.5"
      ],
      "narratives": {
        "en": "Treatment decision algorithm for children with presumptive pulmonary TB (Figure 4.5, Algorithm B). It starts with danger signs (stabilize and/or transfer), then children under 2 years, living with HIV and/or with severe acute malnutrition go straight to specimen collection for mWRD testing (e.g. Xpert MTB/RIF or Ultra) and urine LF-LAM, while others are first treated for the most likely non-TB condition and followed up in 1–2 weeks. If mWRD or LF-LAM detects Mycobacterium tuberculosis, or there was close or household TB contact in the previous 12 months, appropriate TB treatment is initiated; otherwise signs and symptoms alone are scored (e.g. cough longer than 2 weeks +5, fever longer than 2 weeks +10, haemoptysis +9, swollen lymph nodes +7, tachypnoea +2), and TB treatment is started if the sum is > 10, or the child is followed up in 1–2 weeks.",
        "ar": "خوارزمية قرار العلاج للأطفال المشتبه بإصابتهم بالسل الرئوي (الشكل 4.5، الخوارزمية B). تبدأ بعلامات الخطر (التثبيت و/أو النقل)، ثم ينتقل الأطفال دون سن سنتين أو المتعايشون مع فيروس العوز المناعي البشري و/أو المصابون بسوء التغذية الحاد الوخيم مباشرة إلى جمع العينات لاختبار mWRD (مثل Xpert MTB/RIF أو Ultra) واختبار LF-LAM في البول، بينما يُعالَج الآخرون أولاً من الحالة غير السلية الأرجح ويُتابَعون بعد 1–2 أسبوع. إذا كشف اختبار mWRD أو LF-LAM عن المتفطرة السلية، أو وُجد مخالطة وثيقة أو منزلية لمريض سل خلال الأشهر الـ12 السابقة، يُبدأ علاج السل المناسب؛ وإلا تُحتسب درجات العلامات والأعراض وحدها (مثل سعال لأكثر من أسبوعين +5، وحمى لأكثر من أسبوعين +10، ونفث الدم +9، وتورم العقد اللمفية +7، وتسرّع التنفس +2)، ويُبدأ علاج السل إذا كان المجموع > 10، وإلا يُتابَع الطفل بعد 1–2 أسبوع.",
        "zh": "疑似肺结核儿童的治疗决策算法（图4.5，算法B）。首先评估危险体征（稳定病情和/或转诊），随后2岁以下、感染艾滋病毒和/或患有重度急性营养不良的儿童直接采集标本进行mWRD检测（如Xpert MTB/RIF或Ultra）及尿液LF-LAM检测，其他儿童则先治疗最可能的非结核病病症并于1–2周后随访。如mWRD或LF-LAM检出结核分枝杆菌，或过去12个月内有密切或家庭结核病接触史，则开始适当的结核病治疗；否则仅对体征和症状进行评分（如咳嗽超过2周+5，发热超过2周+10，咯血+9，淋巴结肿大+7，呼吸急促+2），若总分>10则开始结核病治疗，否则1–2周后随访。",
        "es": "Algoritmo de decisión terapéutica para niños con presunta TB pulmonar (figura 4.5, algoritmo B). Comienza con los signos de peligro (estabilizar y/o trasladar); después, los niños menores de 2 años, con VIH y/o con malnutrición aguda grave pasan directamente a la recogida de muestras para pruebas mWRD (p. ej., Xpert MTB/RIF o Ultra) y LF-LAM en orina, mientras que los demás reciben primero tratamiento para la afección no tuberculosa más probable y seguimiento en 1–2 semanas. Si la mWRD o la LF-LAM detectan Mycobacterium tuberculosis, o hubo contacto estrecho o domiciliario con TB en los 12 meses anteriores, se inicia el tratamiento antituberculoso adecuado; de lo contrario, se puntúan solo los signos y síntomas (p. ej., tos de más de 2 semanas +5, fiebre de más de 2 semanas +10, hemoptisis +9, adenopatías +7, taquipnea +2) y se inicia el tratamiento si la suma es > 10; si no, se hace seguimiento en 1–2 semanas.",
        "fr": "Algorithme de décision thérapeutique pour les enfants présumés atteints de TB pulmonaire (figure 4.5, algorithme B). Il commence par les signes de danger (stabiliser et/ou transférer) ; ensuite, les enfants de moins de 2 ans, vivant avec le VIH et/ou souffrant de malnutrition aiguë sévère passent directement au prélèvement d'échantillons pour un test mWRD (par ex. Xpert MTB/RIF ou Ultra) et un LF-LAM urinaire, tandis que les autres sont d'abord traités pour l'affection non tuberculeuse la plus probable et revus dans 1 à 2 semaines. Si le mWRD ou le LF-LAM détecte Mycobacterium tuberculosis, ou en cas de contact étroit ou familial avec la TB au cours des 12 mois précédents, un traitement antituberculeux approprié est instauré ; sinon, seuls les signes et symptômes sont notés (par ex. toux de plus de 2 semaines +5, fièvre de plus de 2 semaines +10, hémoptysie +9, adénopathies +7, tachypnée +2), et le traitement est instauré si la somme est > 10, sinon l'enfant est revu dans 1 à 2 semaines.",
        "ru": "Алгоритм принятия решения о лечении детей с предполагаемым туберкулезом легких (рисунок 4.5, алгоритм B). Он начинается с признаков опасности (стабилизировать и/или перевести), затем дети в возрасте до 2 лет, живущие с ВИЧ и/или с тяжелой острой недостаточностью питания, сразу переходят к сбору образцов для тестирования mWRD (например, Xpert MTB/RIF или Ultra) и LF-LAM мочи, а остальных сначала лечат от наиболее вероятного заболевания, не связанного с ТБ, и повторно осматривают через 1–2 недели. Если mWRD или LF-LAM выявляют Mycobacterium tuberculosis или в предыдущие 12 месяцев был тесный или домашний контакт с ТБ, начинается соответствующее лечение ТБ; в противном случае проводится балльная оценка только признаков и симптомов (например, кашель более 2 недель +5, лихорадка более 2 недель +10, кровохарканье +9, увеличение лимфоузлов +7, тахипноэ +2), и лечение ТБ начинается, если сумма > 10, иначе ребенка повторно осматривают через 1–2 недели."
      },
      "state": "draft"
    },
    {
      "id": "vfig-p107",
      "file": "figures/vfig-p107.webp",
      "page": 107,
      "shows": [
        "Figure 5.1"
      ],
      "narratives": {
        "en": "Pathway diagram of TB exposure, infection and disease drawn as coloured bands: from 'Exposed' to an 'Infected' circle with lungs icon, then branching to 'Accessed health care system' (leading to preventive treatment) or 'Did NOT access health care system' (leading to Diseased, Feeling ill, Accessed health care system, Diagnosed and Treated, with a side branch for 'Un/misdiagnosed'). A blue oval highlights the stages covered in Chapter 5: Diagnosed and Treated. The left edge and parts of the top labels are cropped.",
        "ar": "مخطط مسار التعرض للسل والعدوى والمرض مرسوم على شكل أشرطة ملونة: من «التعرض» إلى دائرة «العدوى» مع أيقونة رئتين، ثم يتفرع إلى «الوصول إلى النظام الصحي» (المؤدي إلى العلاج الوقائي) أو «عدم الوصول إلى النظام الصحي» (المؤدي إلى المرض، ثم الشعور بالمرض، ثم الوصول إلى النظام الصحي، ثم التشخيص، ثم العلاج، مع فرع جانبي لـ«عدم التشخيص/التشخيص الخاطئ»). يُبرز شكل بيضاوي أزرق المراحل التي يتناولها الفصل 5: التشخيص والعلاج. والحافة اليسرى وأجزاء من التسميات العلوية مقصوصة.",
        "zh": "以彩色条带绘制的结核病暴露、感染和发病路径图：从“暴露”到带有肺部图标的“感染”圆圈，随后分为“就诊于卫生保健系统”（通向预防性治疗）或“未就诊于卫生保健系统”（通向发病、感觉不适、就诊于卫生保健系统、确诊和治疗，另有“未诊断/误诊”分支）。 蓝色椭圆突出了第5章涵盖的阶段：确诊和治疗。左侧边缘和顶部部分标签被裁剪。",
        "es": "Diagrama de la trayectoria de exposición, infección y enfermedad tuberculosa dibujado como bandas de colores: de «Expuesto» a un círculo «Infectado» con un icono de pulmones, que se bifurca en «Acceso al sistema de atención de salud» (que conduce al tratamiento preventivo) o «Sin acceso al sistema de atención de salud» (que conduce a Enfermo, Sensación de malestar, Acceso al sistema de atención de salud, Diagnosticado y Tratado, con una rama lateral «No diagnosticado o mal diagnosticado»). Un óvalo azul destaca las etapas tratadas en el capítulo 5: Diagnosticado y Tratado. El borde izquierdo y parte de las etiquetas superiores están recortados.",
        "fr": "Schéma du parcours d'exposition, d'infection et de maladie tuberculeuse dessiné sous forme de bandes colorées : de « Exposé » à un cercle « Infecté » avec une icône de poumons, puis bifurcation vers « A accédé au système de santé » (menant au traitement préventif) ou « N'a PAS accédé au système de santé » (menant à Malade, Se sent malade, A accédé au système de santé, Diagnostiqué et Traité, avec une branche latérale « Non diagnostiqué/mal diagnostiqué »). Un ovale bleu met en évidence les étapes traitées au chapitre 5 : Diagnostiqué et Traité. Le bord gauche et une partie des étiquettes du haut sont rognés.",
        "ru": "Схема пути от контакта с ТБ к инфицированию и заболеванию в виде цветных полос: от «Контакт» к кругу «Инфицирован» со значком легких, затем разветвление на «Обращение в систему здравоохранения» (ведет к профилактическому лечению) и «НЕ обращался в систему здравоохранения» (ведет к этапам «Болен», «Плохое самочувствие», «Обращение в систему здравоохранения», «Диагноз поставлен», «Лечение», с боковой ветвью «Не диагностирован/диагностирован неверно»). Синим овалом выделены этапы, рассматриваемые в главе 5: «Диагноз поставлен» и «Лечение». Левый край и часть верхних подписей обрезаны."
      },
      "state": "draft"
    },
    {
      "id": "vfig-p140",
      "file": "figures/vfig-p140.webp",
      "page": 140,
      "shows": [
        "Figure 5.2"
      ],
      "narratives": {
        "en": "Grid showing TB medicines and duration of treatment for the standardized all-oral bedaquiline-containing shorter regimen (Figure 5.2), under the regimen notation '4–6 Bdq(6) – Lfx – Cfz – Z – E – Hh – Eto / 5 Lfx – Cfz – Z – E'. Rows are medicines and columns months 1–11: bedaquiline is orange for months 1–6; high-dose isoniazid and ethionamide/prothionamide are orange for months 1–4 and blue for months 5–6; levofloxacin, clofazimine, pyrazinamide and ethambutol are orange for months 1–9 and blue for months 10–11.",
        "ar": "شبكة تُبيّن أدوية السل ومدة العلاج للنظام العلاجي الأقصر الموحّد الفموي بالكامل المحتوي على البيداكويلين (الشكل 5.2)، تحت رمز النظام «4–6 Bdq(6) – Lfx – Cfz – Z – E – Hh – Eto / 5 Lfx – Cfz – Z – E». الصفوف للأدوية والأعمدة للأشهر 1–11: البيداكويلين باللون البرتقالي في الأشهر 1–6؛ والإيزونيازيد بجرعة عالية والإيثيوناميد/البروثيوناميد باللون البرتقالي في الأشهر 1–4 وبالأزرق في الأشهر 5–6؛ والليفوفلوكساسين والكلوفازيمين والبيرازيناميد والإيثامبوتول باللون البرتقالي في الأشهر 1–9 وبالأزرق في الأشهر 10–11.",
        "zh": "显示标准化全口服含贝达喹啉短程方案的抗结核药物和疗程的网格图（图5.2），上方为方案表示“4–6 Bdq(6) – Lfx – Cfz – Z – E – Hh – Eto / 5 Lfx – Cfz – Z – E”。行为药物，列为第1–11个月：贝达喹啉第1–6个月为橙色；高剂量异烟肼和乙硫异烟胺/丙硫异烟胺第1–4个月为橙色、第5–6个月为蓝色；左氧氟沙星、氯法齐明、吡嗪酰胺和乙胺丁醇第1–9个月为橙色、第10–11个月为蓝色。",
        "es": "Cuadrícula que muestra los medicamentos antituberculosos y la duración del tratamiento del régimen acortado estandarizado totalmente oral con bedaquilina (figura 5.2), bajo la notación «4–6 Bdq(6) – Lfx – Cfz – Z – E – Hh – Eto / 5 Lfx – Cfz – Z – E». Las filas son medicamentos y las columnas los meses 1 a 11: la bedaquilina está en naranja en los meses 1–6; la isoniazida en dosis altas y la etionamida/protionamida están en naranja en los meses 1–4 y en azul en los meses 5–6; la levofloxacina, la clofazimina, la pirazinamida y el etambutol están en naranja en los meses 1–9 y en azul en los meses 10–11.",
        "fr": "Grille indiquant les médicaments antituberculeux et la durée du traitement pour le schéma thérapeutique court standardisé entièrement oral contenant de la bédaquiline (figure 5.2), sous la notation « 4–6 Bdq(6) – Lfx – Cfz – Z – E – Hh – Eto / 5 Lfx – Cfz – Z – E ». Les lignes correspondent aux médicaments et les colonnes aux mois 1 à 11 : la bédaquiline est en orange aux mois 1–6 ; l'isoniazide à forte dose et l'éthionamide/prothionamide sont en orange aux mois 1–4 et en bleu aux mois 5–6 ; la lévofloxacine, la clofazimine, le pyrazinamide et l'éthambutol sont en orange aux mois 1–9 et en bleu aux mois 10–11.",
        "ru": "Таблица-сетка противотуберкулезных препаратов и продолжительности лечения для стандартизированного полностью перорального укороченного режима с бедаквилином (рисунок 5.2) под обозначением режима «4–6 Bdq(6) – Lfx – Cfz – Z – E – Hh – Eto / 5 Lfx – Cfz – Z – E». Строки — препараты, столбцы — месяцы 1–11: бедаквилин — оранжевым в месяцы 1–6; высокодозный изониазид и этионамид/протионамид — оранжевым в месяцы 1–4 и синим в месяцы 5–6; левофлоксацин, клофазимин, пиразинамид и этамбутол — оранжевым в месяцы 1–9 и синим в месяцы 10–11."
      },
      "state": "draft"
    },
    {
      "id": "img-p200-1",
      "file": "images/img-p200-1.webp",
      "page": 200,
      "narratives": {
        "en": "Infographic titled 'What is palliative care?' (Figure 7.1): a stylized tree whose branches point to six statements – it is care for patients with life-threatening illnesses and their families; it can be given in homes, health centres, hospitals and hospices; it improves quality of life; it benefits health systems by reducing unnecessary hospital admissions; it relieves physical, psychosocial and spiritual suffering; it can be done by many types of health professionals and volunteers.",
        "ar": "رسم معلوماتي بعنوان «ما هي الرعاية الملطِّفة؟» (الشكل 7.1): شجرة منمّقة تشير فروعها إلى ست عبارات – هي رعاية للمرضى المصابين بأمراض مهددة للحياة ولأسرهم؛ يمكن تقديمها في المنازل والمراكز الصحية والمستشفيات ودور رعاية المحتضرين؛ تُحسّن نوعية الحياة؛ تفيد النظم الصحية بالحد من حالات الدخول غير الضرورية إلى المستشفيات؛ تخفف المعاناة البدنية والنفسية الاجتماعية والروحية؛ يمكن أن يقدمها العديد من فئات المهنيين الصحيين والمتطوعين.",
        "zh": "题为“什么是姑息治疗？”的信息图（图7.1）：一棵风格化的树，其枝条指向六条陈述——它是为患有危及生命疾病的患者及其家属提供的照护；可在家庭、卫生中心、医院和临终关怀机构提供；可提高生活质量；通过减少不必要的住院使卫生系统受益；可缓解身体、心理社会和精神上的痛苦；可由多种类型的卫生专业人员和志愿者提供。",
        "es": "Infografía titulada «¿Qué son los cuidados paliativos?» (figura 7.1): un árbol estilizado cuyas ramas señalan seis afirmaciones: son cuidados para pacientes con enfermedades potencialmente mortales y sus familias; pueden prestarse en hogares, centros de salud, hospitales y residencias para enfermos terminales; mejoran la calidad de vida; benefician a los sistemas de salud al reducir los ingresos hospitalarios innecesarios; alivian el sufrimiento físico, psicosocial y espiritual; pueden prestarlos muchos tipos de profesionales de la salud y voluntarios.",
        "fr": "Infographie intitulée « Qu'est-ce que les soins palliatifs ? » (figure 7.1) : un arbre stylisé dont les branches renvoient à six affirmations – ce sont des soins pour les patients atteints de maladies potentiellement mortelles et leurs familles ; ils peuvent être dispensés à domicile, dans les centres de santé, les hôpitaux et les établissements de soins palliatifs ; ils améliorent la qualité de vie ; ils profitent aux systèmes de santé en réduisant les hospitalisations inutiles ; ils soulagent les souffrances physiques, psychosociales et spirituelles ; ils peuvent être dispensés par de nombreux types de professionnels de santé et de bénévoles.",
        "ru": "Инфографика «Что такое паллиативная помощь?» (рисунок 7.1): стилизованное дерево, ветви которого указывают на шесть утверждений — это помощь пациентам с угрожающими жизни заболеваниями и их семьям; ее можно оказывать на дому, в медицинских центрах, больницах и хосписах; она улучшает качество жизни; она приносит пользу системам здравоохранения, сокращая число ненужных госпитализаций; она облегчает физические, психосоциальные и духовные страдания; ее могут оказывать медицинские работники многих специальностей и добровольцы."
      },
      "state": "draft"
    }
  ],
  "tables": [
    {
      "label": "Table 3.1",
      "caption": "Table 3.1. TB preventive treatment options",
      "pages": [
        60,
        61
      ],
      "columns": [
        {
          "titles": "Target group"
        },
        {
          "titles": "Preferred regimen"
        },
        {
          "titles": "Alternative regimen(s)"
        },
        {
          "titles": "Notes"
        }
      ],
      "rows": [
        [
          "HIV-negative children aged ≤2 years",
          "3HR if paediatric fixed-dose combination (FDC) a available",
          "If paediatric FDC not available, use 6H (preferably dispersible tablets)",
          "There is a lack of data on appropriate doses of rifapentine to allow use of 3HP in children aged <2 years There are no data for neonates; an expert should be consulted for advice on suitable TPT regimens"
        ],
        [
          "HIV-negative children aged ≥2 years and ≤25 kg body weight",
          "3HR if paediatric FDC a available",
          "If paediatric FDC not available, use 3HP or 6H",
          "A paediatric formulation of rifapentine is not available A rifapentine 150 mg scored and dispersible formulation has been prioritized for development b,c A paediatric FDC for rifapentine and isoniazid is not planned for development"
        ],
        [
          "HIV-negative children >25 kg body weight",
          "3HP using adult formulations",
          "3HR using adult FDC 1HP using adult formulation (age ≥13 years)",
          "An adult isoniazid 300 mg/ rifapentine300 mg scored FDC and an adult rifapentine 150 mg tablet are available"
        ],
        [
          "Children living with HIV",
          "6H (preferably using dispersible tablets)",
          "3HR for children on EFV-based ART 3HP for older children on EFV ART (and able to swallow tablets)",
          "For more details on TPT regimens to use with ART, see Section 7.1 Data on 3HP in children on DTG are not yet available"
        ],
        [
          "Adolescents living with HIV",
          "3HP if on TDF, EFV, DTG or RAL-based ART",
          "1HP (age ≥13 years) if on TDF, EFV, DTG or RAL-based ART 6H",
          "For more details on TPT regimens to use with ART, see Section 7.1 (including dose adjustments for 1HP with DTG or RAL)"
        ]
      ],
      "notes": "1HP: 1 month of isoniazid and rifapentine daily; 3HP: 3 months of isoniazid and rifapentine weekly; 3HR: 3 months of isoniazid and rifampicin daily; 6H: 6 months of isoniazid daily; DTG: dolutegravir; EFV: efavirenz; FDC: fixed-dose combination; RAL; raltegravir; TDF: tenofovir disoproxil fumarate.\na Dispersible FDC, isoniazid 50 mg/rifampicin 75 mg.\nb Report of the meeting to review the Paediatric Antituberculosis Drug Optimization priority list. Geneva: World Health Organization; 2021 (https://www.who.int/publications/i/item/9789240022157).\nc Rifapentine 150 mg tablet (scored and dispersible) is included in the 21st Invitation to Manufacturers of Antituberculosis Medicines to Submit an Expression of Interest (EOI) for Product Evaluation to the WHO Prequalification Unit (https://extranet.who.int/pqweb/sites/default/files/documents/EOI_TB_v21_29June2021.pdf).",
      "narratives": {
        "en": "TB preventive treatment options for children and adolescents by target group (HIV-negative children by age and weight, children living with HIV, adolescents living with HIV), giving the preferred regimen, alternative regimens and notes on formulations and data gaps.",
        "ar": "خيارات العلاج الوقائي من السل للأطفال والمراهقين حسب الفئة المستهدفة (الأطفال غير المصابين بفيروس العوز المناعي البشري حسب العمر والوزن، والأطفال المتعايشون مع الفيروس، والمراهقون المتعايشون معه)، مع النظام المفضّل والأنظمة البديلة وملاحظات عن المستحضرات وثغرات البيانات.",
        "zh": "按目标人群（按年龄和体重划分的艾滋病毒阴性儿童、感染艾滋病毒的儿童、感染艾滋病毒的青少年）列出儿童和青少年结核病预防性治疗方案，包括首选方案、替代方案以及关于剂型和数据缺口的说明。",
        "es": "Opciones de tratamiento preventivo de la tuberculosis para niños y adolescentes según el grupo destinatario (niños sin VIH según edad y peso, niños con el VIH, adolescentes con el VIH), con la pauta preferida, las pautas alternativas y notas sobre formulaciones y lagunas de datos.",
        "fr": "Options de traitement préventif de la tuberculose chez l’enfant et l’adolescent selon le groupe cible (enfants séronégatifs pour le VIH selon l’âge et le poids, enfants vivant avec le VIH, adolescents vivant avec le VIH), avec le schéma privilégié, les schémas alternatifs et des remarques sur les formulations et les lacunes de données.",
        "ru": "Варианты профилактического лечения туберкулёза у детей и подростков в зависимости от целевой группы (ВИЧ-отрицательные дети по возрасту и массе тела, дети, живущие с ВИЧ, подростки, живущие с ВИЧ): предпочтительная схема, альтернативные схемы и примечания о лекарственных формах и пробелах в данных."
      },
      "csv": "tables/table-3-1.csv"
    },
    {
      "label": "Table 3.2",
      "caption": "Table 3.2. Dosing for recommended TB preventive treatment regimens",
      "pages": [
        62,
        63
      ],
      "columns": [
        {
          "titles": "TPT regimen"
        },
        {
          "titles": "Dose by age and weight banda"
        },
        {
          "titles": ""
        },
        {
          "titles": ""
        },
        {
          "titles": ""
        },
        {
          "titles": ""
        },
        {
          "titles": ""
        }
      ],
      "rows": [
        [
          "3HR",
          "Isoniazid: • Age <10 years: 10 mg/kg/day (range 7–15 mg) • Age ≥10 years: 5 mg/kg/day Rifampicin: • Age <10 years: 15 mg/kg/day (range 10–20 mg) • Age ≥10 years: 10 mg/kg/day",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "",
          "Weight band b",
          "4–<8 kg",
          "8–<12 kg",
          "12–<16 kg",
          "16–<25 kg",
          "≥25 kg"
        ],
        [
          "",
          "Isoniazid 50 mg/ rifampicin 75 mg (FDC)",
          "1",
          "2",
          "3",
          "4",
          "Use adult formulations"
        ],
        [
          "3HP",
          "Age 2–14 years c,d",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "",
          "Medicine, formulation",
          "10–<16 kg",
          "16–<24 kg",
          "24–<31 kg",
          "31–<34 kg",
          "≥34 kg"
        ],
        [
          "",
          "Isoniazid 100 mg e",
          "3",
          "5",
          "6",
          "7",
          "7"
        ],
        [
          "",
          "Rifapentine 150 mg",
          "2",
          "3",
          "4",
          "5",
          "5"
        ],
        [
          "",
          "Age >14 years",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "",
          "Medicine, formulation",
          "30–<36 kg",
          "36–<46 kg",
          "46–<56 kg",
          "56–<70 kg",
          "≥70 kg"
        ],
        [
          "",
          "Isoniazid 300 mg",
          "3",
          "3",
          "3",
          "3",
          "3"
        ],
        [
          "",
          "Rifapentine 150 mg",
          "6",
          "6",
          "6",
          "6",
          "6"
        ],
        [
          "",
          "Isoniazid 300 mg + rifapentine 300 mg FDC",
          "3",
          "3",
          "3",
          "3",
          "3"
        ],
        [
          "1HP",
          "Age ≥13 years (regardless of weight band): • Isoniazid 300 mg/day • Rifapentine 600 mg/day",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "6H or 9H f",
          "Age <10 years: 10 mg/kg/day (range 7–15 mg) Age ≥10 years: 5 mg/kg/day",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "",
          "Weight band",
          "4–<8 kg",
          "8–<12 kg",
          "12–<16 kg",
          "16-<25 kg",
          "≥25 kg"
        ],
        [
          "",
          "100 mg (dispersible) tablet",
          "0.5",
          "1",
          "1.5",
          "2",
          "3 (or use 1 300 mg tablet)"
        ],
        [
          "4R",
          "Age <10 years: 15 mg/kg/day (range 10–20 mg) Age ≥10 years: 10 mg/kg/day",
          "",
          "",
          "",
          "",
          ""
        ]
      ],
      "notes": "1HP: 1 month of daily isoniazid and rifapentine (28 doses); 3HP: 3 months of weekly isoniazid and rifapentine (12 doses); 3HR: 3 months of daily isoniazid and rifampicin; 4R: 4 months of daily rifampicin; 6H: 6 months of daily isoniazid; 9H: 9 months of daily isoniazid.\na Presentation of weight bands has been updated – for example, the 4–7 kg weight band is now written as 4–<8 kg. There is no change to the weight range represented in the weight band.\nb For infants weighing less than 4 kg, consult a paediatric TB specialist.\nc Dosage may differ among adults and children in overlapping weight bands.\nd For children aged 2 years and over but weighing less than 10 kg, consult a paediatric TB specialist before using 3HP.\ne A 300 mg formulation can be used to reduce the pill burden.\nf A triple pill combination containing isoniazid 300 mg + pyridoxine 25 mg + sulfamethoxazole 800 mg + trimethoprim 160 mg (co-trimoxazole) (scored) is the preferred alternative regimen for people living with HIV being considered for isoniazid monotherapy (1 tablet daily for adults, 0.5 tablet daily for children aged over 5 years, 0.25 tablet daily for children aged under 5 years).",
      "narratives": {
        "en": "Doses of the recommended TB preventive treatment regimens (3HR, 3HP, 1HP, 6H or 9H, 4R) by age and body weight. Each regimen gives mg/kg doses by age and, where applicable, nested sub-tables with the number of tablets per weight band for each formulation.",
        "ar": "جرعات أنظمة العلاج الوقائي الموصى بها من السل (3HR و3HP و1HP و6H أو 9H و4R) حسب العمر ووزن الجسم. ويبيّن كل نظام الجرعات بالملغ/كغ حسب العمر، وعند الاقتضاء جداول فرعية بعدد الأقراص لكل فئة وزن ولكل مستحضر.",
        "zh": "推荐的结核病预防性治疗方案（3HR、3HP、1HP、6H或9H、4R）按年龄和体重的剂量。每种方案给出按年龄的毫克/千克剂量，并在适用时以嵌套子表列出各剂型在各体重段的片数。",
        "es": "Dosis de las pautas recomendadas de tratamiento preventivo de la tuberculosis (3HR, 3HP, 1HP, 6H o 9H, 4R) según la edad y el peso corporal. Para cada pauta se indican las dosis en mg/kg por edad y, cuando procede, subtablas con el número de comprimidos por franja de peso para cada formulación.",
        "fr": "Posologie des schémas recommandés de traitement préventif de la tuberculose (3HR, 3HP, 1HP, 6H ou 9H, 4R) selon l’âge et le poids corporel. Pour chaque schéma figurent les doses en mg/kg selon l’âge et, le cas échéant, des sous-tableaux indiquant le nombre de comprimés par tranche de poids pour chaque formulation.",
        "ru": "Дозировки рекомендуемых схем профилактического лечения туберкулёза (3HR, 3HP, 1HP, 6H или 9H, 4R) в зависимости от возраста и массы тела. Для каждой схемы приведены дозы в мг/кг по возрасту и, где применимо, вложенные подтаблицы с числом таблеток каждой лекарственной формы по весовым диапазонам."
      },
      "csv": "tables/table-3-2.csv"
    },
    {
      "label": "Table 3.3",
      "caption": "Table 3.3. Dosing recommendations for use of levofloxacin as TB preventive treatment for drug-resistant TB",
      "pages": [
        64
      ],
      "columns": [
        {
          "titles": "TPT regimen"
        },
        {
          "titles": "Dose by age and weight band"
        }
      ],
      "rows": [
        [
          "6 months of levofloxacin daily (preventive treatment of MDR-TB)",
          "Age <15 years (approximate range 15–20 mg/kg/day), by body weight (use levofloxacin 100 mg dispersible tablets for children): • 5–<10 kg: 150 mg/day • 10–<16 kg: 200–300 mg/day • 16–<24 kg: 300–400 mg/day • 24–<35 kg: 500–750 mg/day Age >14 years, by body weight: • <46 kg: 750 mg/day • >45 kg: 1 g/day"
        ]
      ],
      "narratives": {
        "en": "Levofloxacin doses for 6 months of TB preventive treatment in contacts of people with MDR-TB, by age group (under 15 years, over 14 years) and body weight band.",
        "ar": "جرعات الليفوفلوكساسين للعلاج الوقائي من السل لمدة 6 أشهر لمخالطي المصابين بالسل المقاوم للأدوية المتعددة، حسب الفئة العمرية (أقل من 15 سنة، وأكثر من 14 سنة) وفئة وزن الجسم.",
        "zh": "耐多药结核病患者接触者6个月结核病预防性治疗的左氧氟沙星剂量，按年龄组（15岁以下、14岁以上）和体重段列出。",
        "es": "Dosis de levofloxacino para 6 meses de tratamiento preventivo de la tuberculosis en contactos de personas con TB-MDR, según el grupo de edad (menores de 15 años, mayores de 14 años) y la franja de peso corporal.",
        "fr": "Doses de lévofloxacine pour 6 mois de traitement préventif de la tuberculose chez les contacts de personnes atteintes de TB-MR, selon la tranche d’âge (moins de 15 ans, plus de 14 ans) et la tranche de poids corporel.",
        "ru": "Дозы левофлоксацина для 6-месячного профилактического лечения туберкулёза у контактов лиц с МЛУ-ТБ в зависимости от возрастной группы (до 15 лет, старше 14 лет) и весового диапазона."
      },
      "csv": "tables/table-3-3.csv"
    },
    {
      "label": "Table 3.4",
      "caption": "Table 3.4. TB preventive treatment completion criteria",
      "pages": [
        67
      ],
      "columns": [
        {
          "titles": "Regimen"
        },
        {
          "titles": "Total duration (months)"
        },
        {
          "titles": "Expected number of doses"
        },
        {
          "titles": "80% of recommended doses"
        },
        {
          "titles": "Extended time for treatment completion (days): original treatment duration +33% additional time"
        }
      ],
      "rows": [
        [
          "6H (daily)",
          "6",
          "182",
          "146",
          "239"
        ],
        [
          "3HR (daily)",
          "3",
          "84",
          "68",
          "120"
        ],
        [
          "3HP (weekly)",
          "3",
          "12",
          "11 a",
          "120"
        ],
        [
          "1HP (daily)",
          "1",
          "28",
          "23",
          "38"
        ],
        [
          "4R (daily)",
          "4",
          "120",
          "96",
          "160"
        ]
      ],
      "notes": "1HP: 1 month of daily isoniazid and rifapentine; 3HP: 3 months of weekly isoniazid and rifapentine; 3HR: 3 months of daily isoniazid and rifampicin; 4R: 4 months of daily rifampicin; 6H: 6 months of daily isoniazid.\na 90% of recommended number of doses for 3HP.",
      "narratives": {
        "en": "Completion criteria for each TB preventive treatment regimen (6H, 3HR, 3HP, 1HP, 4R): total duration in months, expected number of doses, the number of doses that makes up 80% of recommended doses, and the extended time allowed for completion (duration plus 33%).",
        "ar": "معايير إكمال كل نظام من أنظمة العلاج الوقائي من السل (6H و3HR و3HP و1HP و4R): المدة الإجمالية بالأشهر، والعدد المتوقع للجرعات، وعدد الجرعات الذي يمثل 80% من الجرعات الموصى بها، والوقت الممدد المسموح به للإكمال (المدة مضافاً إليها 33%).",
        "zh": "各结核病预防性治疗方案（6H、3HR、3HP、1HP、4R）的完成标准：总疗程（月）、预期剂数、相当于推荐剂数80%的剂数，以及允许完成治疗的延长时间（疗程加33%）。",
        "es": "Criterios de finalización de cada pauta de tratamiento preventivo de la tuberculosis (6H, 3HR, 3HP, 1HP, 4R): duración total en meses, número de dosis previsto, número de dosis equivalente al 80% de las recomendadas y tiempo ampliado permitido para completarla (duración más un 33%).",
        "fr": "Critères d’achèvement de chaque schéma de traitement préventif de la tuberculose (6H, 3HR, 3HP, 1HP, 4R) : durée totale en mois, nombre de doses attendu, nombre de doses correspondant à 80 % des doses recommandées et délai prolongé autorisé pour terminer le traitement (durée plus 33 %).",
        "ru": "Критерии завершения каждой схемы профилактического лечения туберкулёза (6H, 3HR, 3HP, 1HP, 4R): общая продолжительность в месяцах, ожидаемое число доз, число доз, составляющее 80% рекомендованных, и продлённый срок для завершения (продолжительность плюс 33%)."
      },
      "csv": "tables/table-3-4.csv"
    },
    {
      "label": "Table 4.1",
      "caption": "Table 4.1. WHO-approved respiratory samples for diagnosis of pulmonary TB",
      "pages": [
        80
      ],
      "columns": [
        {
          "titles": "Sample type"
        },
        {
          "titles": "Advantages"
        },
        {
          "titles": "Disadvantages"
        },
        {
          "titles": "Caregiver acceptability"
        }
      ],
      "rows": [
        [
          "Expectorated sputum",
          "Low cost Non-invasive",
          "Not feasible in young children",
          "High"
        ],
        [
          "Induced sputum",
          "Non-invasive (if followed by spontaneous expectoration)",
          "Requires several pieces of equipment, electricity, hypertonic saline and trained personnel May require additional nasopharyngeal aspiration in young children Aerosolized transmission risk to HCWs and others",
          "Moderate"
        ],
        [
          "Gastric aspirate",
          "Feasible in young children",
          "Invasive High level of discomfort Requires fasting Requires consumables and trained personnel",
          "Low"
        ],
        [
          "Nasopharyngeal aspirate",
          "Feasible in young children Less invasive than gastric aspirate",
          "Invasive Requires equipment and trained personnel Aerosolized transmission risk to HCWs and others (lower than for induced sputum)",
          "Moderate"
        ],
        [
          "Stool",
          "Non-invasive",
          "Requires additional laboratory processing, depending on processing method Must wait for bowel movement",
          "High"
        ]
      ],
      "narratives": {
        "en": "Compares the WHO-approved respiratory sample types for diagnosing pulmonary TB in children (expectorated sputum, induced sputum, gastric aspirate, nasopharyngeal aspirate, stool) by advantages, disadvantages and caregiver acceptability.",
        "ar": "مقارنة بين أنواع العينات التنفسية المعتمدة من المنظمة لتشخيص السل الرئوي لدى الأطفال (البلغم المنفوث، والبلغم المستحث، ورشافة المعدة، ورشافة البلعوم الأنفي، والبراز) من حيث المزايا والعيوب ومدى قبول مقدمي الرعاية.",
        "zh": "比较世卫组织认可的用于诊断儿童肺结核的呼吸道样本类型（咳出痰、诱导痰、胃抽吸物、鼻咽抽吸物、粪便）的优点、缺点和照护者接受度。",
        "es": "Compara los tipos de muestras respiratorias aprobados por la OMS para el diagnóstico de la tuberculosis pulmonar en niños (esputo expectorado, esputo inducido, aspirado gástrico, aspirado nasofaríngeo, heces) según sus ventajas, inconvenientes y aceptabilidad para los cuidadores.",
        "fr": "Compare les types d’échantillons respiratoires approuvés par l’OMS pour le diagnostic de la tuberculose pulmonaire chez l’enfant (expectorations, expectorations induites, aspiration gastrique, aspiration nasopharyngée, selles) selon leurs avantages, leurs inconvénients et leur acceptabilité pour les aidants.",
        "ru": "Сравнение одобренных ВОЗ видов респираторных образцов для диагностики туберкулёза лёгких у детей (откашливаемая мокрота, индуцированная мокрота, желудочный аспират, назофарингеальный аспират, кал) по преимуществам, недостаткам и приемлемости для лиц, осуществляющих уход."
      },
      "csv": "tables/table-4-1.csv"
    },
    {
      "label": "Table 4.2",
      "caption": "Table 4.2. Diagnostic accuracy of Xpert MTB/RIF and Ultra in paediatric specimen types against a microbiological reference standarda",
      "pages": [
        81
      ],
      "columns": [
        {
          "titles": "Specimen type (population)"
        },
        {
          "titles": "Sensitivity"
        },
        {
          "titles": "Specificity"
        },
        {
          "titles": "Certainty of evidence"
        }
      ],
      "rows": [
        [
          "Xpert MTB/RIF",
          "",
          "",
          ""
        ],
        [
          "Sputum",
          "0.65",
          "0.99",
          "Moderate"
        ],
        [
          "Gastric aspirate",
          "0.73",
          "0.98",
          "Very low (se) to low (sp)"
        ],
        [
          "NPA",
          "0.46",
          "1.00",
          "Moderate (se) to high (sp)"
        ],
        [
          "Stool",
          "0.61",
          "0.98",
          "Low (se) to moderate (sp)"
        ],
        [
          "Stool (HIV-positive)",
          "0.70",
          "0.98",
          "Low (se) to high (sp)"
        ],
        [
          "Xpert Ultra",
          "",
          "",
          ""
        ],
        [
          "Sputum",
          "0.73",
          "0.97",
          "Low (se) to high (sp)"
        ],
        [
          "Gastric aspirate",
          "0.64",
          "0.95",
          "Moderate"
        ],
        [
          "NPA",
          "0.46",
          "0.98",
          "Very low (se) to low (sp)"
        ],
        [
          "Stool",
          "0.53",
          "0.98",
          "Moderate"
        ]
      ],
      "notes": "se: sensitivity; sp: specificity.\na Microbiological reference standard: TB culture on respiratory samples.",
      "narratives": {
        "en": "Sensitivity, specificity and certainty of evidence of Xpert MTB/RIF and Xpert Ultra in children for each specimen type (sputum, gastric aspirate, nasopharyngeal aspirate, stool), against a microbiological reference standard.",
        "ar": "الحساسية والنوعية ودرجة يقين البيّنات لاختباري Xpert MTB/RIF وXpert Ultra لدى الأطفال لكل نوع من العينات (البلغم، ورشافة المعدة، ورشافة البلعوم الأنفي، والبراز)، مقارنة بمعيار مرجعي ميكروبيولوجي.",
        "zh": "以微生物学参考标准为对照，Xpert MTB/RIF和Xpert Ultra在儿童各类标本（痰、胃抽吸物、鼻咽抽吸物、粪便）中的敏感性、特异性和证据确定性。",
        "es": "Sensibilidad, especificidad y certeza de la evidencia de Xpert MTB/RIF y Xpert Ultra en niños para cada tipo de muestra (esputo, aspirado gástrico, aspirado nasofaríngeo, heces), frente a un patrón de referencia microbiológico.",
        "fr": "Sensibilité, spécificité et degré de certitude des données pour Xpert MTB/RIF et Xpert Ultra chez l’enfant selon le type d’échantillon (expectorations, aspiration gastrique, aspiration nasopharyngée, selles), par rapport à une norme de référence microbiologique.",
        "ru": "Чувствительность, специфичность и достоверность данных для Xpert MTB/RIF и Xpert Ultra у детей по каждому виду образцов (мокрота, желудочный аспират, назофарингеальный аспират, кал) в сравнении с микробиологическим эталонным стандартом."
      },
      "csv": "tables/table-4-2.csv"
    },
    {
      "label": "Table 4.3",
      "caption": "Table 4.3. Commonly used stool processing methods to detect TB using a molecular WHO rapid diagnostic test (see web Annex 4)",
      "pages": [
        82
      ],
      "columns": [
        {
          "titles": "Optimized sucrose floatation"
        },
        {
          "titles": "Simple One-step stool (SOS)"
        }
      ],
      "rows": [
        [
          "0.5 g stool is emulsified in 10 mL Sheather’s solution (56% sucrose in distilled water) using wooden sticks and manual shaking, followed by 30 minutes of sedimentation",
          "0.8–1 g (formed) or 2 mL (liquid) stool is added directly into the Ultra Sample Reagent bottle"
        ],
        [
          "The supernatant (0.5 mL) is mixed with the Ultra Sample Reagent",
          "After incubation and sedimentation, the supernatant is used for Xpert testing similar to sputum testing"
        ],
        [
          "The procedure has a moderate risk for generating aerosols and should be performed in a biosafety cabinet",
          "The procedure has a low risk for generating aerosols and can be performed using the same precautions as for Xpert MTB/RIF or Ultra on sputum"
        ]
      ],
      "narratives": {
        "en": "Side-by-side description of two stool processing methods for molecular TB testing, optimized sucrose floatation and the Simple One-step (SOS) method, covering sample preparation, the processing step and aerosol risk.",
        "ar": "وصف متقابل لطريقتين لمعالجة البراز من أجل الاختبار الجزيئي للسل، هما التعويم المحسّن بالسكروز وطريقة الخطوة الواحدة البسيطة (SOS)، يشمل تحضير العينة وخطوة المعالجة وخطر توليد الهباء.",
        "zh": "并列描述两种用于结核病分子检测的粪便处理方法——优化蔗糖漂浮法和简易一步法（SOS），涵盖样本制备、处理步骤和气溶胶风险。",
        "es": "Descripción comparada de dos métodos de procesamiento de heces para las pruebas moleculares de tuberculosis, la flotación optimizada con sacarosa y el método simple de un solo paso (SOS), que abarca la preparación de la muestra, el paso de procesamiento y el riesgo de aerosoles.",
        "fr": "Description comparée de deux méthodes de traitement des selles pour les tests moléculaires de la tuberculose, la flottation optimisée au saccharose et la méthode simple en une étape (SOS), portant sur la préparation de l’échantillon, l’étape de traitement et le risque d’aérosols.",
        "ru": "Сопоставление двух методов обработки кала для молекулярного тестирования на туберкулёз — оптимизированной сахарозной флотации и простого одноэтапного метода (SOS) — по подготовке образца, этапу обработки и риску образования аэрозолей."
      },
      "csv": "tables/table-4-3.csv"
    },
    {
      "label": "Table 4.4",
      "caption": "Table 4.4. Summary of WHO-recommended rapid diagnostic tests and specimen types that can be used with them for diagnosis of TB in children and adolescents",
      "pages": [
        85
      ],
      "columns": [
        {
          "titles": "Test"
        },
        {
          "titles": "Acceptable specimen types"
        },
        {
          "titles": "Rifampicin resistance detection"
        }
      ],
      "rows": [
        [
          "Xpert MTB/RIF",
          "Sputum Gastric fluid NPA Stool Cerebrospinal fluid (CSF) Lymph node aspirate or biopsy Pleural fluid Peritoneal fluid Pericardial fluid Synovial fluid Urine Blood a",
          "Yes"
        ],
        [
          "Xpert Ultra",
          "Sputum Gastric fluid NPA Stool CSF Lymph node aspirate or biopsy",
          "Yes"
        ],
        [
          "Truenat MTB and MTB Plus (Molbio Diagnostics, Goa, India)",
          "Sputum",
          "Yes"
        ],
        [
          "TB-LAMP",
          "Sputum",
          "No"
        ],
        [
          "LF-LAM",
          "Urine b",
          "No"
        ]
      ],
      "notes": "a Use of a blood specimen is recommended for people living with HIV with signs and symptoms of disseminated TB.\nb Use of urine is recommended for children and adolescents living with HIV (see specific recommendations in Box 4.4).",
      "narratives": {
        "en": "WHO-recommended rapid diagnostic tests for TB in children and adolescents (Xpert MTB/RIF, Xpert Ultra, Truenat MTB and MTB Plus, TB-LAMP, LF-LAM), listing the specimen types each can be used with and whether it detects rifampicin resistance.",
        "ar": "الاختبارات التشخيصية السريعة الموصى بها من المنظمة للسل لدى الأطفال والمراهقين (Xpert MTB/RIF وXpert Ultra وTruenat MTB وMTB Plus وTB-LAMP وLF-LAM)، مع أنواع العينات التي يمكن استخدام كل منها معها وما إذا كان يكشف مقاومة الريفامبيسين.",
        "zh": "世卫组织推荐的儿童和青少年结核病快速诊断检测（Xpert MTB/RIF、Xpert Ultra、Truenat MTB和MTB Plus、TB-LAMP、LF-LAM），列出每种检测可使用的标本类型以及是否能检测利福平耐药。",
        "es": "Pruebas de diagnóstico rápido de la tuberculosis recomendadas por la OMS para niños y adolescentes (Xpert MTB/RIF, Xpert Ultra, Truenat MTB y MTB Plus, TB-LAMP, LF-LAM), con los tipos de muestra con que puede usarse cada una y si detecta la resistencia a la rifampicina.",
        "fr": "Tests de diagnostic rapide de la tuberculose recommandés par l’OMS chez l’enfant et l’adolescent (Xpert MTB/RIF, Xpert Ultra, Truenat MTB et MTB Plus, TB-LAMP, LF-LAM), avec les types d’échantillons utilisables pour chacun et l’indication de la détection ou non de la résistance à la rifampicine.",
        "ru": "Рекомендованные ВОЗ экспресс-тесты для диагностики туберкулёза у детей и подростков (Xpert MTB/RIF, Xpert Ultra, Truenat MTB и MTB Plus, TB-LAMP, LF-LAM) с указанием видов образцов, с которыми можно использовать каждый тест, и того, выявляет ли он устойчивость к рифампицину."
      },
      "csv": "tables/table-4-4.csv"
    },
    {
      "label": "Table 4.5",
      "caption": "Table 4.5. Danger and priority signs of severe illness or health problems in children aged under 10 years",
      "pages": [
        95
      ],
      "columns": [
        {
          "titles": "Danger signs (IMCI)",
          "group": "Aged <5 years"
        },
        {
          "titles": "Danger signs (ETAT)",
          "group": "Aged 5–9 years"
        },
        {
          "titles": "Priority signs",
          "group": "All children aged <10 years"
        }
      ],
      "rows": [
        [
          "Gastrointestinal/circulatory: • Unable to eat or drink • Vomiting up everything • Signs of severe dehydration (sunken eyes, skin pinch returns very slowly) • Severe palmar pallor",
          "Gastrointestinal/circulatory: • Diarrhoea with any two signs of severe dehydration (lethargy, unconsciousness, sunken eyes, very slow return of skin after pinching) • Signs of shock (cold extremities with capillary refill time >3 seconds, weak and fast pulse)",
          "• Any sick child aged <2 months • High fever (>39° C) • Severe pallor • Respiratory distress • Restless, continuously irritable, lethargic • SAM"
        ],
        [
          "Respiratory: • Stridor • Oxygen saturation <90%",
          "Respiratory: • Obstructed or absent breathing • Severe respiratory distress • Central cyanosis",
          ""
        ],
        [
          "Neurological: • Seizures • Profoundly lethargic, unconscious • Neck stiffness or bulging fontanelle",
          "Neurological: • Coma (or seriously reduced level of consciousness) • Seizures",
          ""
        ]
      ],
      "narratives": {
        "en": "Danger signs for children aged under 5 years (IMCI) and aged 5–9 years (ETAT), grouped as gastrointestinal/circulatory, respiratory and neurological, alongside priority signs for all children aged under 10 years.",
        "ar": "علامات الخطر لدى الأطفال دون سن الخامسة (حسب التدبير المتكامل لأمراض الطفولة) ومن سن 5 إلى 9 سنوات (حسب الفرز والتقييم والعلاج في حالات الطوارئ)، مجمّعة في فئات معدية معوية/دورانية وتنفسية وعصبية، إلى جانب العلامات ذات الأولوية لجميع الأطفال دون سن العاشرة.",
        "zh": "5岁以下儿童（儿童疾病综合管理）和5–9岁儿童（急诊分诊、评估和治疗）的危险体征，按胃肠/循环、呼吸和神经系统分组，以及所有10岁以下儿童的优先体征。",
        "es": "Signos de peligro en niños menores de 5 años (AIEPI) y de 5 a 9 años (ETAT), agrupados en gastrointestinales/circulatorios, respiratorios y neurológicos, junto con los signos prioritarios para todos los niños menores de 10 años.",
        "fr": "Signes de danger chez l’enfant de moins de 5 ans (PCIME) et de 5 à 9 ans (ETAT), regroupés en signes gastro-intestinaux/circulatoires, respiratoires et neurologiques, ainsi que les signes prioritaires pour tous les enfants de moins de 10 ans.",
        "ru": "Опасные признаки у детей до 5 лет (ИВБДВ) и 5–9 лет (ЕТАТ), сгруппированные как желудочно-кишечные/циркуляторные, респираторные и неврологические, а также приоритетные признаки для всех детей до 10 лет."
      },
      "csv": "tables/table-4-5.csv"
    },
    {
      "label": "Table 4.6",
      "caption": "Table 4.6. Typical clinical features of extrapulmonary TB and suggested investigations",
      "pages": [
        101,
        102
      ],
      "columns": [
        {
          "titles": "Site of EPTB"
        },
        {
          "titles": "Typical clinical presentation"
        },
        {
          "titles": "Investigations"
        }
      ],
      "rows": [
        [
          "Common forms of EPTB",
          "",
          ""
        ],
        [
          "TB of lymph nodes (TB lymphadenopathy)",
          "Asymmetrical, painless, non-tender lymph node enlargement (often >2 × 2 cm) for >1 month not responding to other treatment (e.g. antibiotics) With or without discharging sinus Most commonly cervical nodes a",
          "CXR Ultrasound (if available) Fine-needle aspiration biopsy or excision biopsy with histology, Xpert MTB/RIF or Ultra, culture (if available) Respiratory specimens for Xpert MTB/RIF or Ultra"
        ],
        [
          "Pleural TB",
          "Dullness on percussion and reduced breath sounds with or without pleuritic chest pain No acute illness",
          "CXR Ultrasound (if available) TST/IGRA Pleural tap with biochemical analysis and cell counts, Xpert MTB/RIF or Ultra or culture (if available) b,c Respiratory specimens for Xpert MTB/RIF or Ultra"
        ],
        [
          "Usually children aged <5 years with disseminated disease and severely ill",
          "",
          ""
        ],
        [
          "TBM",
          "Subacute onset (>5 days) of headache, irritability or abnormal behaviour, vomiting (without diarrhoea), lethargy, reduced level of consciousness, convulsions, neck stiffness, bulging fontanelle, cranial nerve palsies",
          "CXR Lumbar puncture with biochemical analysis and cell counts and Xpert MTB/RIF or Ultra (rather than culture initially) completed on CSF b Brain imaging (if available) Respiratory specimens for Xpert MTB/RIF or Ultra TST/IGRA"
        ],
        [
          "Miliary TB d",
          "Nonspecific symptoms with persistent fever, lethargy and wasting",
          "CXR (typical miliary pattern) Respiratory specimens for Xpert MTB/RIF or Ultra Lumbar puncture with biochemical analysis and cell counts and Xpert MTB/RIF or Ultra on CSF to exclude TBM b TST/IGRA"
        ],
        [
          "Usually children aged ≥5 years",
          "",
          ""
        ],
        [
          "Abdominal TB",
          "Abdominal swelling with ascites or abdominal masses No acute illness",
          "CXR Abdominal ultrasound Ascitic tap with biochemical analysis and cell counts, Xpert MTB/RIF, Xpert Ultra, or culture (if available) b Respiratory specimens for Xpert MTB/RIF or Ultra"
        ],
        [
          "Spinal TB",
          "Deformity of spine, narrow-angle kyphosis (gibbus) May have lower-limb weakness, paralysis, or loss of bowel or bladder control",
          "X-ray spine Fine-needle aspiration biopsy or excision biopsy with histology and Xpert MTB/RIF, Ultra or culture (if available)"
        ],
        [
          "Pericardial TB",
          "Cardiac failure Distant or muffled heart sounds Apex beat difficult to palpate",
          "CXR Cardiac ultrasound Pericardial tap with Xpert MTB/RIF, Xpert Ultra or culture (if available) b Respiratory specimens for Xpert MTB/RIF or Ultra"
        ],
        [
          "TB bone and joint",
          "Limitation of movement and abnormal gait Unilateral joint effusion (usually knee or hip) Swelling at end of long bones or small hand bones (dactylitis)",
          "Radiograph of joint or bone Joint tap or synovial biopsy, microscopy, Xpert MTB/RIF, Xpert Ultra or culture (if available) b Respiratory specimens for Xpert MTB/RIF or Ultra"
        ]
      ],
      "notes": "a If axillary node enlargement on same side as BCG vaccination, consider BCG disease.\nb Typical findings suggesting TB on effusions (straw-coloured fluid, exudate with high protein, white blood cells (typically predominance of lymphocytes) on microscopy, positive Xpert MTB/RIF, Xpert Ultra or culture) or CSF (high protein, low glucose, white blood cells (typically predominance of lymphocytes) on microscopy, positive Xpert MTB/RIF, Xpert Ultra or culture).\nc If pus in tap, consider empyema.\nd Miliary TB is classified as PTB but often involves extrapulmonary features that can occur anywhere in the body.\nSource: adapted from Guidance for national tuberculosis programmes on the management of tuberculosis in children, second edition. Geneva: World Health Organization; 2014 (https://apps.who.int/iris/rest/bitstreams/514493/retrieve) (6); and The Union’s desk guide for diagnosis and management of TB in children, third edition. Paris: International Union Against Tuberculosis and Lung Disease; 2016 (https://theunion.org/sites/default/files/2020–08/2016_Desk-guide_Africa_Web.pdf) (72).",
      "narratives": {
        "en": "Forms of extrapulmonary TB in children, grouped as common forms, forms usually seen in severely ill children under 5 years with disseminated disease, and forms usually seen in children aged 5 years and over. For each site the table gives the typical clinical presentation and suggested investigations.",
        "ar": "أشكال السل خارج الرئة لدى الأطفال، مجمّعة في أشكال شائعة، وأشكال تُشاهد عادة لدى الأطفال دون الخامسة المصابين بمرض منتشر وحالتهم شديدة، وأشكال تُشاهد عادة لدى الأطفال في سن الخامسة فما فوق. ويعرض الجدول لكل موضع الصورة السريرية النموذجية والفحوص المقترحة.",
        "zh": "儿童肺外结核的类型，分为常见类型、通常见于患播散性疾病且病情严重的5岁以下儿童的类型，以及通常见于5岁及以上儿童的类型。表中针对每个部位给出典型临床表现和建议的检查。",
        "es": "Formas de tuberculosis extrapulmonar en niños, agrupadas en formas comunes, formas observadas habitualmente en menores de 5 años con enfermedad diseminada y gravemente enfermos, y formas observadas habitualmente en niños de 5 años o más. Para cada localización se indican la presentación clínica típica y las pruebas recomendadas.",
        "fr": "Formes de tuberculose extrapulmonaire chez l’enfant, regroupées en formes courantes, formes observées habituellement chez les enfants de moins de 5 ans gravement malades atteints d’une maladie disséminée, et formes observées habituellement chez les enfants de 5 ans et plus. Pour chaque localisation, le tableau indique la présentation clinique typique et les examens suggérés.",
        "ru": "Формы внелёгочного туберкулёза у детей, сгруппированные как распространённые формы, формы, обычно встречающиеся у тяжелобольных детей до 5 лет с диссеминированным процессом, и формы, обычно встречающиеся у детей 5 лет и старше. Для каждой локализации приведены типичная клиническая картина и рекомендуемые обследования."
      },
      "csv": "tables/table-4-6.csv"
    },
    {
      "label": "Table 5.1",
      "caption": "Table 5.1. Pulmonary TB treatment regimens by age group, disease severity and local epidemiology",
      "pages": [
        111
      ],
      "columns": [
        {
          "titles": "Age and severity of TB"
        },
        {
          "titles": "Intensive phase",
          "group": "Duration and composition of treatment regimena"
        },
        {
          "titles": "Continuation phase",
          "group": "Duration and composition of treatment regimena"
        }
      ],
      "rows": [
        [
          "Infants aged <3 months or weighing <3 kg",
          "",
          ""
        ],
        [
          "PTB of any severity",
          "2HRZ or 2HRZE b",
          "4HR"
        ],
        [
          "Children and adolescents aged 3 months to <12 years",
          "",
          ""
        ],
        [
          "Non-severe PTB",
          "2HRZ or 2HRZE b",
          "2HR c"
        ],
        [
          "Severe PTB",
          "2HRZE c",
          "4HR"
        ],
        [
          "Adolescents aged 12–<16 years",
          "",
          ""
        ],
        [
          "Non-severe PTB",
          "2HRZ or 2HRZE b",
          "2HR"
        ],
        [
          "Severe PTB",
          "2HRZE d",
          "4HR"
        ],
        [
          "PTB of any severity",
          "2HPZM",
          "2HPM"
        ],
        [
          "Adolescents aged 16–<20 years",
          "",
          ""
        ],
        [
          "PTB of any severity",
          "2HRZE e",
          "4HR"
        ],
        [
          "PTB of any severity",
          "2HPZM f",
          "2HPM"
        ]
      ],
      "notes": "a The standard code for TB treatment regimens uses an abbreviation for each medicine: isoniazid (H), rifampicin (R), pyrazinamide (Z), ethambutol (E), rifapentine (P) and moxifloxacin (M). A regimen consists of two phases – the intensive and continuation phases. The number at the front of each phase represents the duration of that phase in months. For example, 2HRZE consists of treatment with isoniazid, rifampicin, pyrazinamide and ethambutol for 2 months.\nb In settings with a high HIV prevalence and/or a high isoniazid resistance prevalence, ethambutol should be added to the intensive phase of treatment. High HIV prevalence settings are defined as HIV prevalence ≥1% among adult pregnant women or ≥5% among people with TB. Thresholds for low, moderate or high levels of isoniazid resistance prevalence are established by country NTPs.\nc The SHINE trial was a non-inferiority trial that compared a 4-month regimen (2HRZ(E)/2HR) with a 6-month regimen (2HRZ(E)/4HR). The 4-month regimen was shown to be non-inferior. Therefore, the 6-month regimen may also be used for children with non-severe PTB if the 4-month regimen has not been adopted.\nd This regimen applies regardless of HIV prevalence and prevalence of isoniazid resistance.\ne This regimen applies to older adolescents regardless of disease severity, HIV prevalence and prevalence of isoniazid resistance.\nf This regimen applies to older adolescents regardless of disease severity, HIV prevalence and prevalence of isoniazid resistance, except for people weighing less than 40 kg and adolescents living with HIV with a CD4 count below 100 cells/mm3.",
      "narratives": {
        "en": "Treatment regimens for pulmonary TB by age group (infants under 3 months, children 3 months to under 12 years, adolescents 12–<16 and 16–<20 years) and disease severity, giving the intensive-phase and continuation-phase regimens.",
        "ar": "أنظمة علاج السل الرئوي حسب الفئة العمرية (الرضّع دون 3 أشهر، والأطفال من 3 أشهر إلى أقل من 12 سنة، والمراهقون من 12 إلى أقل من 16 سنة ومن 16 إلى أقل من 20 سنة) وشدة المرض، مع نظامي المرحلة المكثفة ومرحلة الاستمرار.",
        "zh": "按年龄组（3个月以下婴儿、3个月至12岁以下儿童、12–<16岁和16–<20岁青少年）和疾病严重程度列出的肺结核治疗方案，给出强化期和继续期方案。",
        "es": "Pautas de tratamiento de la tuberculosis pulmonar según el grupo de edad (lactantes menores de 3 meses, niños de 3 meses a menos de 12 años, adolescentes de 12 a <16 y de 16 a <20 años) y la gravedad de la enfermedad, con las pautas de la fase intensiva y de la fase de continuación.",
        "fr": "Schémas thérapeutiques de la tuberculose pulmonaire selon la tranche d’âge (nourrissons de moins de 3 mois, enfants de 3 mois à moins de 12 ans, adolescents de 12 à <16 ans et de 16 à <20 ans) et la gravité de la maladie, avec les schémas de la phase intensive et de la phase de continuation.",
        "ru": "Схемы лечения туберкулёза лёгких в зависимости от возрастной группы (дети до 3 месяцев, дети от 3 месяцев до <12 лет, подростки 12–<16 и 16–<20 лет) и тяжести заболевания: схемы интенсивной фазы и фазы продолжения."
      },
      "csv": "tables/table-5-1.csv"
    },
    {
      "label": "Table 5.2",
      "caption": "Table 5.2. Treatment regimens for extrapulmonary TB",
      "pages": [
        117
      ],
      "columns": [
        {
          "titles": "Age and type of EPTB"
        },
        {
          "titles": "Intensive phase",
          "group": "Treatment regimen a"
        },
        {
          "titles": "Continuation phase",
          "group": "Treatment regimen a"
        }
      ],
      "rows": [
        [
          "Infants aged <3 months or weighing <3 kg",
          "",
          ""
        ],
        [
          "Peripheral lymph node TB",
          "2HRZ or 2HRZE b",
          "4HR"
        ],
        [
          "Children and adolescents aged 3 months–<16 years",
          "",
          ""
        ],
        [
          "Peripheral lymph node TB",
          "2HRZ or 2HRZE b",
          "2HR"
        ],
        [
          "Adolescents aged >16 years",
          "",
          ""
        ],
        [
          "Peripheral lymph node TB",
          "2HRZ or 2HRZE b",
          "4HR"
        ],
        [
          "Children and adolescents aged 0–19 years",
          "",
          ""
        ],
        [
          "EPTB c",
          "2HRZE",
          "4HR"
        ],
        [
          "TBM d (strong recommendation)",
          "2HRZE",
          "10HR"
        ],
        [
          "TBM d (conditional recommendation)",
          "6HRZEto",
          ""
        ],
        [
          "Osteoarticular TB",
          "2HRZE",
          "10HR"
        ]
      ],
      "notes": "a The standard code for TB treatment regimens uses an abbreviation for each medicine: isoniazid (H), rifampicin (R), pyrazinamide (Z), ethambutol (E) and ethionamide (Eto). A regimen consists of two phases – the intensive and continuation phases (except for the 6HRZEto regimen). The number at the front of each phase represents the duration of that phase in months. For example, 2HRZE consists of treatment with isoniazid, rifampicin, pyrazinamide and ethambutol for 2 months.\nb High HIV prevalence settings are defined as HIV prevalence ≥1% among adult pregnant women or ≥5% among people with TB. Thresholds for low, moderate or high levels of isoniazid resistance prevalence are established by country NTPs.\nc This includes all forms of EPTB except peripheral lymph node TB, TBM and osteoarticular TB.\nd This includes all forms of TB involving the CNS.",
      "narratives": {
        "en": "Treatment regimens for extrapulmonary TB by age group and type (peripheral lymph node TB, other EPTB, TB meningitis, osteoarticular TB), giving intensive-phase and continuation-phase regimens; the 6-month intensive TBM regimen has no separate continuation phase.",
        "ar": "أنظمة علاج السل خارج الرئة حسب الفئة العمرية والنوع (سل العقد اللمفية المحيطية، وأشكال السل خارج الرئة الأخرى، والتهاب السحايا السلي، والسل العظمي المفصلي)، مع نظامي المرحلة المكثفة ومرحلة الاستمرار؛ ولا يتضمن النظام المكثف لمدة 6 أشهر لالتهاب السحايا السلي مرحلة استمرار منفصلة.",
        "zh": "按年龄组和类型（外周淋巴结结核、其他肺外结核、结核性脑膜炎、骨关节结核）列出的肺外结核治疗方案，给出强化期和继续期方案；6个月强化结核性脑膜炎方案没有单独的继续期。",
        "es": "Pautas de tratamiento de la tuberculosis extrapulmonar según el grupo de edad y el tipo (tuberculosis ganglionar periférica, otras formas extrapulmonares, meningitis tuberculosa, tuberculosis osteoarticular), con las pautas de la fase intensiva y de continuación; la pauta intensiva de 6 meses para la meningitis tuberculosa no tiene fase de continuación separada.",
        "fr": "Schémas thérapeutiques de la tuberculose extrapulmonaire selon la tranche d’âge et le type (tuberculose ganglionnaire périphérique, autres formes extrapulmonaires, méningite tuberculeuse, tuberculose ostéo-articulaire), avec les schémas de phase intensive et de continuation ; le schéma intensif de 6 mois contre la méningite tuberculeuse ne comporte pas de phase de continuation distincte.",
        "ru": "Схемы лечения внелёгочного туберкулёза в зависимости от возрастной группы и формы (туберкулёз периферических лимфоузлов, другие формы ВЛТБ, туберкулёзный менингит, костно-суставной туберкулёз) с указанием схем интенсивной фазы и фазы продолжения; 6-месячная интенсивная схема при ТБ-менингите не имеет отдельной фазы продолжения."
      },
      "csv": "tables/table-5-2.csv"
    },
    {
      "label": "Table 5.3",
      "caption": "Table 5.3. Recommended dosages of first-line TB medicines for use in children and young adolescents aged 0–14 years (excluding TB meningitis treated with alternative short intensive regimen)",
      "pages": [
        118
      ],
      "columns": [
        {
          "titles": "Medicine"
        },
        {
          "titles": "Dose (mg/kg body weight)"
        },
        {
          "titles": "Range (mg/kg body weight)"
        }
      ],
      "rows": [
        [
          "Isoniazid (H)",
          "10",
          "7–15 a"
        ],
        [
          "Rifampicin (R)",
          "15",
          "10-20"
        ],
        [
          "Pyrazinamide (Z)",
          "35",
          "30–40"
        ],
        [
          "Ethambutol (E)",
          "20",
          "15–25"
        ]
      ],
      "notes": "a The higher end of the range for isoniazid applies to younger children. With older children, the lower end of the dosing range becomes more appropriate.",
      "narratives": {
        "en": "Recommended dose and dose range in mg/kg body weight for the four first-line TB medicines (isoniazid, rifampicin, pyrazinamide, ethambutol) in children and young adolescents aged 0–14 years.",
        "ar": "الجرعة الموصى بها ومدى الجرعة بالملغ/كغ من وزن الجسم للأدوية الأربعة من الخط الأول لعلاج السل (الإيزونيازيد والريفامبيسين والبيرازيناميد والإيثامبوتول) لدى الأطفال والمراهقين الصغار من عمر 0 إلى 14 سنة.",
        "zh": "0–14岁儿童和低龄青少年使用的四种一线抗结核药物（异烟肼、利福平、吡嗪酰胺、乙胺丁醇）按毫克/千克体重计的推荐剂量和剂量范围。",
        "es": "Dosis recomendada e intervalo de dosis en mg/kg de peso corporal de los cuatro medicamentos antituberculosos de primera línea (isoniazida, rifampicina, pirazinamida, etambutol) en niños y adolescentes jóvenes de 0 a 14 años.",
        "fr": "Dose recommandée et fourchette posologique en mg/kg de poids corporel des quatre antituberculeux de première intention (isoniazide, rifampicine, pyrazinamide, éthambutol) chez l’enfant et le jeune adolescent de 0 à 14 ans.",
        "ru": "Рекомендуемая доза и диапазон доз в мг/кг массы тела для четырёх противотуберкулёзных препаратов первого ряда (изониазид, рифампицин, пиразинамид, этамбутол) у детей и младших подростков 0–14 лет."
      },
      "csv": "tables/table-5-3.csv"
    },
    {
      "label": "Table 5.4",
      "caption": "Table 5.4. Recommended interim dosing for the 6-month intensive regimen (6HRZEto) to treat drug-susceptible TB meningitis in children and adolescents",
      "pages": [
        119
      ],
      "columns": [
        {
          "titles": "Medicine"
        },
        {
          "titles": "Recommended dose range in the interim dosing strategy (mg/kg body weight)"
        }
      ],
      "rows": [
        [
          "Isoniazid (H)",
          "15–20 a"
        ],
        [
          "Rifampicin (R)",
          "22.5–30"
        ],
        [
          "Pyrazinamide (Z)",
          "35–45"
        ],
        [
          "Ethionamide (Eto)",
          "17.5–22.5"
        ]
      ],
      "notes": "a The higher end of the range for isoniazid applies to younger children. With older children, the lower end of the dosing range becomes more appropriate.",
      "narratives": {
        "en": "Interim dose ranges in mg/kg body weight for the four medicines of the 6-month intensive regimen (6HRZEto) for drug-susceptible TB meningitis in children and adolescents.",
        "ar": "مديات الجرعات المؤقتة بالملغ/كغ من وزن الجسم للأدوية الأربعة في النظام المكثف لمدة 6 أشهر (6HRZEto) لعلاج التهاب السحايا السلي الحساس للأدوية لدى الأطفال والمراهقين.",
        "zh": "用于治疗儿童和青少年药物敏感性结核性脑膜炎的6个月强化方案（6HRZEto）中四种药物按毫克/千克体重计的临时剂量范围。",
        "es": "Intervalos de dosis provisionales en mg/kg de peso corporal de los cuatro medicamentos de la pauta intensiva de 6 meses (6HRZEto) para la meningitis tuberculosa farmacosensible en niños y adolescentes.",
        "fr": "Fourchettes posologiques provisoires en mg/kg de poids corporel des quatre médicaments du schéma intensif de 6 mois (6HRZEto) contre la méningite tuberculeuse pharmacosensible chez l’enfant et l’adolescent.",
        "ru": "Временные диапазоны доз в мг/кг массы тела для четырёх препаратов 6-месячной интенсивной схемы (6HRZEto) лечения лекарственно-чувствительного туберкулёзного менингита у детей и подростков."
      },
      "csv": "tables/table-5-4.csv"
    },
    {
      "label": "Table 5.5",
      "caption": "Table 5.5. Dosing table for first-line medicines (excluding the short intensive TBM regimen)",
      "pages": [
        120
      ],
      "columns": [
        {
          "titles": "Weight (kg)"
        },
        {
          "titles": "Intensive phase: HRZ 50/75/150 mg",
          "group": "Number of tablets a"
        },
        {
          "titles": "E 100 mg b",
          "group": "Number of tablets a"
        },
        {
          "titles": "Continuation phase: HR 50/75 mg",
          "group": "Number of tablets a"
        }
      ],
      "rows": [
        [
          "4–<8",
          "1",
          "1",
          "1"
        ],
        [
          "8–<12",
          "2",
          "2",
          "2"
        ],
        [
          "12–<16",
          "3",
          "3",
          "3"
        ],
        [
          "16–<25",
          "4",
          "4",
          "4"
        ],
        [
          "≥25",
          "Adult dosages recommended",
          "",
          ""
        ]
      ],
      "notes": "Presentation of weight bands has been updated – for example, the 4–7 kg weight band is now written as 4–<8 kg. A child weighing 7.9 kg is dosed as per the 4-<8 kg weight band, a child weighing 8 kg is dosed as per the 8-<12 kg weight band.\na Ideally, tablets should be dissolved in 50 mL water. The child should consume the complete fluid within 10 minutes of dissolving the tablets. If the child cannot consume the full amount, the tablets can be dissolved in a smaller amount of liquid.\nb Ethambutol (preferably using a dispersible tablet) should be added in the intensive phase for children with extensive disease, or if living with HIV, or if living in a setting where the prevalence of HIV or of isoniazid resistance is high.",
      "narratives": {
        "en": "Number of child-friendly tablets of first-line TB medicines per weight band: HRZ 50/75/150 mg and ethambutol 100 mg in the intensive phase and HR 50/75 mg in the continuation phase; adult dosages are recommended from 25 kg.",
        "ar": "عدد الأقراص الملائمة للأطفال من أدوية الخط الأول لعلاج السل لكل فئة وزن: HRZ 50/75/150 ملغ والإيثامبوتول 100 ملغ في المرحلة المكثفة وHR 50/75 ملغ في مرحلة الاستمرار؛ ويوصى بجرعات البالغين ابتداءً من 25 كغ.",
        "zh": "各体重段一线抗结核药物儿童友好型片剂的片数：强化期为HRZ 50/75/150毫克和乙胺丁醇100毫克，继续期为HR 50/75毫克；25千克及以上建议使用成人剂量。",
        "es": "Número de comprimidos pediátricos de medicamentos antituberculosos de primera línea por franja de peso: HRZ 50/75/150 mg y etambutol 100 mg en la fase intensiva y HR 50/75 mg en la fase de continuación; a partir de 25 kg se recomiendan las dosis de adulto.",
        "fr": "Nombre de comprimés adaptés aux enfants des antituberculeux de première intention par tranche de poids : HRZ 50/75/150 mg et éthambutol 100 mg en phase intensive, HR 50/75 mg en phase de continuation ; les doses adultes sont recommandées à partir de 25 kg.",
        "ru": "Число детских таблеток противотуберкулёзных препаратов первого ряда по весовым диапазонам: HRZ 50/75/150 мг и этамбутол 100 мг в интенсивной фазе и HR 50/75 мг в фазе продолжения; начиная с 25 кг рекомендуются дозы для взрослых."
      },
      "csv": "tables/table-5-5.csv"
    },
    {
      "label": "Table 5.7",
      "caption": "Table 5.7. Recommended dosage by weight for children and adolescents weighing over 25 kg using adult fixed-dose combinations (excluding the short intensive TB meningitis regimen)",
      "pages": [
        123
      ],
      "columns": [
        {
          "titles": "Weight band (kg)"
        },
        {
          "titles": "HRZE 75/150/400/275 mg",
          "group": "Intensive phase"
        },
        {
          "titles": "HR 75/150 mg",
          "group": "Intensive phase"
        }
      ],
      "rows": [
        [
          "25–<30 a",
          "2",
          "2"
        ],
        [
          "30–<35",
          "3",
          "3"
        ],
        [
          "35–<50",
          "4",
          "4"
        ],
        [
          "50–<65",
          "4",
          "4"
        ],
        [
          "≥65",
          "5",
          "5"
        ]
      ],
      "notes": "a Dosages based on expert opinion.",
      "narratives": {
        "en": "Number of adult fixed-dose combination tablets (HRZE 75/150/400/275 mg and HR 75/150 mg) by weight band for children and adolescents weighing over 25 kg.",
        "ar": "عدد أقراص التوليفات الثابتة الجرعة للبالغين (HRZE 75/150/400/275 ملغ وHR 75/150 ملغ) حسب فئة الوزن للأطفال والمراهقين الذين يزيد وزنهم على 25 كغ.",
        "zh": "体重超过25千克的儿童和青少年按体重段使用的成人固定剂量复方片（HRZE 75/150/400/275毫克和HR 75/150毫克）片数。",
        "es": "Número de comprimidos de combinaciones de dosis fijas para adultos (HRZE 75/150/400/275 mg y HR 75/150 mg) por franja de peso para niños y adolescentes de más de 25 kg.",
        "fr": "Nombre de comprimés d’associations à doses fixes pour adultes (HRZE 75/150/400/275 mg et HR 75/150 mg) par tranche de poids chez l’enfant et l’adolescent de plus de 25 kg.",
        "ru": "Число таблеток комбинаций с фиксированными дозами для взрослых (HRZE 75/150/400/275 мг и HR 75/150 мг) по весовым диапазонам для детей и подростков массой тела более 25 кг."
      },
      "csv": "tables/table-5-7.csv"
    },
    {
      "label": "Table 5.8",
      "caption": "Table 5.8. Recommended dosage by weight for adolescents being treated with the 4-month HPZM regimen",
      "pages": [
        123
      ],
      "columns": [
        {
          "titles": "Weight band (kg)"
        },
        {
          "titles": "Isoniazid (H)",
          "group": "4-month 2HPMZ/2HPM regimen / Intensive and continuation phase"
        },
        {
          "titles": "Rifapentine (P)",
          "group": "4-month 2HPMZ/2HPM regimen / Intensive and continuation phase"
        },
        {
          "titles": "Moxifloxacin (M)",
          "group": "4-month 2HPMZ/2HPM regimen / Intensive and continuation phase"
        },
        {
          "titles": "Pyrazinamide (Z)",
          "group": "4-month 2HPMZ/2HPM regimen / Intensive phase only"
        }
      ],
      "rows": [
        [
          "40–<50",
          "300 mg",
          "1200 mg",
          "400 mg",
          "1500–1600 mg a"
        ],
        [
          "50–<65",
          "",
          "",
          "",
          "1500–1600 mg a"
        ],
        [
          "≥65",
          "",
          "",
          "",
          "2000 mg"
        ]
      ],
      "notes": "a Dose depends on use of Z 400 mg or 500 mg tablets.",
      "narratives": {
        "en": "Doses by weight band for adolescents on the 4-month 2HPMZ/2HPM regimen: isoniazid, rifapentine and moxifloxacin doses are the same for all weight bands in both phases, while the pyrazinamide dose (intensive phase only) varies by weight.",
        "ar": "الجرعات حسب فئة الوزن للمراهقين الذين يتلقون النظام لمدة 4 أشهر 2HPMZ/2HPM: جرعات الإيزونيازيد والريفابنتين والموكسيفلوكساسين هي نفسها لجميع فئات الوزن في المرحلتين، بينما تختلف جرعة البيرازيناميد (في المرحلة المكثفة فقط) حسب الوزن.",
        "zh": "接受4个月2HPMZ/2HPM方案的青少年按体重段的剂量：异烟肼、利福喷丁和莫西沙星在两个阶段对所有体重段剂量相同，而吡嗪酰胺（仅强化期）剂量随体重而异。",
        "es": "Dosis por franja de peso para adolescentes con la pauta de 4 meses 2HPMZ/2HPM: las dosis de isoniazida, rifapentina y moxifloxacino son iguales para todas las franjas de peso en ambas fases, mientras que la dosis de pirazinamida (solo en la fase intensiva) varía según el peso.",
        "fr": "Doses par tranche de poids chez l’adolescent sous le schéma de 4 mois 2HPMZ/2HPM : les doses d’isoniazide, de rifapentine et de moxifloxacine sont identiques pour toutes les tranches de poids dans les deux phases, tandis que la dose de pyrazinamide (phase intensive uniquement) varie selon le poids.",
        "ru": "Дозы по весовым диапазонам для подростков, получающих 4-месячную схему 2HPMZ/2HPM: дозы изониазида, рифапентина и моксифлоксацина одинаковы для всех весовых диапазонов в обеих фазах, а доза пиразинамида (только интенсивная фаза) зависит от массы тела."
      },
      "csv": "tables/table-5-8.csv"
    },
    {
      "label": "Table 5.10",
      "caption": "Table 5.10. Management of treatment interruption in children and adolescents on drug-susceptible TB treatment",
      "pages": [
        132
      ],
      "columns": [
        {
          "titles": "Treatment phase of interruption"
        },
        {
          "titles": "Details of interruption"
        },
        {
          "titles": "Management"
        }
      ],
      "rows": [
        [
          "Intensive phase",
          "",
          ""
        ],
        [
          "Intensive phase: applies to 4- and 6-month regimens",
          "Interruption <14 days",
          "Continue treatment and complete all intensive phase doses"
        ],
        [
          "",
          "Interruption ≥ 14 days",
          "Restart intensive phase"
        ],
        [
          "Continuation phase (4-month 2HRZ(E)/2HR regimen)",
          "",
          ""
        ],
        [
          "Continuation phase (4-month regimen)",
          "Completed ≥80% of doses within 8 weeks",
          "Further treatment not necessary"
        ],
        [
          "Continuation phase (4-month regimen)",
          "Completed <80% of doses and cumulative interruption <1 month",
          "Complete remaining doses of treatment"
        ],
        [
          "Continuation phase (4-month regimen)",
          "Completed <80% of doses and cumulative interruption >1 month",
          "Restart treatment from beginning of intensive phase"
        ],
        [
          "Continuation phase (6-month 2HRZE/4HR regimen)",
          "",
          ""
        ],
        [
          "Continuation phase (6-month regimen) and bacteriologically negative at initiation",
          "Completed ≥80% of doses within 16 weeks",
          "Further treatment not necessary"
        ],
        [
          "Continuation phase (6-month regimen) and bacteriologically positive at initiation",
          "Completed ≥80% of doses within 16 weeks",
          "Complete remaining doses of treatment If consecutive lapse is >2 months, use clinical judgement"
        ],
        [
          "Continuation phase (6-month regimen)",
          "Completed <80% of doses and cumulative interruption <2 months",
          "Complete remaining doses of treatment"
        ],
        [
          "Continuation phase (6-month regimen)",
          "Completed <80% of doses and cumulative interruption ≥2 months",
          "Restart treatment from beginning of intensive phase, particularly if interruption was consecutive"
        ]
      ],
      "notes": "In all circumstances, if TB symptoms recur during the interruption, reassess the child or adolescent with a rapid molecular test and culture/DST to assess for drug resistance.",
      "narratives": {
        "en": "How to manage interruptions of drug-susceptible TB treatment in children and adolescents, by treatment phase (intensive phase, continuation phase of the 4-month and 6-month regimens) and by the length of the interruption and proportion of doses completed.",
        "ar": "كيفية التعامل مع انقطاع علاج السل الحساس للأدوية لدى الأطفال والمراهقين، حسب مرحلة العلاج (المرحلة المكثفة، ومرحلة الاستمرار في نظامي الأشهر الأربعة والستة) وحسب مدة الانقطاع ونسبة الجرعات المكتملة.",
        "zh": "儿童和青少年药物敏感性结核病治疗中断的处理方法，按治疗阶段（强化期、4个月和6个月方案的继续期）以及中断时长和已完成剂数比例列出。",
        "es": "Cómo manejar las interrupciones del tratamiento de la tuberculosis farmacosensible en niños y adolescentes, según la fase del tratamiento (fase intensiva, fase de continuación de las pautas de 4 y 6 meses) y la duración de la interrupción y la proporción de dosis completadas.",
        "fr": "Prise en charge des interruptions du traitement de la tuberculose pharmacosensible chez l’enfant et l’adolescent, selon la phase du traitement (phase intensive, phase de continuation des schémas de 4 et 6 mois), la durée de l’interruption et la proportion de doses prises.",
        "ru": "Тактика при перерывах в лечении лекарственно-чувствительного туберкулёза у детей и подростков в зависимости от фазы лечения (интенсивная фаза, фаза продолжения 4- и 6-месячных схем), продолжительности перерыва и доли принятых доз."
      },
      "csv": "tables/table-5-10.csv"
    },
    {
      "label": "Table 5.11",
      "caption": "Table 5.11. WHO drug groupings",
      "pages": [
        137
      ],
      "columns": [
        {
          "titles": "Group"
        },
        {
          "titles": "Drug"
        },
        {
          "titles": "Abbreviation"
        }
      ],
      "rows": [
        [
          "A",
          "Levofloxacin or moxifloxacin",
          "Lfx or Mfx (or M)"
        ],
        [
          "",
          "Bedaquiline",
          "Bdq (or B)"
        ],
        [
          "",
          "Linezolid",
          "Lzd (or L)"
        ],
        [
          "B",
          "Clofazimine",
          "Cfz"
        ],
        [
          "",
          "Cycloserine or terizidone",
          "Cs or Trd"
        ],
        [
          "C",
          "Ethambutol",
          "E"
        ],
        [
          "",
          "Delamanid",
          "Dlm"
        ],
        [
          "",
          "Pyrazinamide",
          "Z"
        ],
        [
          "",
          "Imipenem-cilastatin in combination with clavulanic acid (amoxiclav)",
          "Ipm-Cln"
        ],
        [
          "",
          "Meropenem in combination with clavulanic acid (amoxiclav)",
          "Mpm"
        ],
        [
          "",
          "Amikacin or streptomycin a",
          "Am or S"
        ],
        [
          "",
          "Ethionamide or prothionamide",
          "Eto or Pto"
        ],
        [
          "",
          "P-aminosalicylic acid",
          "PAS"
        ]
      ],
      "notes": "a Amikacin and streptomycin are to be considered only in adolescents aged over 18 years and only if DST results confirm susceptibility, and if high-quality audiometry monitoring for hearing loss can be ensured. Streptomycin is to be considered only if amikacin cannot be used (i.e. is unavailable or there is documented resistance) and if DST results confirm susceptibility (i.e. resistance to streptomycin is not detectable with second-line molecular LPAs and phenotypic DST is required). Kanamycin and capreomycin are no longer recommended for use in MDR-TB regimens.",
      "narratives": {
        "en": "WHO grouping of medicines used in longer MDR/RR-TB regimens into Groups A, B and C, with each drug's abbreviation.",
        "ar": "تصنيف المنظمة للأدوية المستخدمة في الأنظمة الأطول لعلاج السل المقاوم للأدوية المتعددة/المقاوم للريفامبيسين إلى المجموعات A وB وC، مع اختصار كل دواء.",
        "zh": "世卫组织将用于较长耐多药/利福平耐药结核病方案的药物分为A、B、C三组，并列出各药物的缩写。",
        "es": "Clasificación de la OMS de los medicamentos utilizados en las pautas largas contra la TB-MDR/RR en los grupos A, B y C, con la abreviatura de cada medicamento.",
        "fr": "Classement par l’OMS des médicaments utilisés dans les schémas longs contre la TB-MR/RR en groupes A, B et C, avec l’abréviation de chaque médicament.",
        "ru": "Классификация ВОЗ препаратов, применяемых в длительных схемах лечения МЛУ/РУ-ТБ, по группам A, B и C с сокращением для каждого препарата."
      },
      "csv": "tables/table-5-11.csv"
    },
    {
      "label": "Table 5.12",
      "caption": "Table 5.12. Possible individualized multidrug-resistant and rifampicin-resistant TB treatment regimens for children of all ages and adolescents, by fluoroquinolone resistance and disease severity",
      "pages": [
        143
      ],
      "columns": [
        {
          "titles": "Fluoroquinolone susceptibility"
        },
        {
          "titles": "Regimen a"
        },
        {
          "titles": "Additional medicines"
        }
      ],
      "rows": [
        [
          "Fluoroquinolone-susceptible",
          "Bdq–Lfx–Lzd–Cfz-(Cs)",
          "Cs, Dlm, PAS, Eto b,c (E, Z) d"
        ],
        [
          "Fluoroquinolone-resistant",
          "Bdq–Lzd–Cfz–Cs–(Dlm) e",
          "Dlm e, PAS, Eto b,c (E, Z) d"
        ],
        [
          "Fluoroquinolone-resistant and bedaquiline (±clofazimine)-resistant",
          "Lzd–Cs–Dlm e–E–Z d",
          "Mpm/Clav, Eto b,c, PAS c"
        ]
      ],
      "notes": "Bdq: bedaquiline; Cfz: clofazimine; Cs: cycloserine; Dlm: delamanid; E:ethambutol; Eto: ethionamide; FQ: fluoroquinolone; Lfx: levofloxacin; Lzd: linezolid; Mpm/Clav: meropenem–clavulanate; PAS: P-aminosalicylic acid; Z: pyrazinamide.\na Medicines in parentheses in this column are suggestions for a fifth medicine when there is severe disease.\nb Use ethionamide only if the child or source case does not have a known or suspected inhA mutation.\nc P-aminosalicylic acid and ethionamide showed effectiveness only in regimens without bedaquiline, linezolid, clofazimine or delamanid, and are proposed only when other options to compose a regimen are not possible.\nd Ethambutol and pyrazinamide should be considered if there is evidence of susceptibility and a regimen with sufficient medicines cannot be composed.\ne When administering delamanid and cycloserine concurrently, monitoring for neuropsychiatric side-effects is important.",
      "narratives": {
        "en": "Possible individualized MDR/RR-TB regimens for children and adolescents according to fluoroquinolone susceptibility (susceptible, resistant, or resistant also to bedaquiline with or without clofazimine), with the core regimen and additional medicines that may be added.",
        "ar": "أنظمة علاجية فردية ممكنة للسل المقاوم للأدوية المتعددة/المقاوم للريفامبيسين لدى الأطفال والمراهقين حسب الحساسية للفلوروكينولونات (حساس، أو مقاوم، أو مقاوم أيضاً للبيداكويلين مع الكلوفازيمين أو بدونه)، مع النظام الأساسي والأدوية الإضافية التي يمكن إضافتها.",
        "zh": "根据氟喹诺酮类药物敏感性（敏感、耐药、或同时对贝达喹啉耐药（伴或不伴氯法齐明耐药））为儿童和青少年制定的可能的个体化耐多药/利福平耐药结核病治疗方案，包括核心方案和可添加的其他药物。",
        "es": "Posibles pautas individualizadas contra la TB-MDR/RR en niños y adolescentes según la sensibilidad a las fluoroquinolonas (sensible, resistente, o resistente también a la bedaquilina con o sin clofazimina), con la pauta básica y los medicamentos adicionales que pueden añadirse.",
        "fr": "Schémas individualisés possibles contre la TB-MR/RR chez l’enfant et l’adolescent selon la sensibilité aux fluoroquinolones (sensible, résistante, ou résistante aussi à la bédaquiline avec ou sans clofazimine), avec le schéma de base et les médicaments supplémentaires pouvant être ajoutés.",
        "ru": "Возможные индивидуализированные схемы лечения МЛУ/РУ-ТБ у детей и подростков в зависимости от чувствительности к фторхинолонам (чувствительность, устойчивость или устойчивость также к бедаквилину с клофазимином или без него): основная схема и дополнительные препараты, которые можно добавить."
      },
      "csv": "tables/table-5-12.csv"
    },
    {
      "label": "Table 5.13",
      "caption": "Table 5.13. Cerebrospinal fluid penetration of TB medicines used for treatment of multidrug-resistant and rifampicin-resistant TB",
      "pages": [
        144
      ],
      "columns": [
        {
          "titles": "Medicine"
        },
        {
          "titles": "CSF penetration"
        }
      ],
      "rows": [
        [
          "Levofloxacin, moxifloxacin, linezolid, cycloserine, ethionamide, meropenem, pyrazinamide",
          "Good penetration"
        ],
        [
          "Isoniazid in presence of isoniazid resistance, P-aminosalicylic acid, amikacin",
          "Poor penetration, except in presence of meningeal inflammation"
        ],
        [
          "Ethambutol",
          "Poor penetration"
        ],
        [
          "Bedaquiline, delamanid, clofazimine",
          "Limited data available"
        ]
      ],
      "narratives": {
        "en": "Groups TB medicines used for MDR/RR-TB by how well they penetrate the cerebrospinal fluid: good, poor except with meningeal inflammation, poor, or limited data.",
        "ar": "تصنيف أدوية السل المستخدمة لعلاج السل المقاوم للأدوية المتعددة/المقاوم للريفامبيسين حسب قدرتها على النفاذ إلى السائل الدماغي الشوكي: جيد، أو ضعيف إلا في حال التهاب السحايا، أو ضعيف، أو بيانات محدودة.",
        "zh": "按脑脊液穿透能力对用于耐多药/利福平耐药结核病的药物进行分组：穿透良好、除脑膜炎症外穿透差、穿透差或数据有限。",
        "es": "Agrupa los medicamentos antituberculosos usados contra la TB-MDR/RR según su penetración en el líquido cefalorraquídeo: buena, escasa salvo en presencia de inflamación meníngea, escasa, o datos limitados.",
        "fr": "Classe les antituberculeux utilisés contre la TB-MR/RR selon leur pénétration dans le liquide céphalorachidien : bonne, faible sauf en cas d’inflammation méningée, faible, ou données limitées.",
        "ru": "Группировка противотуберкулёзных препаратов, применяемых при МЛУ/РУ-ТБ, по проникновению в спинномозговую жидкость: хорошее, плохое (кроме случаев воспаления мозговых оболочек), плохое или данные ограничены."
      },
      "csv": "tables/table-5-13.csv"
    },
    {
      "label": "Table 5.14",
      "caption": "Table 5.14. Adverse effects of medicines used for multidrug-resistant and rifampicin-resistant TB by group",
      "pages": [
        147,
        148,
        149
      ],
      "columns": [
        {
          "titles": "Group and name"
        },
        {
          "titles": "Main adverse effects"
        }
      ],
      "rows": [
        [
          "WHO Group A",
          ""
        ],
        [
          "Levofloxacin (Lfx)",
          "Sleep disturbance Gastrointestinal disturbance Arthralgia/arthritis Headache Idiopathic raised intracranial pressure"
        ],
        [
          "Moxifloxacin (Mfx)",
          "As for levofloxacin QT interval prolongation"
        ],
        [
          "Bedaquiline (Bdq)",
          "Headache Nausea Liver dysfunction QT interval prolongation Arthralgia"
        ],
        [
          "Linezolid (Lzd)",
          "Diarrhoea Headache Nausea Myelosuppression Peripheral neuritis Optic neuritis Lactic acidosis Pancreatitis"
        ],
        [
          "WHO Group B",
          ""
        ],
        [
          "Clofazimine (Cfz)",
          "Skin discolouration Ichthyosis QT interval prolongation Abdominal pain"
        ],
        [
          "Cycloserine (Cs)/terizidone (Trd)",
          "Neurological and psychological adverse effects Severe depression and suicidal ideation in adolescents"
        ],
        [
          "WHO Group C",
          ""
        ],
        [
          "Ethambutol (E)",
          "Optic neuritis"
        ],
        [
          "Delamanid (Dlm)",
          "Nausea and vomiting Dizziness Paraesthesia Anxiety QTc prolongation Hallucinations and night terrors"
        ],
        [
          "Pyrazinamide (Z)",
          "Arthralgia/arthritis (especially together with fluoroquinolone use) Hepatitis Skin rashes"
        ],
        [
          "Meropenem (Mpm)",
          "Hypersensitivity reactions Seizures Nausea and vomiting Diarrhoea Hepatic and renal dysfunction"
        ],
        [
          "Amikacina (Am) or streptomycin (S)",
          "Ototoxicity (irreversible) Nephrotoxicity"
        ],
        [
          "Ethionamide (Eto)/ prothionamide (Pto)",
          "Gastrointestinal intolerance Metallic taste Hypothyroidism"
        ],
        [
          "P-aminosalicylic acid (PAS)",
          "Gastrointestinal intolerance Hypothyroidism Hepatitis"
        ],
        [
          "Other medicines",
          ""
        ],
        [
          "Isoniazid (H) high-doseb",
          "Hepatitis Peripheral neuropathy"
        ],
        [
          "Amoxicillin-clavulanate (amoxiclav)",
          "Gastrointestinal intolerance Hypersensitivity reactions Seizures Hepatic and renal dysfunction"
        ],
        [
          "Pretomanid",
          "Peripheral neuropathy Acne Anaemia Nausea and vomiting Headache Liver dysfunction Rash Pruritus Gastrointestinal intolerance"
        ]
      ],
      "notes": "a Not recommended for use in children and adolescents aged under 18 years.\nb If isoniazid is used, supplement with pyridoxine (vitamin B6) in infants and adolescents, in malnourished children, in children living with HIV, and when high-dose isoniazid is used to prevent peripheral neuropathy.\nSource: adapted from Schaaf HS, Thee S, van der Laan L, et al. Adverse effects of oral second-line antituberculosis drugs in children. Expert Opin Drug Saf. 2016;15(10):1369–1381 (124); and https://www.tballiance.org/sites/default/files/assets/Pretomanid_Full-Prescribing-Information.pdf.",
      "narratives": {
        "en": "Main adverse effects of each medicine used for MDR/RR-TB, grouped by WHO Group A, B and C and other medicines (high-dose isoniazid, amoxicillin-clavulanate, pretomanid).",
        "ar": "الآثار الضارة الرئيسية لكل دواء يُستخدم لعلاج السل المقاوم للأدوية المتعددة/المقاوم للريفامبيسين، مجمّعة حسب مجموعات المنظمة A وB وC وأدوية أخرى (الإيزونيازيد بجرعة عالية، والأموكسيسيلين-كلافولانات، والبريتومانيد).",
        "zh": "用于耐多药/利福平耐药结核病的各药物的主要不良反应，按世卫组织A、B、C组及其他药物（大剂量异烟肼、阿莫西林-克拉维酸、普托马尼）分组。",
        "es": "Principales efectos adversos de cada medicamento utilizado contra la TB-MDR/RR, agrupados según los grupos A, B y C de la OMS y otros medicamentos (isoniazida en dosis altas, amoxicilina-clavulanato, pretomanid).",
        "fr": "Principaux effets indésirables de chaque médicament utilisé contre la TB-MR/RR, regroupés selon les groupes A, B et C de l’OMS et d’autres médicaments (isoniazide à forte dose, amoxicilline-clavulanate, prétomanide).",
        "ru": "Основные нежелательные явления каждого препарата, применяемого при МЛУ/РУ-ТБ, сгруппированные по группам ВОЗ A, B и C и прочим препаратам (изониазид в высоких дозах, амоксициллин-клавуланат, претоманид)."
      },
      "csv": "tables/table-5-14.csv"
    },
    {
      "label": "Table 5.15",
      "caption": "Table 5.15. End-of-treatment clinical assessment in children with TB meningitis",
      "pages": [
        154
      ],
      "columns": [
        {
          "titles": "Specialist"
        },
        {
          "titles": "Post-treatment assessment"
        }
      ],
      "rows": [
        [
          "Neurologist",
          "Clinical assessment and screen for signs and symptoms, with additional referral as needed"
        ],
        [
          "",
          "Pain relief"
        ],
        [
          "",
          "Shunt assessment for ventriculoperitoneal shunts every 6 months"
        ],
        [
          "",
          "Neurological cognitive and functional impairment assessment"
        ],
        [
          "",
          "Neuroimaging only if clinically indicated (magnetic resonance imaging if available)"
        ],
        [
          "Physiotherapist Occupational therapist",
          "Muscle tone management and transport needs (e.g. wheelchair)"
        ],
        [
          "Speech therapist Surgeon Gastrointestinal specialist",
          "Feeding options, including percutaneous endoscopic gastrostomy with or without fundoplication"
        ],
        [
          "Endocrinologist",
          "Endocrine assessment in case of thalamic injury"
        ]
      ],
      "narratives": {
        "en": "Post-treatment assessments for children who have completed treatment for TB meningitis, listed by the specialist responsible (neurologist, physiotherapist and occupational therapist, speech therapist, surgeon and gastrointestinal specialist, endocrinologist).",
        "ar": "التقييمات بعد انتهاء العلاج للأطفال الذين أكملوا علاج التهاب السحايا السلي، مرتبة حسب الأخصائي المسؤول (طبيب الأعصاب، وأخصائي العلاج الطبيعي والعلاج المهني، وأخصائي النطق، والجرّاح وأخصائي الجهاز الهضمي، وأخصائي الغدد الصماء).",
        "zh": "完成结核性脑膜炎治疗的儿童在治疗后的评估，按负责的专科人员列出（神经科医生、物理治疗师和作业治疗师、言语治疗师、外科医生和胃肠病专科医生、内分泌科医生）。",
        "es": "Evaluaciones posteriores al tratamiento en niños que han completado el tratamiento de la meningitis tuberculosa, según el especialista responsable (neurólogo, fisioterapeuta y terapeuta ocupacional, logopeda, cirujano y gastroenterólogo, endocrinólogo).",
        "fr": "Évaluations après traitement chez l’enfant ayant terminé le traitement d’une méningite tuberculeuse, selon le spécialiste responsable (neurologue, kinésithérapeute et ergothérapeute, orthophoniste, chirurgien et gastro-entérologue, endocrinologue).",
        "ru": "Оценка состояния детей после завершения лечения туберкулёзного менингита по ответственным специалистам (невролог, физиотерапевт и эрготерапевт, логопед, хирург и гастроэнтеролог, эндокринолог)."
      },
      "csv": "tables/table-5-15.csv"
    },
    {
      "label": "Table 5.16",
      "caption": "Table 5.16. End-of-treatment assessment of post-TB lung disease in children",
      "pages": [
        155
      ],
      "columns": [
        {
          "titles": ""
        },
        {
          "titles": "Non-severe PTB"
        },
        {
          "titles": "Severe PTB"
        }
      ],
      "rows": [
        [
          "Clinical assessment and symptom/sign screen",
          "Yes a",
          "Yes"
        ],
        [
          "Imaging (CXR)",
          "",
          "Yes"
        ],
        [
          "Lung function (spirometry)",
          "",
          "Yes"
        ],
        [
          "Health-related quality of life",
          "",
          "Yes"
        ]
      ],
      "notes": "a If there are any residual symptoms, further investigations should be performed.",
      "narratives": {
        "en": "Assessments recommended at the end of treatment to detect post-TB lung disease in children with non-severe and severe pulmonary TB (clinical assessment, chest X-ray, spirometry, health-related quality of life).",
        "ar": "التقييمات الموصى بها في نهاية العلاج للكشف عن مرض الرئة التالي للسل لدى الأطفال المصابين بالسل الرئوي غير الوخيم والوخيم (التقييم السريري، والتصوير الشعاعي للصدر، وقياس التنفس، ونوعية الحياة المرتبطة بالصحة).",
        "zh": "非重症和重症肺结核儿童在治疗结束时为发现结核后肺病而建议进行的评估（临床评估、胸部X光、肺量测定、健康相关生活质量）。",
        "es": "Evaluaciones recomendadas al final del tratamiento para detectar la enfermedad pulmonar postuberculosa en niños con tuberculosis pulmonar no grave y grave (evaluación clínica, radiografía de tórax, espirometría, calidad de vida relacionada con la salud).",
        "fr": "Évaluations recommandées en fin de traitement pour détecter une maladie pulmonaire post-tuberculeuse chez l’enfant atteint de tuberculose pulmonaire non grave ou grave (évaluation clinique, radiographie thoracique, spirométrie, qualité de vie liée à la santé).",
        "ru": "Обследования, рекомендуемые по окончании лечения для выявления посттуберкулёзного поражения лёгких у детей с нетяжёлым и тяжёлым туберкулёзом лёгких (клиническая оценка, рентгенография грудной клетки, спирометрия, качество жизни, связанное со здоровьем)."
      },
      "csv": "tables/table-5-16.csv"
    },
    {
      "label": "Table 5.17",
      "caption": "Table 5.17. Practical guidance to mitigate and assess post-TB morbidity in children with osteoarticular TB",
      "pages": [
        155,
        156
      ],
      "columns": [
        {
          "titles": "Specialist"
        },
        {
          "titles": "Role during and after treatment to prevent morbidity"
        }
      ],
      "rows": [
        [
          "Clinician",
          "Look for contractures, joint destructions and recurrent TB"
        ],
        [
          "",
          "Repeat X-ray every 3 months (as clinically indicated) and at end of treatment to assess joint integrity"
        ],
        [
          "",
          "Long-term follow-up for spinal TB for further collapse until age 18 years"
        ],
        [
          "Physiotherapist",
          "From diagnosis to maintain range of motion and prevent contractures"
        ],
        [
          "Occupational therapist",
          "Provide night splints to immobilize joints in functional positions"
        ],
        [
          "Dietician",
          "Improve nutrition Give vitamin D and multivitamins"
        ]
      ],
      "narratives": {
        "en": "Roles of each specialist (clinician, physiotherapist, occupational therapist, dietician) during and after treatment to prevent and assess long-term morbidity in children with osteoarticular TB.",
        "ar": "أدوار كل أخصائي (الطبيب السريري، وأخصائي العلاج الطبيعي، وأخصائي العلاج المهني، وأخصائي التغذية) أثناء العلاج وبعده للوقاية من المراضة طويلة الأمد وتقييمها لدى الأطفال المصابين بالسل العظمي المفصلي.",
        "zh": "各专科人员（临床医生、物理治疗师、作业治疗师、营养师）在治疗期间和治疗后为预防和评估骨关节结核儿童的长期并发症所承担的职责。",
        "es": "Funciones de cada especialista (clínico, fisioterapeuta, terapeuta ocupacional, dietista) durante y después del tratamiento para prevenir y evaluar la morbilidad a largo plazo en niños con tuberculosis osteoarticular.",
        "fr": "Rôle de chaque spécialiste (clinicien, kinésithérapeute, ergothérapeute, diététicien) pendant et après le traitement pour prévenir et évaluer la morbidité à long terme chez l’enfant atteint de tuberculose ostéo-articulaire.",
        "ru": "Задачи каждого специалиста (клиницист, физиотерапевт, эрготерапевт, диетолог) во время и после лечения для профилактики и оценки отдалённых последствий у детей с костно-суставным туберкулёзом."
      },
      "csv": "tables/table-5-17.csv"
    },
    {
      "label": "Table 6.1",
      "caption": "Table 6.1. Health care workers’ tasks at different levels of care",
      "pages": [
        162,
        163
      ],
      "columns": [
        {
          "titles": "Level"
        },
        {
          "titles": "Tasks"
        }
      ],
      "rows": [
        [
          "Primary care (e.g. health post)",
          "Provider-initiated identification of children and adolescents with symptoms and signs suggestive of TB Application of treatment decision algorithms with initiation of treatment for children with a treatment decision Specimen collection (using less invasive specimens where feasible and available) or referral Registration of all children and adolescents treated for TB or with TPT with district NTP office TB contact investigation to identify children and adolescents who: • have symptoms and signs of TB and apply the relevant treatment decision algorithms or refer them to the first referral level of care as per national guidelines • have no symptoms and signs of TB and are eligible for TPT Identification of source cases and screen close contacts for any child or adolescent diagnosed with TB Arranging follow-up for children and adolescents on TB treatment or TPT Referral of sick children (with danger signs) and adolescents to the first referral level of care as per national guidelines Referral in case of non-response to TB treatment Arranging patient- and family-centred care, including nutritional support, counselling on the disease, treatment adherence and treatment completion, and treatment support Provision of TB health education, including infection prevention, side-effects of TB medicines and what to do Provision of HIV counselling and testing Arranging follow-up for HIV-related care Addressing special needs of adolescents in terms of confidentiality, linkages to adolescent-friendly services and opportunities Establishment and maintenance of linkages with schools to enhance TB contact investigation and treatment support"
        ],
        [
          "First referral (e.g. primary health centre)",
          "Specimen collection (using less invasive specimens where feasible and available) Make a treatment decision using algorithms or diagnosis of TB disease or infection with M. tuberculosis Start treatment for TB and HIV when indicated Identify source case and screen close contacts for any child or adolescent diagnosed with TB Ensure registration of all children and adolescents treated for TB or with TPT with district NTP office Refer child or adolescent back to primary care level or appropriate HCW for ongoing treatment and follow-up Provide inpatient care as appropriate, including nutritional support Manage common side-effects Refer child or adolescent to second referral level in cases of severe or complicated TB Refer child or adolescent to second referral level in cases of diagnostic uncertainty Refer child or adolescent to second referral level in cases of treatment failure Refer child or adolescent to second referral level in cases of suspected MDR/RR-TB"
        ],
        [
          "Second referral (e.g. secondary or tertiary hospital)",
          "Diagnose and manage complicated forms of TB, including most cases of disseminated TB, TBM and MDR/RR-TB in children and adolescents Identify source case and screen close contacts for any child or adolescent diagnosed with TB Advise NTP on management of people with complicated forms of TB Be part of the child and adolescent TB technical working group, contributing to guideline and training curriculum development Ensure registration of all children and adolescents treated for TB with district NTP office Refer child or adolescent back to primary or secondary care level or appropriate HCWs for ongoing treatment and follow-up"
        ]
      ],
      "narratives": {
        "en": "Tasks of health care workers in child and adolescent TB care at three levels of the health system: primary care, first referral level and second referral level.",
        "ar": "مهام العاملين الصحيين في رعاية الأطفال والمراهقين المصابين بالسل على ثلاثة مستويات من النظام الصحي: الرعاية الأولية، ومستوى الإحالة الأول، ومستوى الإحالة الثاني.",
        "zh": "卫生保健工作者在儿童和青少年结核病诊疗中在卫生系统三个层级（初级卫生保健、一级转诊和二级转诊）的任务。",
        "es": "Tareas de los trabajadores de la salud en la atención de la tuberculosis infantil y adolescente en tres niveles del sistema de salud: atención primaria, primer nivel de referencia y segundo nivel de referencia.",
        "fr": "Tâches des agents de santé dans la prise en charge de la tuberculose de l’enfant et de l’adolescent à trois niveaux du système de santé : soins primaires, premier niveau de recours et second niveau de recours.",
        "ru": "Задачи медицинских работников по оказанию помощи детям и подросткам с туберкулёзом на трёх уровнях системы здравоохранения: первичная помощь, первый и второй уровни направления."
      },
      "csv": "tables/table-6-1.csv"
    },
    {
      "label": "Table 6.2",
      "caption": "Table 6.2. Aspects to consider when planning for the provision of decentralized, family-centred, integrated TB services",
      "pages": [
        164,
        165
      ],
      "columns": [
        {
          "titles": "Step"
        },
        {
          "titles": "Description"
        },
        {
          "titles": "Rationale"
        }
      ],
      "rows": [
        [
          "Health service delivery mapping and assessment",
          "Map out health care levels and service delivery points where unwell children and adolescents seek care or are managed Map out health care levels and service delivery points where unwell children and adolescents with TB are managed Assess services at different health system levels, including health facility and community level",
          "Identify services or service components that can be decentralized or integrated and opportunities that can be leveraged to bring TB services closer to where children, adolescents and families live Assess needs of health care facilities to implement TB services"
        ],
        [
          "Stakeholder analysis",
          "Map stakeholders engaged in TB service delivery, including for children and adolescents, and child and adolescent health at different levels of health care",
          "Identify opportunities and strategies for engagement and collaboration Identify mechanisms for coordination and collaboration Identify platforms for advocacy Conduct stakeholder consultations (which can be linked to the development of a national multisectoral accountability framework)"
        ],
        [
          "Policy analysis and analysis of existing regulatory framework",
          "Review existing regulatory framework and policy guidelines on TB and child and adolescent TB service delivery, child health and management of childhood illnesses (e.g. HIV, malnutrition, pneumonia), and adolescent health",
          "Identify opportunities for decentralization and integration and update regulatory framework as needed Develop, adapt or update implementation guidelines, standard operating procedures and job aides"
        ],
        [
          "Human resources for health capacity assessment",
          "Establish staffing norms and related tasks, roles and responsibilities Establish capacity of health care providers and training needs Develop training programmes",
          "Identify capacity gaps Identify roles and tasks to decentralize or integrate Train or orient health care providers Implement supportive supervision Establish mentorship and coaching"
        ],
        [
          "Resource mapping",
          "Map funding sources and gaps for prevention and management of TB in children and adolescents and child and adolescent health services at different health system levels",
          "Identify funding opportunities Identify platforms for advocacy"
        ],
        [
          "Assessment of access to TB medicines, including child-friendly formulations and supplies",
          "Assess availability of TB medicines and supplies, including child-friendly formulations, supplies (including supplies for non-invasive sample collection) Quantification",
          "To inform procurement planning, budgeting and forecasting Provision of supplies and TB medicine, including child-friendly formulations"
        ],
        [
          "Health information management",
          "Review existing recording and reporting tools Adapt electronic recording and reporting",
          "Identify opportunities for data capture, reporting and use Promote or prioritize electronic recording and reporting Identify indicators for tracking progress and ensure data analysis is used to improve TB services"
        ]
      ],
      "narratives": {
        "en": "Planning steps for decentralized, family-centred, integrated TB services for children and adolescents (service mapping, stakeholder analysis, policy review, human resources, resource mapping, access to medicines and supplies, health information), each with a description and rationale.",
        "ar": "خطوات التخطيط لخدمات السل اللامركزية والمتمحورة حول الأسرة والمتكاملة للأطفال والمراهقين (رسم خرائط الخدمات، وتحليل أصحاب المصلحة، ومراجعة السياسات، والموارد البشرية، ورسم خرائط الموارد، والحصول على الأدوية والإمدادات، والمعلومات الصحية)، مع وصف كل خطوة ومسوّغاتها.",
        "zh": "为儿童和青少年规划分散化、以家庭为中心的综合结核病服务的步骤（服务摸底、利益相关方分析、政策审查、人力资源、资源摸底、药品和物资可及性、卫生信息），每一步均附说明和理由。",
        "es": "Etapas de planificación de servicios antituberculosos descentralizados, centrados en la familia e integrados para niños y adolescentes (mapeo de servicios, análisis de partes interesadas, examen de políticas, recursos humanos, mapeo de recursos, acceso a medicamentos y suministros, información sanitaria), cada una con su descripción y justificación.",
        "fr": "Étapes de planification de services antituberculeux décentralisés, centrés sur la famille et intégrés pour les enfants et les adolescents (cartographie des services, analyse des parties prenantes, examen des politiques, ressources humaines, cartographie des ressources, accès aux médicaments et fournitures, information sanitaire), chacune avec sa description et sa justification.",
        "ru": "Этапы планирования децентрализованных, ориентированных на семью интегрированных услуг по туберкулёзу для детей и подростков (картирование услуг, анализ заинтересованных сторон, анализ политики, кадровые ресурсы, картирование ресурсов, доступ к лекарствам и расходным материалам, медицинская информация) с описанием и обоснованием каждого этапа."
      },
      "csv": "tables/table-6-2.csv"
    },
    {
      "label": "Table 6.3",
      "caption": "Table 6.3. Opportunities for integrating TB services into other services",
      "pages": [
        166,
        167
      ],
      "columns": [
        {
          "titles": "Target population"
        },
        {
          "titles": "Opportunities"
        },
        {
          "titles": "Actions required to enable delivery of TB services"
        }
      ],
      "rows": [
        [
          "Children",
          "IMCI Immunization Nutrition Outpatient department Inpatient department iCCM Focused programmes for orphans and vulnerable children",
          "TB health education and counselling for HCWs Provider-initiated TB screening and linkages and referral to TB diagnosis and treatment HIV testing TB contact investigation TPT for eligible contacts and children and adolescents living with HIV Strengthening of recording and reporting systems and practices for TB data to reach NTP"
        ],
        [
          "Children and adolescents living with HIV",
          "HIV and ART services Differentiated HIV service delivery",
          "TB health education and counselling Provider-initiated TB screening TB diagnosis and treatment TB contact investigation TPT for eligible contacts and children and adolescents living with HIV Psychosocial support Strengthening of recording and reporting system and practices for TB data to reach NTP"
        ],
        [
          "Adolescents, girls and young women",
          "Adolescent-friendly services Family planning services HIV and ART services Outreach programmes",
          "TB health education and counselling Provider-initiated TB screening and linkages to TB diagnosis and treatment HIV testing TB contact investigation Psychosocial support Strengthening of recording and reporting system and practices for TB data to reach NTP"
        ],
        [
          "Pregnant women",
          "Antenatal care services Prevention of mother-to-child transmission",
          "TB health education and counselling Provider-initiated TB screening and linkages to TB diagnosis and treatment HIV testing TB contact investigation Psychosocial support Strengthening of recording and reporting systems and practices for TB data to reach NTP"
        ],
        [
          "Postnatal women",
          "Postnatal care services Prevention of mother-to-child transmission Mother and baby care points",
          "TB health education and counselling Provider-initiated TB screening and linkages to TB diagnosis and treatment HIV testing Psychosocial support TB contact investigation TPT for eligible postnatal women Strengthening of recording and reporting systems and practices for TB data to reach NTP"
        ]
      ],
      "narratives": {
        "en": "Opportunities to integrate TB services into other health services for five target populations (children; children and adolescents living with HIV; adolescents, girls and young women; pregnant women; postnatal women), with the actions required to deliver TB services through each.",
        "ar": "فرص إدماج خدمات السل في الخدمات الصحية الأخرى لخمس فئات مستهدفة (الأطفال؛ والأطفال والمراهقون المتعايشون مع فيروس العوز المناعي البشري؛ والمراهقون والفتيات والشابات؛ والحوامل؛ والنساء بعد الولادة)، مع الإجراءات اللازمة لتقديم خدمات السل من خلال كل منها.",
        "zh": "针对五类目标人群（儿童；感染艾滋病毒的儿童和青少年；青少年、少女和年轻妇女；孕妇；产后妇女）将结核病服务整合到其他卫生服务中的机会，以及通过各项服务提供结核病服务所需采取的行动。",
        "es": "Oportunidades para integrar los servicios antituberculosos en otros servicios de salud para cinco poblaciones destinatarias (niños; niños y adolescentes con el VIH; adolescentes, niñas y mujeres jóvenes; embarazadas; puérperas), con las medidas necesarias para prestar servicios antituberculosos a través de cada uno.",
        "fr": "Possibilités d’intégrer les services antituberculeux dans d’autres services de santé pour cinq populations cibles (enfants ; enfants et adolescents vivant avec le VIH ; adolescentes, filles et jeunes femmes ; femmes enceintes ; femmes en post-partum), avec les mesures nécessaires pour fournir des services antituberculeux par chacun d’eux.",
        "ru": "Возможности интеграции услуг по туберкулёзу в другие медицинские службы для пяти целевых групп (дети; дети и подростки, живущие с ВИЧ; девочки-подростки и молодые женщины; беременные; родильницы) и меры, необходимые для оказания услуг по туберкулёзу через каждую из них."
      },
      "csv": "tables/table-6-3.csv"
    },
    {
      "label": "Table 7.1",
      "caption": "Table 7.1. Preferred and alternative first-line antiretroviral therapy regimens for neonates, children and adolescents on TB treatment",
      "pages": [
        192
      ],
      "columns": [
        {
          "titles": "Age"
        },
        {
          "titles": "Preferred first-line regimen, including initiation while on TB treatment"
        },
        {
          "titles": "Alternative first-line regimen"
        },
        {
          "titles": "Special circumstancesa"
        }
      ],
      "rows": [
        [
          "Neonates",
          "AZT + 3TC + RAL b",
          "AZT + 3TC + NVP",
          "AZT + 3TC + LPV/r c"
        ],
        [
          "Children",
          "ABC + 3TC + DTG d",
          "ABC + 3TC + LPV/r TAF + 3TC (or FTC) + DTG e",
          "ABC + 3TC + EFV (or NVP) ABC + 3TC + RAL f AZT + 3TC + EFV g (or NVP) AZT + 3TC + LPV/r (or RAL)"
        ],
        [
          "Adolescents",
          "TDF + 3TC (or FTC) + DTG h",
          "TDF + 3TC + EFV 400 mg i",
          "TDF + 3TC (or FTC) + EFV 600 mg i AZT + 3TC + EFV 600 mg i TDF + 3TC (or FTC) + PI/r i TDF + 3TC (or FTC) + RAL TAF j + 3TC (or FTC) + DTG ABC + 3TC + DTG h"
        ]
      ],
      "notes": "3TC: lamivudine; ABC: abacavir; AZT: zidovudine; DTG: dolutegravir; EFV: efavirenz; FTC: emtricitabine; LPV/r: lopinavir/ritonavir; NVP: nevirapine, PI/r: protease inhibitor boosted with ritonavir; RAL: raltegravir; TAF: tenofovir alafenamide; TDF: tenofovir disoproxil fumarate.\n[green] No dose adjustment needed with TB treatment.\n[blue] Dose adjustment needed with TB treatment.\n[red] Change of regimen needed with TB treatment.\nFor details on required adjustments in dose or regimen, see Table 7.2.\na Special circumstances include where it is not possible to give the preferred or alternative regimens, including toxicity, intolerance, inability to take the preferred or alternative medicine in the available formulation, and unavailability or stockouts.\nb Neonates starting ART with a RAL-based regimen should transition to an LPV/r solid formulation as soon as possible.\nc LPV/r syrup or granules can be used if starting after age 2 weeks.\nd For age and weight groups with approved DTG dosing.\ne For age and weight groups with approved TAF dosing.\nf RAL should be used as an alternative regimen only if LPV/r solid formulations are not available.\ng Efavirenz should not be used in children aged under 3 years.\nh Effective contraception should be offered to adolescent girls of childbearing age or potential. DTG can be prescribed for adolescent girls of childbearing age or potential who wish to become pregnant or who are not otherwise using or accessing consistent and effective contraception if they have been fully informed of the potential increase in the risk of neural tube defects (at conception and until the end of the first trimester). If women identify pregnancy after the first trimester, DTG should be initiated or continued for the duration of the pregnancy.\ni EFV-based ART should not be used in settings with national estimates of pre-treatment resistance to EFV of 10% or higher. DTG-based ART is preferred. If DTG is unavailable, a boosted PI-based regimen should be used. The choice of PI/r depends on programmatic characteristics.\nj TAF may be considered for people with established osteoporosis or impaired kidney function. TAF has drug–drug interactions with rifamycin; as dose adjustments have not been established, concurrent use should be avoided.",
      "narratives": {
        "en": "Preferred, alternative and special-circumstance first-line antiretroviral regimens for neonates, children and adolescents on TB treatment. In the printed table, colour indicates whether each regimen needs no change, a dose adjustment or a change of regimen with TB treatment.",
        "ar": "أنظمة العلاج بمضادات الفيروسات القهقرية من الخط الأول المفضّلة والبديلة والخاصة بالظروف الخاصة لحديثي الولادة والأطفال والمراهقين الذين يتلقون علاج السل. وفي الجدول المطبوع، يشير اللون إلى ما إذا كان كل نظام لا يحتاج إلى تغيير أو يحتاج إلى تعديل الجرعة أو إلى تغيير النظام مع علاج السل.",
        "zh": "正在接受结核病治疗的新生儿、儿童和青少年的首选、替代及特殊情况下一线抗逆转录病毒治疗方案。在印刷表格中，颜色表示各方案在结核病治疗期间无需调整、需调整剂量或需更换方案。",
        "es": "Pautas antirretrovíricas de primera línea preferidas, alternativas y para circunstancias especiales en neonatos, niños y adolescentes en tratamiento antituberculoso. En la tabla impresa, el color indica si cada pauta no requiere cambios, requiere ajuste de dosis o requiere cambio de pauta con el tratamiento antituberculoso.",
        "fr": "Schémas antirétroviraux de première intention privilégiés, alternatifs et pour circonstances particulières chez le nouveau-né, l’enfant et l’adolescent sous traitement antituberculeux. Dans le tableau imprimé, la couleur indique si chaque schéma ne nécessite aucun changement, un ajustement de dose ou un changement de schéma avec le traitement antituberculeux.",
        "ru": "Предпочтительные, альтернативные и применяемые в особых обстоятельствах схемы АРТ первого ряда для новорождённых, детей и подростков, получающих лечение туберкулёза. В печатной таблице цвет показывает, требует ли схема при лечении туберкулёза изменений, коррекции дозы или замены схемы."
      },
      "csv": "tables/table-7-1.csv"
    },
    {
      "label": "Table 7.2",
      "caption": "Table 7.2. Changes needed to antiretroviral therapy regimens for neonates, children and adolescents on drug-susceptible TB treatment",
      "pages": [
        193,
        194
      ],
      "columns": [
        {
          "titles": "Age"
        },
        {
          "titles": "ART regimen"
        },
        {
          "titles": "Changes needed for children on ART who are starting TB treatment, or for children starting ART while on TB treatment"
        }
      ],
      "rows": [
        [
          "Neonates (first 28 days of life)",
          "RAL-based a",
          "Dose adjustment is needed: double the twice-daily dose while on TB treatment From age 4 weeks and weight >3 kg, transition to DTG-based regimen If neonate is on AZT, switch to ABC after neonatal period"
        ],
        [
          "",
          "NVP-based",
          "Change of regimen is needed: substitute NVP as soon as possible with DTG or LPV/r (with appropriate dose adjustment; see under DTG- and LPV/r-based regimens for children)"
        ],
        [
          "Children",
          "DTG-based a",
          "Dose adjustment is needed: dose DTG twice daily instead of once daily while on TB treatment"
        ],
        [
          "",
          "LPV/r-based",
          "Transition to DTG-based regimen (with appropriate dose adjustment) is preferable If not possible, LPV/r dose adjustment is needed: ritonavir (RTV) dose needs to be “super-boosted” to achieve same dose as LPV in mg, in a ratio equal to or approaching 1 : 1"
        ],
        [
          "",
          "RAL-based",
          "Transition to DTG-based regimen (with appropriate dose adjustment) is preferable; if not possible, RAL dose adjustment is needed: double the twice-daily dose while on TB treatment"
        ],
        [
          "",
          "TAF-containing",
          "Change of regimen is needed: substitute TAF with ABC or TDF"
        ],
        [
          "",
          "ATV/r-based",
          "Change of regimen is needed: replace ATV/r with DTG if DTG-naive or with LPV/r if DTG-experienced (with appropriate dose adjustment)"
        ],
        [
          "",
          "DRV/r-based",
          "Change of regimen is needed: replace DRV/r with DTG if DTG-naive or with LPV/r if DTG-experienced (with appropriate dose adjustment)"
        ],
        [
          "Adolescents",
          "DTG-based",
          "Dose adjustment is needed: adjust dose of DTG (50 mg twice daily instead of 50 mg once daily)"
        ],
        [
          "",
          "LPV/r-based",
          "Transition to DTG-based regimen (with appropriate dose adjustment) is preferable If not possible, LPV/r dose adjustment is needed: “double-dose” LPV 800 mg/RTV 200 mg twice daily or “super-boosted” with LPV 400 mg/RTV 100 mg twice daily plus additional doses of RTV 300 mg twice daily Note: rifapentine (e.g. the 4-month treatment regimen for drug-susceptible TB consisting of HPZM) should not be used"
        ],
        [
          "",
          "RAL-based",
          "Transition to DTG-based regimen (with appropriate dose adjustment) is preferable If not possible, RAL dose adjustment is needed: adjusted dose of RAL (800 mg twice daily instead of 400 mg twice daily)"
        ],
        [
          "",
          "Other regimens",
          "See under children"
        ]
      ],
      "notes": "a Preferred ART regimen for initiation in neonates and children on TB treatment.\n3TC: lamivudine; ABC: abacavir; ATV/r: atazanavir/ritonavir; AZT: zidovudine; DRV/r: darunavir/ritonavir; DTG: dolutegravir; EFV: efavirenz; FTC: emtricitabine; LPV/r: lopinavir/ritonavir; NVP: nevirapine; RAL: raltegravir; RTV: ritonavir; TAF: tenofovir alafenamide; TDF: tenofovir disoproxil fumarate.",
      "narratives": {
        "en": "Changes needed to each type of antiretroviral regimen when neonates, children or adolescents on ART start drug-susceptible TB treatment, or start ART while on TB treatment, including dose adjustments and regimen substitutions.",
        "ar": "التغييرات اللازمة على كل نوع من أنظمة العلاج بمضادات الفيروسات القهقرية عندما يبدأ حديثو الولادة أو الأطفال أو المراهقون الذين يتلقون هذا العلاج علاجَ السل الحساس للأدوية، أو عندما يبدؤونه أثناء علاج السل، بما في ذلك تعديل الجرعات واستبدال الأنظمة.",
        "zh": "正在接受抗逆转录病毒治疗的新生儿、儿童或青少年开始药物敏感性结核病治疗时，或在结核病治疗期间开始抗逆转录病毒治疗时，各类抗逆转录病毒方案所需的调整，包括剂量调整和方案替换。",
        "es": "Cambios necesarios en cada tipo de pauta antirretrovírica cuando neonatos, niños o adolescentes en TAR inician el tratamiento de la tuberculosis farmacosensible, o inician el TAR durante el tratamiento antituberculoso, incluidos ajustes de dosis y sustituciones de pauta.",
        "fr": "Modifications nécessaires pour chaque type de schéma antirétroviral lorsque des nouveau-nés, enfants ou adolescents sous TAR commencent un traitement de la tuberculose pharmacosensible, ou commencent le TAR pendant le traitement antituberculeux, y compris ajustements de dose et substitutions de schéma.",
        "ru": "Изменения, необходимые для каждого типа схемы АРТ, когда новорождённые, дети или подростки, получающие АРТ, начинают лечение лекарственно-чувствительного туберкулёза или начинают АРТ на фоне лечения туберкулёза, включая коррекцию доз и замену схем."
      },
      "csv": "tables/table-7-2.csv"
    },
    {
      "label": "Table 7.3",
      "caption": "Table 7.3. TB preventive treatment options for children and adolescents on antiretroviral therapy",
      "pages": [
        195
      ],
      "columns": [
        {
          "titles": "6H"
        },
        {
          "titles": "3HP"
        },
        {
          "titles": "3HR"
        },
        {
          "titles": "4R"
        },
        {
          "titles": "1HP"
        },
        {
          "titles": "H+B6+CTX (Q-TIB)"
        }
      ],
      "rows": [
        [
          "No restrictions",
          "Contraindicated: • all PIs • NVP and NNRTIs • TAF",
          "Contraindicated: • all PIs • NVP and most NNRTIs",
          "Contraindicated: • all PIs • NVP and most NNRTIs • TAF",
          "Contraindicated: • all PIs • NVP and most NNRTIs • TAF",
          "No restrictions"
        ],
        [
          "",
          "",
          "Use with caution: • TAF",
          "",
          "",
          ""
        ],
        [
          "",
          "",
          "Adjust dose: • DTG • RAL",
          "Adjust dose: • DTG • RAL",
          "",
          ""
        ],
        [
          "",
          "Use: • TDF • EFV (600 mg) • DTG • RAL a",
          "Use: • TDF • EFV (600 mg) b",
          "Use: • TDF • EFV (600 mg) b",
          "Use: • TDF • EFV (600 mg) b • DTG c • RAL c",
          ""
        ]
      ],
      "notes": "a Drug interaction has been studied in adults but not children; applies only to adolescents and adults taking DTG or RAL only.\nb EFV 600 mg applies to adolescents and adults; EFV is not recommended in children aged under 3 years.\nc For adolescents on 1HP who are taking DTG or RAL, dosing of DTG and RAL needs to be adjusted as per Table 7.2.\nAbbreviations: B6: pyridoxine; CTX: co-trimoxazole; DTG: dolutegravir; EFV: efavirenz; H: isoniazid; NNRTIs: non-nucleoside reverse-transcriptase inhibitors; NVP: nevirapine; PIs: protease inhibitors; RAL: raltegravir; TAF: tenofovir alafenamide; TDF: tenofovir disoproxil fumarate.",
      "narratives": {
        "en": "For each TB preventive treatment regimen (6H, 3HP, 3HR, 4R, 1HP, isoniazid–pyridoxine–co-trimoxazole), which antiretroviral medicines are contraindicated, should be used with caution, need dose adjustment, or can be used.",
        "ar": "لكل نظام من أنظمة العلاج الوقائي من السل (6H و3HP و3HR و4R و1HP والإيزونيازيد مع البيريدوكسين والكوتريموكسازول)، الأدوية المضادة للفيروسات القهقرية التي يُمنع استعمالها، أو تُستخدم بحذر، أو تحتاج إلى تعديل الجرعة، أو يمكن استخدامها.",
        "zh": "对于每种结核病预防性治疗方案（6H、3HP、3HR、4R、1HP、异烟肼+吡哆醇+复方新诺明），哪些抗逆转录病毒药物禁用、需慎用、需调整剂量或可以使用。",
        "es": "Para cada pauta de tratamiento preventivo de la tuberculosis (6H, 3HP, 3HR, 4R, 1HP, isoniazida–piridoxina–cotrimoxazol), qué antirretrovíricos están contraindicados, deben usarse con precaución, requieren ajuste de dosis o pueden utilizarse.",
        "fr": "Pour chaque schéma de traitement préventif de la tuberculose (6H, 3HP, 3HR, 4R, 1HP, isoniazide–pyridoxine–cotrimoxazole), les antirétroviraux contre-indiqués, à utiliser avec prudence, nécessitant un ajustement de dose ou utilisables.",
        "ru": "Для каждой схемы профилактического лечения туберкулёза (6H, 3HP, 3HR, 4R, 1HP, изониазид–пиридоксин–ко-тримоксазол) указано, какие антиретровирусные препараты противопоказаны, применяются с осторожностью, требуют коррекции дозы или могут применяться."
      },
      "csv": "tables/table-7-3.csv"
    },
    {
      "label": "Table 7.4",
      "caption": "Table 7.4. Diagnostic accuracy of WHO-recommended screening tools in pregnant women living with HIV",
      "pages": [
        197
      ],
      "columns": [
        {
          "titles": "Diagnostic accuracy compared with culture reference standard"
        },
        {
          "titles": "Sensitivity"
        },
        {
          "titles": "Specificity"
        }
      ],
      "rows": [
        [
          "W4SS",
          "61%",
          "58%"
        ],
        [
          "CRP (cut-off value >5 mg/L)",
          "70%",
          "41%"
        ],
        [
          "W4SS combined with CXR (any abnormality)",
          "75%",
          "56%"
        ],
        [
          "mWRDs",
          "55%",
          "99%"
        ]
      ],
      "narratives": {
        "en": "Sensitivity and specificity, against a culture reference standard, of four WHO-recommended TB screening tools in pregnant women living with HIV: the WHO four-symptom screen (W4SS), C-reactive protein, W4SS combined with chest X-ray, and molecular WHO-recommended rapid diagnostic tests.",
        "ar": "حساسية ونوعية أربع أدوات للتحري عن السل توصي بها المنظمة لدى الحوامل المتعايشات مع فيروس العوز المناعي البشري، مقارنة بمعيار مرجعي هو الزرع: فحص الأعراض الأربعة للمنظمة (W4SS)، والبروتين التفاعلي C، وW4SS مع التصوير الشعاعي للصدر، والاختبارات التشخيصية السريعة الجزيئية الموصى بها من المنظمة.",
        "zh": "以培养为参考标准，世卫组织推荐的四种结核病筛查工具在感染艾滋病毒孕妇中的敏感性和特异性：世卫组织四症状筛查（W4SS）、C反应蛋白、W4SS联合胸部X光，以及世卫组织推荐的分子快速诊断检测。",
        "es": "Sensibilidad y especificidad, frente a un patrón de referencia de cultivo, de cuatro herramientas de cribado de la tuberculosis recomendadas por la OMS en embarazadas con el VIH: el cribado de cuatro síntomas de la OMS (W4SS), la proteína C reactiva, el W4SS combinado con radiografía de tórax y las pruebas moleculares de diagnóstico rápido recomendadas por la OMS.",
        "fr": "Sensibilité et spécificité, par rapport à une norme de référence par culture, de quatre outils de dépistage de la tuberculose recommandés par l’OMS chez les femmes enceintes vivant avec le VIH : dépistage des quatre symptômes de l’OMS (W4SS), protéine C-réactive, W4SS associé à une radiographie thoracique et tests moléculaires de diagnostic rapide recommandés par l’OMS.",
        "ru": "Чувствительность и специфичность четырёх рекомендованных ВОЗ инструментов скрининга на туберкулёз у беременных женщин, живущих с ВИЧ, по сравнению с эталоном — посевом: скрининг ВОЗ по четырём симптомам (W4SS), C-реактивный белок, W4SS в сочетании с рентгенографией грудной клетки и молекулярные экспресс-тесты, рекомендованные ВОЗ."
      },
      "csv": "tables/table-7-4.csv"
    },
    {
      "label": "Table 7.5",
      "caption": "Table 7.5. Actions to promote accessibility and availability of palliative care for children",
      "pages": [
        202
      ],
      "columns": [
        {
          "titles": "Area for action"
        },
        {
          "titles": "Action"
        }
      ],
      "rows": [
        [
          "Policy",
          "Develop a national policy on children’s palliative care, with guidance on providing palliative care to children"
        ],
        [
          "Integration into health system",
          "Develop national and local policies and standard operating procedures for children’s palliative care Gain management support for children’s palliative care Include human resources for provision of palliative care in planning human resources for health"
        ],
        [
          "Training and education",
          "Train HCWs at basic, intermediate and specialist levels in providing palliative care to children"
        ],
        [
          "Access to essential medicines",
          "Ensure essential palliative care medicines are included in the Essential Medicines List for paediatric care, are available in the country, and are accessible to children and adolescents when needed"
        ],
        [
          "Research",
          "Provide data showing the impact of and need for palliative care to influence decision-makers and ensure quality of services provided"
        ],
        [
          "Awareness and understanding of palliative care",
          "Develop a communication strategy and awareness campaigns to promote public understanding of palliative care This also targets policy- and decision-makers, many of whom may not be aware of the need for and impact of children’s palliative care"
        ]
      ],
      "narratives": {
        "en": "Actions to make palliative care for children more accessible and available, grouped by area: policy, integration into the health system, training and education, access to essential medicines, research, and awareness.",
        "ar": "إجراءات لزيادة إتاحة الرعاية الملطّفة للأطفال وتوافرها، مجمّعة حسب المجال: السياسات، والإدماج في النظام الصحي، والتدريب والتعليم، والحصول على الأدوية الأساسية، والبحوث، والتوعية.",
        "zh": "提高儿童姑息治疗可及性和可获得性的行动，按领域分组：政策、纳入卫生系统、培训和教育、基本药物可及性、研究以及提高认识。",
        "es": "Medidas para mejorar la accesibilidad y disponibilidad de los cuidados paliativos para niños, agrupadas por ámbito: políticas, integración en el sistema de salud, formación y educación, acceso a medicamentos esenciales, investigación y sensibilización.",
        "fr": "Mesures visant à rendre les soins palliatifs pédiatriques plus accessibles et disponibles, regroupées par domaine : politiques, intégration dans le système de santé, formation et éducation, accès aux médicaments essentiels, recherche et sensibilisation.",
        "ru": "Меры по повышению доступности и наличия паллиативной помощи детям, сгруппированные по направлениям: политика, интеграция в систему здравоохранения, подготовка и обучение, доступ к основным лекарственным средствам, исследования и повышение осведомлённости."
      },
      "csv": "tables/table-7-5.csv"
    },
    {
      "label": "Table 7.6",
      "caption": "Table 7.6. Examples of symptom management for children and adolescents with TB in need of palliative care (207, 208)",
      "pages": [
        203
      ],
      "columns": [
        {
          "titles": "Symptom"
        },
        {
          "titles": "Recommended management"
        }
      ],
      "rows": [
        [
          "Dyspnoea",
          "Use of handheld fan directed at face Oxygen supplementation Oral, intravenous or subcutaneous opioids (starting at 25% of dose recommended for pain management) Integrative and supportive therapies"
        ],
        [
          "Cough",
          "Over-the-counter cough medicines (e.g. honey preparations) Nebulized saline (for children with thick secretions or insufficient cough strength) Chest physiotherapy Opioids if needed (starting at 25% of dose recommended for pain management)"
        ],
        [
          "Haemoptysis",
          "Antifibrinolytics as prevention or to stop haemoptysis"
        ],
        [
          "Retained secretions at end of life",
          "Gentle suctioning"
        ]
      ],
      "notes": "Source: adapted from Craig F, Henderson EM, Bluebond-Langner M. Management of respiratory symptoms in paediatric palliative care. Curr Opin Support Palliat Care. 2015;9(3):217–226; and Ringholz F, Devins M, McNally P. Managing end stage lung disease in children. Paediatr Respir Rev. 2014;15(1):75–80.",
      "narratives": {
        "en": "Recommended management of four respiratory symptoms (dyspnoea, cough, haemoptysis, retained secretions at end of life) in children and adolescents with TB who need palliative care.",
        "ar": "التدبير العلاجي الموصى به لأربعة أعراض تنفسية (ضيق التنفس، والسعال، ونفث الدم، واحتباس الإفرازات في نهاية الحياة) لدى الأطفال والمراهقين المصابين بالسل الذين يحتاجون إلى رعاية ملطّفة.",
        "zh": "对需要姑息治疗的结核病儿童和青少年四种呼吸道症状（呼吸困难、咳嗽、咯血、临终分泌物潴留）的推荐处理方法。",
        "es": "Tratamiento recomendado de cuatro síntomas respiratorios (disnea, tos, hemoptisis, secreciones retenidas al final de la vida) en niños y adolescentes con tuberculosis que necesitan cuidados paliativos.",
        "fr": "Prise en charge recommandée de quatre symptômes respiratoires (dyspnée, toux, hémoptysie, sécrétions retenues en fin de vie) chez l’enfant et l’adolescent atteints de tuberculose ayant besoin de soins palliatifs.",
        "ru": "Рекомендуемое лечение четырёх респираторных симптомов (одышка, кашель, кровохарканье, задержка секрета в конце жизни) у детей и подростков с туберкулёзом, нуждающихся в паллиативной помощи."
      },
      "csv": "tables/table-7-6.csv"
    },
    {
      "label": "Table A2.1",
      "caption": "Table A2.1. Causes of false-negative and false-positive tuberculin skin tests",
      "pages": [
        236
      ],
      "columns": [
        {
          "titles": "False-negative"
        },
        {
          "titles": "False-positive"
        }
      ],
      "rows": [
        [
          "Incorrect administration or interpretation of test HIV Recent TB infection (within 8–10 weeks of exposure) Severe forms of TB (e.g. disseminated TB, TB meningitis) Viral infections (e.g. measles, varicella, Epstein–Barr virus) Vaccinated with live viral vaccines (within 6 weeks) Malnutrition Bacterial infection (e.g. typhoid, leprosy, pertussis) Immunosuppressive medicines (e.g. corticosteroids) Neonates and infants aged <6 months Primary immunodeficiencies Diseases of lymphoid tissue (e.g. Hodgkin disease, lymphoma, leukaemia, sarcoidosis) Low protein states Improper storage of tuberculin",
          "Incorrect interpretation of reaction Previous BCG vaccination Infection with non-tuberculosis mycobacteria Incorrect method of TST administration Incorrect bottle of antigen used"
        ]
      ],
      "notes": "Source: adapted from Guidance for national tuberculosis programmes on the management of tuberculosis in children, second edition. Geneva: World Health Organization; 2014; WHO operational handbook on tuberculosis. Module 1: prevention – tuberculosis preventive treatment. Geneva: World Health Organization; 2020 (https://www.who.int/publications/i/item/9789240002906); and https://www.cdc.gov/tb/publications/factsheets/testing/skintesting.htm.",
      "narratives": {
        "en": "Lists the causes of false-negative tuberculin skin test results (e.g. HIV, recent infection, severe TB, malnutrition, immunosuppression) alongside the causes of false-positive results (e.g. previous BCG vaccination, non-tuberculous mycobacteria, incorrect administration).",
        "ar": "يسرد الجدول أسباب النتائج السلبية الكاذبة لاختبار السلين الجلدي (مثل فيروس العوز المناعي البشري، والعدوى الحديثة، والسل الوخيم، وسوء التغذية، وكبت المناعة) إلى جانب أسباب النتائج الإيجابية الكاذبة (مثل التطعيم السابق بلقاح BCG، والمتفطرات غير السلية، والخطأ في إعطاء الاختبار).",
        "zh": "列出结核菌素皮肤试验假阴性结果的原因（如艾滋病毒、近期感染、重症结核病、营养不良、免疫抑制）以及假阳性结果的原因（如既往接种卡介苗、非结核分枝杆菌感染、试验操作不当）。",
        "es": "Enumera las causas de resultados falsos negativos de la prueba cutánea de la tuberculina (p. ej., VIH, infección reciente, tuberculosis grave, malnutrición, inmunosupresión) junto con las causas de falsos positivos (p. ej., vacunación previa con BCG, micobacterias no tuberculosas, administración incorrecta).",
        "fr": "Énumère les causes de résultats faussement négatifs du test cutané à la tuberculine (p. ex. VIH, infection récente, tuberculose grave, malnutrition, immunosuppression) ainsi que les causes de résultats faussement positifs (p. ex. vaccination antérieure par le BCG, mycobactéries non tuberculeuses, administration incorrecte).",
        "ru": "Перечислены причины ложноотрицательных результатов туберкулиновой кожной пробы (например, ВИЧ, недавнее инфицирование, тяжелые формы ТБ, недостаточность питания, иммуносупрессия) и причины ложноположительных результатов (например, предшествующая вакцинация БЦЖ, нетуберкулезные микобактерии, неправильная постановка пробы)."
      },
      "csv": "tables/table-a2-1.csv"
    },
    {
      "label": "Table A5.1",
      "caption": "Table A5.1. Danger and priority signs of severe illness or health problems in children aged under 10 years",
      "pages": [
        250,
        251
      ],
      "columns": [
        {
          "titles": "Danger signs (IMCI)",
          "group": "Aged <5 years"
        },
        {
          "titles": "Danger signs (ETAT)",
          "group": "Aged 5–9 years"
        },
        {
          "titles": "Priority signs",
          "group": "All children aged <10 years"
        }
      ],
      "rows": [
        [
          "Gastrointestinal/circulatory: • Unable to eat or drink • Vomiting up everything • Signs of severe dehydration (sunken eyes, skin pinch returns very slowly) • Severe palmar pallor",
          "Gastrointestinal/circulatory: • Diarrhoea with any two signs of severe dehydration (lethargy, unconsciousness, sunken eyes, very slow return of skin after pinching) • Signs of shock (cold extremities with capillary refill time >3 seconds, weak and fast pulse)",
          "• Any sick child aged <2 months • High fever (>39° C) • Severe pallor • Respiratory distress • Restless, continuously irritable, lethargic • SAM"
        ],
        [
          "Respiratory: • Stridor • Oxygen saturation <90%",
          "Respiratory: • Obstructed or absent breathing • Severe respiratory distress • Central cyanosis",
          ""
        ],
        [
          "Neurological: • Seizures • Profoundly lethargic, unconscious • Neck stiffness or bulging fontanelle",
          "Neurological: • Coma (or seriously reduced level of consciousness) • Seizures",
          ""
        ]
      ],
      "narratives": {
        "en": "Danger signs for children aged under 5 years (IMCI) and aged 5–9 years (ETAT), grouped as gastrointestinal/circulatory, respiratory and neurological, alongside priority signs for all children aged under 10 years.",
        "ar": "علامات الخطر لدى الأطفال دون سن الخامسة (حسب التدبير المتكامل لأمراض الطفولة) ومن سن 5 إلى 9 سنوات (حسب الفرز والتقييم والعلاج في حالات الطوارئ)، مجمّعة في فئات معدية معوية/دورانية وتنفسية وعصبية، إلى جانب العلامات ذات الأولوية لجميع الأطفال دون سن العاشرة.",
        "zh": "5岁以下儿童（儿童疾病综合管理）和5–9岁儿童（急诊分诊、评估和治疗）的危险体征，按胃肠/循环、呼吸和神经系统分组，以及所有10岁以下儿童的优先体征。",
        "es": "Signos de peligro en niños menores de 5 años (AIEPI) y de 5 a 9 años (ETAT), agrupados en gastrointestinales/circulatorios, respiratorios y neurológicos, junto con los signos prioritarios para todos los niños menores de 10 años.",
        "fr": "Signes de danger chez l’enfant de moins de 5 ans (PCIME) et de 5 à 9 ans (ETAT), regroupés en signes gastro-intestinaux/circulatoires, respiratoires et neurologiques, ainsi que les signes prioritaires pour tous les enfants de moins de 10 ans.",
        "ru": "Опасные признаки у детей до 5 лет (ИВБДВ) и 5–9 лет (ЕТАТ), сгруппированные как желудочно-кишечные/циркуляторные, респираторные и неврологические, а также приоритетные признаки для всех детей до 10 лет."
      },
      "csv": "tables/table-a5-1.csv"
    },
    {
      "label": "Table A7.1",
      "caption": "Table A7.1. Options for neurocognitive and functional testing at end of treatment for TB meningitis",
      "pages": [
        260,
        261
      ],
      "columns": [
        {
          "titles": "Outcome"
        },
        {
          "titles": "Measure"
        },
        {
          "titles": "Timing"
        }
      ],
      "rows": [
        [
          "Neurodevelopmental",
          "Minimal: • Ages and Stages Questionnaire (age range 0–5 years) a Optimal: • Bailey Scale of Infant Development, 3rd edition (age range 1–42 months) b • Mullen Scale Early Learning (age range 0–68 months) c",
          "Post-acute: 6–9 months, 2 years, 4 years"
        ],
        [
          "Neurocognitive",
          "• Wechsler Intelligence Scales for Children (age range 6–16 years) d • Kauffman Assessment Battery for Children, 2nd edition (age range 3–8 years) e",
          "Post-acute: 6–9 months Long-term throughout schooling (2 and 5 years minimum)"
        ],
        [
          "Functional",
          "Minimal: • Modified Rankin Scale (age range 1 year–adult) • WHO Disability Assessment Schedule 2.0 (age range 12 years–adult) f Optimal: • Vineland Adaptive Behaviour Scale (age range birth to adult) g",
          "Post-acute: 6–9 months Long-term throughout schooling (2 and 5 years minimum)"
        ],
        [
          "Neurobehavioural",
          "Minimal: • Strengths and Difficulties Questionnaire (age range 4–17 years) • Child, parent, teachers forms",
          "Post-acute: 6–9 months Long-term throughout schooling (2 and 5 years minimum)"
        ]
      ],
      "notes": "Note: these developmental assessment tools have not been formally adapted for use in low- and middle-income countries, and locally determined norms have not been developed. Interpretation of results requires careful consideration of the local context. A number of in-country locally developed screening tools are also available. a Ages and stages questionnaire, 3rd edition. Baltimore, MD: Brookes Publishing; 2009. b Bayley N. Scales of Infant and Toddler Development III (screening test). San Antonio, TX: Pearson; 2005. c Torrance CW, editor. Mullen Scales of Early Learning. 1995. d Wechsler Intelligence Scale for Children (WISC-IV), 4th edition. San Antonio, TX: Psychological Corporation; 2003. e Kaufman Assessment Battery for Children 2. Circle Pines, MN: American Guidance Service; 2004. f WHO Disability Assessment Schedule 2.0. Geneva: World Health Organization; 2010 (https://www.who.int/standards/classifications/international-classification-of-functioning-disability-and-health/who-disability-assessment-schedule). g Sparrow SS, Cicchetti DV B DA. Vineland Adaptive Behavior Scales, 2nd edition. Minneapolis, MN: Pearson; 2005. h http://www.sdqinfo.com. Source: adapted from Davis AG, Nightingale S, Springer PE, et al. Neurocognitive and functional impairment in adult and paediatric tuberculous meningitis. 2019.",
      "narratives": {
        "en": "For each outcome domain after TB meningitis (neurodevelopmental, neurocognitive, functional, neurobehavioural), the table lists minimal and optimal assessment tools with their age ranges and the recommended timing of testing.",
        "ar": "يعرض الجدول، لكل مجال من مجالات النتائج بعد التهاب السحايا السلي (النمو العصبي، والوظائف المعرفية العصبية، والأداء الوظيفي، والسلوك العصبي)، أدوات التقييم الدنيا والمثلى مع الفئات العمرية الخاصة بها والتوقيت الموصى به للاختبار.",
        "zh": "针对结核性脑膜炎后的各结局领域（神经发育、神经认知、功能和神经行为），列出最低限度和最佳的评估工具及其适用年龄范围，以及建议的检测时间。",
        "es": "Para cada ámbito de resultados tras la meningitis tuberculosa (neurodesarrollo, neurocognitivo, funcional y neuroconductual), el cuadro enumera las herramientas de evaluación mínimas y óptimas con sus rangos de edad y el momento recomendado para la evaluación.",
        "fr": "Pour chaque domaine de résultats après une méningite tuberculeuse (neurodéveloppemental, neurocognitif, fonctionnel, neurocomportemental), le tableau présente les outils d’évaluation minimaux et optimaux avec leurs tranches d’âge et le calendrier recommandé des tests.",
        "ru": "Для каждой области исходов после туберкулезного менингита (нейроразвитие, нейрокогнитивные функции, функциональное состояние, нейроповедение) в таблице приведены минимальные и оптимальные инструменты оценки с возрастными диапазонами и рекомендуемые сроки тестирования."
      },
      "csv": "tables/table-a7-1.csv"
    }
  ],
  "coverage": [
    {
      "kind": "contents",
      "state": "found",
      "count": 53,
      "note": "outline"
    },
    {
      "kind": "sections",
      "state": "found",
      "count": 54,
      "note": "2 levels"
    },
    {
      "kind": "figures",
      "state": "found",
      "count": 22
    },
    {
      "kind": "tables",
      "state": "found",
      "count": 37
    },
    {
      "kind": "references",
      "state": "not-extracted",
      "note": "a references section is in the text (p217); its entries are not extracted"
    },
    {
      "kind": "glossary",
      "state": "not-extracted",
      "note": "a glossary section is in the text (p11); its entries are not extracted"
    },
    {
      "kind": "footnotes",
      "state": "not-extracted"
    },
    {
      "kind": "summaries",
      "state": "partial",
      "count": 53,
      "note": "53 of 54 sections"
    }
  ],
  "links": {
    "repo": "litlfred/who-iris",
    "branch": "main",
    "dir": "library/10665-352523"
  }
}
